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Abstract
Abstract
Selenium (Se) is an essential trace element that has a role in cancer chemoprevention. 
DNA methylation is an important factor in carcinogenesis and one-carbon metabolism 
may influence this by providing methyl groups for DNA methylation. In previous 
studies Se was shown to be inversely correlated with homocysteine (Hey), a product of 
one-carbon metabolism, in humans but it is unclear whether Se has a direct effect on 
DNA methylation. The relationship between Se and one-carbon metabolism was 
therefore investigated on two levels: (i) an investigation into the effect of Se 
supplementation on nutritional factors involved in one-carbon metabolism and (ii) an 
integrative epigenomic analysis using prostate cell lines and tissues to determine the 
effect of Se supplementation on DNA methylation.
The interaction between Se, tHcy and B vitamins was investigated in a double-blind, 
placebo-controlled trial where 501 healthy UK elderly volunteers received 100, 200, or 
300 fig Se/day as high-Se-yeast, or placebo-yeast for 6 months. Plasma Se, tHcy, 
folate, vitamin B-12, pyridoxal-5'-phosphate and its catabolite, 4-pyridoxic acid, were 
measured. At baseline, Se was inversely correlated with tHcy in males (p<0.05). Before 
supplementation, tHcy concentration was significantly lower in the highest compared to 
the lowest Se tertile in males (p<0.05), and in females when folate concentrations were 
also in the top tertile (p<0.05). After 6 months of Se supplementation, only Se 
concentration had changed significantly.
A genome-wide experimental design combining demethylation with 5-aza-2'- 
deoxycitidine (5-AZA) and subsequent gene re-expression, with methylome mapping
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via methylated DNA immunoprecipitation (MeDIP), investigated the global effect of Se 
supplementation on prostate cell lines RWPE-1, DU145, LnCAP and PC-3 and tissues. 
Se supplementation increased expression of hypermethylated genes and, in combination 
with 5-AZA, reduced global methylation levels in the PC-3 prostate cancer cell line 
(P<.05). Se and 5-AZA individually activated anti-carcinogenic pathways while Se 
also inhibited cellular proliferation pathways. Genes that were Se-responsive after 
demethylation were involved in DNA repair, cell motility, the JAK/STAT pathway and 
stress-mediated translational regulation. MeDIP identified genes involved in vesicle- 
mediated transport, in all prostate cancer cell lines. Novel hypermethylated genes 
included GPx2, an anti-inflammatory and anti-carcinogenic selenoprotein. GPx3, 
known to be hypermethylated in prostate cancer, was shown to be re-expressed with 5- 
AZA and had a further increase in gene expression with Se supplementation. Clusters 
of hypermethylated genes were identified on almost all chromosomes.
In conclusion, supplementation with Se does not affect tHcy concentration in the UK 
elderly population whereas in vitro Se supplementation of prostate cancer cells causes 
an increase in gene expression of hypermethylated genes. Hypermethylated Se- 
responsive genes are involved in anti-carcinogenic pathways and can be targeted for 
cancer therapy by demethylation and Se supplementation.
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Chapter 1 - Introduction
Chapter One
Introduction
Over the past decades, genetic studies on cancer have identified numerous types of 
aberrations of the DNA sequence in tumour cells compared to normal cells, but it is 
only recently that another level, the aberrant epigenetic code, was suggested to be a 
major factor in carcinogenesis. Although the underlying cause behind aberrant 
methylation has not been determined yet, it has become clear that DNA and histone 
methylation play a major role in cancer aetiology. One-carbon metabolism is 
responsible for the production of methyl groups used during DNA methylation and is 
influenced by a number of nutrients. Besides the availability of methyl groups, the 
concentration of homocysteine (Hey) before its re-methylation to methionine is also 
determined by the nutrients involved in one-carbon metabolism. Both folate and 
selenium (Se) have an effect on one-carbon metabolism and consequently on Hey and 
DNA methylation, although the effects manifest themselves in different ways.
This introduction aims to explore the interaction between one-carbon metabolism, Se 
and DNA methylation by reviewing past and current literature.
1.1 One-carbon metabolism
The metabolic pathway for the generation of one-carbon (CH3) molecules is complex 
and essential in all organisms for nucleic acid synthesis/DNA repair and methylation 
of biomolecules. Folate has a central role within this pathway (Figure 1) and its 
metabolism is largely limited to the liver or the kidney (Jacobsen et al. 2005). The
1
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process is initiated by the transfer of a carbon unit from serine or glycine to 
tetrahydrofolate to form 5,10-methylenetetrahydrofolate (5,10-MeTHF). This form of 
folate can be used for the synthesis of thymidine, for the oxidation to 
formyltetrahydrofolate for the synthesis of purines or it can be reduced to 5- 
methyltetrahydrofolate by methyl tetrahydrofolate reductase (MTHFR) and used to 
methylate Hey to form methionine. The vitamin B 12-dependent enzyme, methionine 
synthase (MS or MTR), catalyzes the conversion of Hey to methionine. Methionine 
is subsequently converted to S-adenosylmethionine (SAM) by an ATP-dependent 
transfer of adenosine to methionine through methionine adenosyltransferase (MAT). 
SAM then donates its methyl groups in more than 100 biological methylation 
reactions, including the methylation of DNA, RNA, and proteins [Figure I; (Davis 
and Uthus 2004)]. An alternative pathway for re-methylating Hey involves its 
acceptance of a methyl group from betaine, which is catalysed by betaine- 
homocysteine methyltransferase (BHMT) as catalyser. Excess Hey can be eliminated 
with the trans-sulphuration pathway in which glutathione is produced by a number of 
cysteine metabolising enzymes (Figure 1).
2
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SAM <----- METHIONINE
A MAT
FOLATE
\ i
DHF
'
TH F
Serine
Glycine
Methyl acceptor 
substrate
5 .1 0 -M e T H FGNMT BHMT
(Riboflavin]
Betaine
Methylated product MTHFR
SAHH
HOMOCYSTEINE 5-M eT H F
Cystathionine
Cysteine y-Glutamylcysteine G utathione
Figure 1 One-carbon metabolism. Nutrients and genes interacting determine the 
concentration of Hey and influence its related pathologies. Dihydrofolate (DHF); 
Tetrahydrofolate (THF); Serine hydroxymethyltransferase (SHM); 5,10- 
methylenetetrahydrofolate (5,10-MeTHF); Methyltetrahydrofolate reductase 
(MTHFR); 5-methyltetrahydrofolate (5-MeTHF); Methionine synthase (MS); Betaine 
homocysteine methyltransferase (BHMT); Dimethylglycine (DMG); S-adenosyl 
methionine (SAM); methionine adenosyl transferase (MAT); Glycine-N- 
methyltransferase (GNMT); S-adenosyl homocysteine (SAH); S- 
adenosylhomocysteine hydrolase (SAHH); Cystathionine 13-synthase (CBS); Cysteine 
lyase (CL); Glutamate cysteine ligase (GCL); Glutathione synthase (GS). Enzymes 
are underlined.
1.1.1 Homocysteine and complex disease
Elevated Hey concentrations have been associated with a plethora of complex 
diseases including cardiovascular disease (Bates et al. 1997), neurodegenerative 
diseases (Jacobsen et al 2005), osteoporosis (Herrmann 2005; Refsum et al 2006), 
cognitive decline in the elderly (Teunissen et al 2005) and cancer (Kato et al 1999; 
Zhang et al 2003; Hultdin et al 2005).
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A prerequisite for the pathway to deal efficiently with Hey is an adequate supply of 
the B vitamins folate, B12, B6 and B2. Concentrations of Hey are therefore inversely 
related to that of these vitamins (Bates et al. 1997; McNulty et al 2002). Folate in 
particular has the largest influence on Hey, lowering it by approximately 25%. This 
decrease in Hey would suggest a potential reduction in cardiovascular disease (CVD) 
by 30-40% (Boushey et al 1995).
1.1.2 Biological effects of Homocysteine
When one-carbon metabolism fails to remove excess Hey, it is secreted out of the cell 
into the circulation where it rapidly binds to proteins and small molecules like 
cysteine. Less than 1% of Hey is normally present in the free reduced form while 10- 
20% of the total Hey is present as a Hcy-cysteine or Hcy-Hcy dimer. The rest is 
protein bound (Sharma et al 2006) with 12% bound to globulins and the rest to 
albumin (Hortin et al 2006).
Hey has been shown to cause endothelial dysfunction and damage by impairing the 
action of glutathione peroxidase 1 (GPxl), superoxide dismutase (SOD) and tumour 
necrosis factor alpha [TNFa; (Jacobsen et al 2005)]. It upregulates the expression of 
pro-apoptotic genes and may impair endothelial cell growth. It reduces endothelium- 
dependent vasodilation and accelerates thrombin formation by increasing the activity 
of the clotting cascade and enhancing platelet aggregation. Hey also induces vascular 
smooth muscle cell proliferation and lipid peroxidation through reactive oxygen 
species (ROS) formation and is involved in the migration of monocytes (Splaver et al 
2004; Jacobsen et al 2005). Folic acid deficiency and increased concentrations of 
Hey also promote the accumulation of DNA damage in neurons by impairing DNA
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repair (Kruman et al. 2002). According to Nakano and colleagues (Nakano et al 
2005), excess Hey is exported from endothelial cells and oxidised to form free 
radicals. These radicals oxidise low density lipoproteins that are taken up by 
macrophages and can subsequently transform into foam cells leading to 
atherosclerosis (Nakano et al. 2005; Sharma et al. 2006). Hey may also limit the 
bioavailability of endothelial-derived nitric oxide, a potent vasodilator, by targeting 
dimethylarginine dimethylaminohydrolase that hydrolyzes asymmetric 
dimethylarginine, an inhibitor of nitric oxide (Jacobsen et al. 2005).
High concentrations of Hey can lead to hyperhomocysteinemia. This can be caused 
by a combination of nutritional and genetic disturbances. Severe 
hyperhomocysteinemia (>50 pmol/1) induces a greater risk of cardiovascular disease 
(Heil et al. 2000; Tesselaar et al. 2004), Alzheimer’s disease (Seshadri et al. 2002) 
and may also stimulate bone resorption by elevated osteoclast activity (Herrmann 
2005).
1.1.4 Homocysteine reducing trials
Folate has the ability to lower Hey concentrations but it does not appear to influence 
the risk of the clinical consequences of atherosclerosis (Bazzano et al. 2006). Two 
major intervention trials have supplemented a great number of CVD patients with 
large amounts of B vitamins only finding that folate lowers Hey without reducing the 
risk of other CVD events [except for stroke in the HOPE-2 study (Bonaa et al. 2006; 
Lonn et al. 2006)]. On the other hand, folate supplementation for three years 
significantly improved cognitive function while decreasing Hey concentration (Durga 
et al. 2007).
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Betaine is a trimethylated amino acid that can be used by BHMT as a methyl donor to 
re-methylate Hey to methionine. Though folate is the primary methyl donor in one- 
carbon metabolism, the association between betaine as a methyl donor and Hey is 
only evident when subjects who have low folate levels are given a methionine load. 
(Ueland et al 2005).
1.1.5 Homocysteine association studies
A review of the American based Framingham study that investigated the relationship 
between Hey, folate, and vitamins B12 and B6 in 1401 survivors of the original study 
in 1948 revealed that the B vitamins were inversely correlated with Hey (Selhub 
1999; Sundstrom and Vasan 2005). Hey was found to be an independent risk factor 
for stroke incidence, all-cause and CVD mortality, development of dementia and 
Alzheimer’s disease and congestive heart failure. Hey was also suggested to be an 
important risk factor for hip fracture in older persons and was directly related to left 
ventricular mass and wall thickness in women (Selhub 1999; Sundstrom and Vasan 
2005). Similar results were obtained from a UK population where individuals with 
plasma Hey in the top tertile compared to the bottom tertile had a two-fold increased 
risk of all-cause and CVD mortality (Dangour et al 2008).
With regard to cancer, increased Hey concentrations correlated with colorectal cancer 
but not with breast cancer risk in women (Kato et al 1999; Battistelli et al 2006). 
Elevated Hey was also related to increased risk for head and neck carcinomas 
(Eleftheriadou et al 2006) but with a lower risk for prostate cancer (Hultdin et al 
2005).
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1.1.6 Folate and cancer risk
Folate concentrations, which are very strongly correlated with Hey levels, have been 
investigated in a number of studies for their association with cancer risk. In the 
American Cancer Society Cancer Prevention Study II Nutrition Cohort 5,158 men 
were diagnosed with prostate cancer and a non-significant decreased risk of advanced 
prostate cancer was observed with higher folate levels (Stevens et al. 2006). Similar 
results were obtained in a study where folate concentrations were measured in 
individuals who developed colorectal cancer (CC) within two years. The results 
showed a reduced risk for those with folate concentrations in the highest quintile [HR 
0.42, 95% Cl 0.20-0.88 for colorectal cancer cancer-mortality; (Wolpin et al 2008)]. 
An intervention trial held in the US, however, did not find the inverse association 
between folate concentrations and CC risk but actually saw a higher risk of having 
three or more adenomas and of non-colorectal cancers with folate supplementation (1 
mg/day) (Cole et al. 2007).
1.1.7 One-carbon enzyme single nucleotide polymorphisms and prostate 
cancer risk
A number of single nucleotide polymorphisms (SNPs) have been described in genes 
whose products are involved in one-carbon metabolism. Some of them have been 
associated with prostate cancer risk. The MTHFR C677T SNP is associated with 
prostate carcinogenesis while the C allele of MS A2756C was associated with 
Gleason grade (Marchal et al. 2008). The result of the next study does not 
corroborate Marchal and colleagues’ results: they observed no association with the 
MTHFR C677T SNP and prostate cancer unless men had high folate levels (Van
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Guelpen et al. 2006). Evidently more work needs to be undertaken to investigate the 
effect of these SNPs on prostate cancer.
1.1.8 Homocysteine and B vitamins
A hierarchy seems to exist between the different B vitamins with respect to the 
influence they have on Hey concentrations, going from folate to vitamin B12 (Clarke 
et al. 1998; Selhub 1999; Bonaa et al. 2006; Gonzalez et al. 2006; Lonn et al. 2006; 
Moore et al. 2006) to vitamin B6 (Bates et al. 1999; Lonn et al. 2006; Selhub 2006) to 
riboflavin (McNulty et al. 2002), although the relationship between riboflavin and 
Hey only exists if subjects are homozygous 677TT for MTHFR (McNulty et al. 
2002). As riboflavin is an activating cofactor for MTHFR in the form of FAD, 
MTHFR becomes inactive and can cause low folate status (called ‘the methyl trap’) 
whereby methyl groups become trapped in the form of 5,10-MeTHF causing a 
reduction of the remethylation rate of Hey to methionine (McNulty et al. 2002). 
Because the association of the MTHFR genotype with Hey depends on riboflavin 
status, it might explain why some studies do and some do not find an effect of the 
677TT genotype.
1.1.9 Reverse causality hypothesis
Impaired renal function and renal disease can lead to significant elevation of Hey. 
Impaired renal function is also associated with atherosclerosis, and atherosclerotic 
changes in the kidney (nephrosclerosis) may negatively influence the metabolism of 
Hey causing an increase in plasma Hey making it a marker and not a consequence of 
atherosclerosis (Brattstrom and Wilcken 2000; Scott 2000).
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1.1.10 One-carbon and DNA/histone methylation
Within the one-carbon pathway, methyl groups are produced primarily from folate 
that can be used in DNA methylation reactions. A number of studies have 
investigated the effect of folate deficiency on methylation levels of lymphocyte DNA 
in healthy elderly women (Jacob et al 1998; Rampersaud et al. 2000). Folate 
supplementation of patients with confirmed colorectal adenoma increased global 
DNA methylation levels in leucocytes and colonic mucosa (Pufulete et al 2005). 
These studies directly link folate, the only nutrient, which is able to produce de novo 
methyl groups (Jacob 2000), with global DNA methylation in humans.
More recently, Dobosy and colleagues (Dobosy et al 2008) proved that dietary 
factors can influence gene expression by supplementing rats with a methyl-deficient 
diet. Dimethylation and trimethylation of lysine residues on histones is associated 
with gene silencing (Jackson et al 2004) and the lack of one-carbon units caused 
demethylation of the normally dimethylated lysine 9 of histone 3 in two oncogenic 
but normally imprinted genes Igf2 and H I9 with a subsequent increase in gene 
expression.
1.1.11 One-carbon enzyme SNPs and DNA methylation
Alterations in the DNA sequence of enzymes caused by SNPs or inherited mutations 
involved in the production of methyl donors could in theory influence DNA 
methylation levels in the rest of the genome although no such association has been 
reported yet. A mathematical model published by Reed and colleagues provides some 
evidence for this (Reed et al 2006). DNA methylation levels were influenced by
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SNPs in one-carbon metabolising enzymes, but were relatively insensitive to low 
folate except when vitamin B12 was low as well.
1.1.12 Selenium and one-carbon metabolism
Because of its chemical resemblance to sulphur, Se can replace this element in a 
number of compounds. It has a role in one-carbon metabolism by replacing sulphur 
in methionine molecules and thereby producing selenomethionine, which is the 
common form of Se found in all organisms (Figure 2).
Selenium
Selenoproteins
Selenocysteine
Selenocystathionine
Selenohom ocysteine
Selenomethionine
S-Adenosyl-selenohomocysteine
S-Adenosyl-selenomethionine
Figure 2. Metabolism pathway of selenomethionine.
This results in the formation of S-adenosyl-selenomethionine, which has been 
suggested to be a more reactive methyl donor than normal SAM (Dausch and 
Fullerton 1993) because of the chemical properties of Se.
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Folate and vitamin B12 have been described by several studies as powerful nutritional 
factors for reducing plasma tHcy (Clarke et al 1998; Moore et al. 2006) but recently, 
however, results of a Spanish study (Gonzalez et al 2004) suggested that there was a 
stronger inverse correlation between serum Se and tHcy than between folate and tHcy 
in elderly volunteers (age range 63 -  86 years). Other examples of a significant 
inverse association between Se status and plasma tHcy were found in an Inuit 
population (Belanger et al 2006), in middle-aged and elderly subjects from Upper 
Silesia (Klapcinska et al 2005) and in the UK National Diet and Nutrition Survey 
(NDNS) of people aged 65 years and over (Bates et al 2002).
Animal studies, however, gave different results: Uthus and colleagues (Uthus et al
2002) found tHcy concentration to be lower in Se deficient rats than in rats 
supplemented with adequate or supranutritional amounts of Se. Following on from 
these findings and to see if they would be reproduced in humans, a New Zealand 
group investigated the effect of Se supplementation on tHcy concentrations in healthy 
volunteers (Venn et al 2002). After 20 weeks of supplementing 189 volunteers aged 
18-64 y with placebo or 200 jig Se/day as selenomethionine, plasma Hey was 
unchanged, neither rising, as might have been expected from the results of Uthus and 
colleagues, nor falling, as might have been predicted from observational studies.
The discrepancy in results between the human and animal studies may be due to the 
extreme level of Se deficiency attained in the animal studies or to the type of Se 
administered to the rats i.e. selenite rather than selenomethionine, as in the human 
study.
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An interesting observation in the rat study was that the expression and activity of 
BHMT, an enzyme that catalyzes the transfer of a methyl group from betaine to Hey 
(see Figure 1), were significantly decreased in Se deficiency resulting in less re- 
methylation of Hey to methionine. The authors suggested that if the level of Se is 
inadequate for BHMT expression, one-carbon metabolism may be shunted towards 
the trans-sulphuration pathway to reduce the excessive amounts of tHcy.
In further rat studies (Uthus et al. 2006; Uthus and Ross 2007), Se deficiency was also 
found to reduce the activity of GNMT, a liver enzyme, inhibited by folate, which is 
thought to provide an alternative route for the conversion of excess S- 
adenosylmethionine to S-adenosylhomocysteine (Figure 1). However, neither gene 
expression nor activity of BHMT or activity of GNMT was influenced by Se 
deficiency in mice, demonstrating a species-specific effect. Se may also influence the 
activity of GCL, an enzyme that converts cysteine to y-glutamyl cysteine (on the 
pathway to glutathione) and may thereby aid removal of tHcy (Figure 1): its activity 
has been shown to be dependent on Se status in rats and mice, though again with a 
species difference (Uthus and Ross 2007).
1.2 Selenium as an essential trace element
Se was discovered by Jons Jakob Berzelius, a Swedish physician and chemist, in 1817 
when he was trying to determine the cause of a disease amongst sulphuric acid plant 
workers in Gripsholm, Sweden (Gromer et al. 2005). Se is situated in group 16 in the 
periodic table and has both metallic and non-metallic properties (NRC 1983). It is part 
of the chalcogen family of atoms together with oxygen, sulphur, tellurium and 
polonium. They share the same electron arrangement (each has six free electrons in its
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outer shell) enabling them to interact with others to form disulfide-like bonds. 
Because Berzelius thought Se closely resembled tellurium, translated as “earth” from 
Latin, he named the new element “selenium” after the Greek moon goddess, Selene.
This trace mineral was recognized as an essential mineral when Schwarz and Foltz 
published a paper in 1958 (Schwarz and Foltz 1958), which provided strong evidence 
for an essential role for Se in preventing liver necrosis. Before its beneficial roles 
were discovered, Se deficiency and toxicity were first recognized in animals and it 
was not until 1977 that Schrauzer (Schrauzer 1977) suggested it might have an anti- 
carcinogenic role.
A great number of trials and studies have investigated the effects of Se on an array of 
different diseases and have provided the scientific community with a wealth of 
information. There are indications that Se might play a role in preventing 
cardiovascular (Flores-Mateo et al 2006) and muscle diseases (Chariot and Bignani
2003) and could delay the progression of AIDS in HIV positive patients (Hurwitz et 
al. 2007). Additional roles for Se have also been found in immune function 
(Spallholz et al. 1990; Broome et al. 2004) and sperm motility (Ursini et al. 1999) but 
it is in the prevention of cancer, especially prostate cancer (Clark et al. 1996), that Se 
has received the most attention.
1.2.3 Selenium and diet
Se is taken up from the soil by crops while livestock gets its Se from fodder. We 
obtain most of our Se through eating meat, poultry, cereals and fish (Reilly 2006). Se 
present in soil enters the food chain through plants that incorporate it by the sulphur
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pathway to give selenomethionine (in place of methionine) because of its resemblance 
to sulphur (Burk et al 1998). Animals cannot distinguish between methionine and 
selenomethionine and incorporate it within normal body proteins. Because of this 
process, concentrations of Se in humans are generally related to the concentration in 
soil and livestock. Table 1 gives an overview of the Se concentration in foods from 
different countries (Reilly 2006).
Table 1. Se concentrations in foods from different countries (pg/kg). Adapted 
from (Reilly 2006).
Food UK USA Australia Ireland Thailand
New
Zealand
Bread 43-92 282-366 92.6-125 15-158 - 31.6-59.4
Rice 4-13 75 25 10-17 29-65 0
Beef 30-76 134-190 72-121 61-105 72-226 22.3-83
Pork 140 144-450 94-205 82-129 142-250 19.3-150
Chicken 60-70 190-276 116-280 86-147 156-271 137-145
Eggs 90-120 225-308 190-414 56-282 145-420 157-161
Fish 200-500 126-502 20-632 268-298 196-1137 195-512
Milk 10-15 20-21 2.5-25.9 14-22 19-36 1.0-14
Cheese 7.4-12 13.9 70-78.9 9.5-11.5 - 23
Vegetables 3-22 2-19 0.5-32 10-38 1-127 0-2.5
Mushrooms 90 88 255 25-38 8-15 76.6
Peanuts 30 75 140 - 32-186 46-105
In the UK and in other countries of Europe, Se concentrations have fallen since the 
importation of Se-rich wheat from North America dropped dramatically. Other 
reasons for the decline of Se concentrations in Europe include increased use of 
sulphur fertilisers, breeding for higher grain yield per plant, lower atmospheric 
deposition of Se from coal combustion and the reported decline in cereal consumption 
are other important factors (Rayman 2008).
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This makes that the average intake of Se in these countries is below the daily intake 
for Se recommended by the Committee On Medical Aspects of Food policy (COMA 
1991): 75 p.g a day for men and 60 pg a day for women based on the concentration 
needed to optimise the plasma selenoprotein glutathione peroxidase 3 (GPx3).
1.2.4 Selenium metabolism in humans and animals
The metabolic pathway of Se when it enters the human body is shown in Figure 3.
Non-specific 
incorporation into 
proteins instead 
of methionine Inorganic
selenium
metabolism
Excretion
Urine
SeMet
(Plants) Selenate
Seleno-Sugar-B
Trans-selenation
Pathway
DIET Selenite
Seleno-Sugar-A
SeCys
(Animals) G SS eS G & 
GSSeH
y-glutamyl-CHjjSeCys 
(Garlic, Se-yeast) Degraded by (3-lyase Ser-tRNAUGAy-lyase
Selenoprotein
synthesis
Methylation by 
SAM H20;
Degraded by 
(3-lyase S e 0 2
Re-use in case of Se 
'deficiency
Excretion
Figure 3. Metabolic pathway of Se in the human body. Adapted from (Rayman 
2004). SeMet, selenomethionine; SeCys, selenocysteine; ITzSe, hydrogen selenide; y- 
glutamyl-CH3SeCys, gamma glutamyl-Se-methyl selenocysteine; CHsSeCys, Se- 
methylselenocysteine; CH3SeH, methylselenol; (C F^Se, dimethyl selenide; 
(CHs)3Se, trimethyl selenide; Se0 2 , selenium dioxide; HSeP0 3 2', selenophosphate; 
GSSeSG, selenodiglutathione; GSSeH, selenoglutathione.
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Non-specific incorporation of selenomethionine into proteins instead of methionine 
can act as a storage facility where it can be released by catabolism (Rayman 2004). 
Selenomethionine can be converted directly to methylselenol via y-lyase activity or it 
can go through the trans-selenation pathway to form hydrogen selenide. Inorganic 
selenocompounds such as selenite and selenate can also enter this metabolic process 
by binding to glutathione to form hydrogen selenide. Hydrogen selenide can be 
oxidised or methylated and excreted by the body or it can be used as a substrate for 
selenoprotein production. The major urinary excretion product is a selenosugar B 
(Suzuki et al. 2006). Plants from the Allium species and Se enriched supplements 
contain y-glutamyl selenocysteine that can be converted to &e-methylselenocysteine 
(MSeC). Degradation of MSeC by p-lyase produces methylselenol (CHsSeH) that can 
be further methylated by SAM to dimethylselenol and trimethylselenol and excreted 
in breath and urine respectively (Abdulah et al. 2005).
1.2.5 Recognized Se deficiency associated d iseases in humans
Keshan disease (named after the Keshan region of China) (Chen et al. 1980) is a 
potentially fatal form of cardiomyopathy and expresses itself by an enlarged heart 
together with poor heart function. In this condition, Se deficiency was found to be 
more a predisposing than a causal factor. Kashin-Beck disease is an example of 
endemic osteoarthritis and affects fingers, elbows and ankles (Figure 4). A 
combination of iodine and Se deficiency together with the ingestion of Fusarium 
sporotrichiella and exposure to fulvic water was suggested to be causally involved 
(Peng et al. 1992).
16
Chapter 1 - Introduction
Figure 4. 16-year old Tibetan adolescent with stage III Kashin-Beck disease. The
boy was 1.45 m and smaller than other Tibetans of his age. His hands and joints of the 
lower limbs were affected (Moreno-Reyes et al. 2003).
1.2.6 Effects of marginal selenium deficiency
Oxidative stress and inflammation
Patients suffering from pancreatitis (McCloy 1998), rheumatoid arthritis (Peretz et al. 
2001) and asthma (Shaheen et al. 2001) may see some benefit with Se 
supplementation or higher Se status. Other studies however did not observe an 
inverse correlation between plasma Se and asthma (Shaheen et al. 2007) and 
pancreatitis (Virlos et al. 2003). In fact, Selenoprotein T was shown to be 15-fold 
more highly expressed in intraductal papillary mucinous neoplasms of the pancreas 
compared with normal pancreatic ductal epithelium (Sato et al. 2004). These results 
warrant further studies to elucidate the true role of Se in oxidative stress and 
inflammation.
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Anti-viral and immune system effects
The coxsackie virus has been implicated in the aetiology of Keshan disease and 
selenium can prevent it from becoming virulent by the expression of glutathione 
peroxidase 1 (GPxl), which can protect the viral RNA genome from mutations (Beck 
et al. 1998). Although Se supplementation has been shown to decrease the viral 
burden of HIV and improve CD4 count (Hurwitz et al. 2007), in the early stages of 
infection, Se might actually facilitate the entry of HIV into cells by preventing 
apoptosis (Moghadaszadeh and Beggs 2006). Suboptimal levels of Se have been 
associated with poor T-cell counts, impaired lymphocyte proliferation and 
responsiveness (Alissa et al 2003). In AIDS patients, T-cell loss or stage of HIV 
infection (Brown and Arthur 2001) correlated with decreased Se concentrations.
On the other hand, the acute phase response seems to be able to decrease Se 
concentrations in two ways; firstly, Se can be incorporated into albumin, which is a 
negative acute phase response (Drain et al. 2006); secondly, pro-inflammatory 
cytokines have been shown to be able to decrease expression levels of a specific 
protein, selenoprotein P or SEPP1 (Dreher et al. 1997; Mostert et al. 1999; Hesse- 
Bahr et al. 2000). This protein also contains Se and together with albumin could 
account for the decrease of Se concentrations in plasma during acute phase response.
Male and female reproduction
Low serum Se has also been associated with low birth weight (Bogden et al. 2006), 
increased risk of miscarriages (Barrington et al. 1996), decreased sperm quality and 
sperm count (Beckett and Arthur 2005) and greater risk of pre-eclampsia (Rayman et 
al. 2003).
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Protection o f the thyroid
GPxl, GPx3 and Txnrdl are up-regulated during thyroid hormone synthesis and 
protect the thyrocytes from peroxidative damage (Beckett and Arthur 2005).
Anti-cancer
Although other confounding issues most probably play a part as well such as mal­
nutrition and exposure to environmental carcinogens, communities in specific parts of 
China, New Zealand, Finland and the Balkan area have serious Se deficiencies, which 
correlate well with an increased risk of cancer incidence and mortality (Maksimovic 
et al. 1998).
1.2.7 Selenium and human cancer
The analysis of the Nutritional Prevention of Cancer (NPC) trial data where 1312 
American subjects were supplemented daily with 200 pg Se-enriched yeast or a 
placebo, revealed a decrease in several secondary endpoints: 37% for total cancer 
incidence, a 50% decrease in total cancer mortality and a 63%, 46% and 58% in 
prostate, lung and colorectal cancer respectively (Clark et al 1996). Se 
supplementation was shown to decrease liver cancer incidence in a healthy population 
(Yu et al 1991) and in hepatitis B surface antigen-positive patients (Yu et al. 1997). 
Serum Se measured in plasma taken at the time of colonoscopy was inversely 
correlated with later development of colorectal adenoma (Jacobs et al. 2004; 
Connelly-Frost et al. 2006) although this was limited to smokers in one study (Peters 
et al. 2006). Dietary selenium intake was inversely associated with oesophageal 
squamous cell carcinoma (OR 0.31, 95% Cl, 0.13-0.70) (Cai et al. 2006).
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1.2.8 Prostate cancer
Prostate cancer is the most frequent noncutaneous cancer in males and known risk 
factors are age, race and a positive family history (Abate-Shen and Shen 2000). 
Several genetic loci have been linked to the hereditary predisposition to prostate 
cancer but they all account for a relatively small portion of cases (Schaid 2004). For 
some time, dietary factors have been implicated in cancer risk but the strongest 
evidence for an advantageous effect of Se on cancer, specifically prostate cancer 
incidence, comes from the NPC trial in, which prostate cancer incidence was reduced 
by 52% after a mean follow-up period of 7.5 years (Duffield-Lillico et al. 2003). 
Although prostate cancer incidence was defined as a secondary endpoint only after the 
trial had started, it is still the only intervention trial with Se, which actually had 
prostate cancer as an endpoint.
A number of prospective studies including nested case-control studies have also 
looked at the association between prostate cancer and Se. From these, 4 out of 9 have 
found a decreased risk for prostate cancer with higher selenium concentrations (Table 
2). The confidence interval given in Table 2 is an interval estimate to indicate the 
reliability of the risk of prostate cancer for the study population.
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Table 2. Summary of prospective studies investigating the relationship between 
prostate cancer and Se.
Reference
Source of 
Se sample
Incidence
ratio
95% C.I. Comparison
(Knekt et al 1990) serum RR 1.15 - Highest vs. lowest quintile
(Yoshizawa et al 
1998)
toenails OR 0.35 0.16-0.78 Highest vs. lowest quintile
(Nomura et al 2000) serum OR 0.50 0.3-0.9 Highest vs. lowest quartile
(Helzlsouer et al 
2000)
toenails OR 0.58 0.29-1.18 Highest vs. lowest quintile
(Brooks et al 2001) plasma OR 0.24 0.08-0.77 Highest vs. lowest quartile
(Goodman et al 2001) serum OR 1.02 0.7-1.6 Highest vs. lowest quartile
(van den Brandt et al 
2003)
toenails IR 0.69 0.48-0.99 Highest vs. lowest quintile
(Li et al 2004) plasma OR 0.78 0.54-1.13 Highest vs. lowest quintile
(Peters et al 2006) serum RR0.84 0.62-1.14 Highest vs. lowest quartile
A meta-analysis conducted by Etminan and colleagues (Etminan et al 2005) of 11 
cohort studies and 5 case-control studies investigating the effect of Se on prostate 
cancer showed that the relative risk for prostate cancer with any intake of selenium 
was 0.72 (95% C.I. 0.61-0.84) for cohort studies and 0.74 (95% C.I. 0.61-1.39) for 
case-control studies. The pooled relative risk of moderate intake was 0.74 (95% C.I.
0.61-0.90) for cohort studies and 0.74 (95% C.I. 0.39-1.39) for case-control studies 
(Etminan et al 2005).
A recent nested-case control study (Peters et al 2007) showed that Se was not 
associated with prostate cancer risk unless the men had a high vitamin E intake (OR =
0.58, 95% C.I. 0.37-0.91) or were multivitamin users (OR = 0.61, C.I. 95% 0.36-
1.04). Smokers with a higher Se concentration had a reduced prostate cancer risk
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with an OR = 0.65 (95% C.I. 0.44-0.97) for the highest compared to the lowest 
quartile of Se concentrations (Peters et al 2007). This is in contrast with a study 
where heavy multivitamin users had an increased risk of advanced and fatal prostate 
cancers (RR = 1.32, 95% Cl = 1.04 to 1.67 and RR = 1.98, 95% Cl = 1.07 to 3.66, 
respectively) (Lawson et al 2007). In this study, other associations were found with a 
family history of prostate cancer or in those who took individual supplements, 
including Se, (3-carotene, or zinc. Heavy multivitamin users who took extra Se 
increased their risk for localized prostate cancer by 37% and had a 5.8-fold increased 
risk of fatal prostate cancer (Lawson et al 2007). The self-reported use of vitamins is 
one fair criticism of this paper but it might also be that people who take single 
supplements could for example already be symptomatic, which might confound the 
association.
In another prospective study vitamin E (>400 IU/day vs. no use) intake was not 
associated with overall prostate cancer risk but only with advanced prostate cancer 
risk (HR 0.43, 95% C.I. 0.19-1.00). Se did not influence prostate cancer risk at any 
stage (Peters et al 2007).
When Se concentrations in serum were measured in a large (13,887 individuals) US 
population, participants who had Se concentrations in the top two tertiles had a lower 
risk for all-cause and cancer mortality (0.83 and 0.69 for the top tertile respectively) 
(Bleys et al 2008). This relationship was not linear however and hazard ratios 
increased for all-cause mortality, all-cancer and lung cancer mortality when 
concentrations rose above 150 ng/mL (1.5 jug/L). This was in contrast with prostate
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and colorectal cancer risk, which kept decreasing with increasing Se concentrations 
(Figure 5).
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Figure 5. Hazard ratios for all-cancer and colorectal, lung and prostate cancer 
mortality by serum Se concentrations. The red dotted line represents the cut-off 
value from which hazard ratios increased for all-cause mortality, all-cancer and lung 
cancer mortality. Figure adapted from (Bleys et al. 2008).
Importantly, from all subgroups, only smoking (P=.001) and age (P=.02) had a 
significant interaction with all-cause mortality and cancer mortality respectively, with 
smokers and younger people benefiting most from a higher Se concentration.
According to Burk and colleagues (Burk et al. 2006) SEPP1 expression levels are 
already optimised at Se concentrations of approximately 120 ng/mL, which is the 
level where the curve in Figure 5 starts to plateau off. After this plateau one might 
expect Se to be metabolised into small molecular weight selenocompounds such as 
methylselenol, which might explain a further decrease in risk. Why colorectal and 
prostate cancer but not lung cancer has a further decrease in risk remains an 
unanswered question.
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1.2.9 Evidence of anti-carcinogenic activity attributed to 
selenocom pounds in vitro
Several anti-carcinogenic mechanisms of selenocompounds have been proposed 
(Davis et al. 2000; Gopalakrishna and Gundimeda 2002; Davis and Uthus 2003; 
Rayman 2005; Zhao et al. 2006):
1. Protection against oxidative damage to DNA by maintaining GPx activity 
levels.
2. Enhanced removal of carcinogenic intermediate metabolites or chemical 
carcinogens.
3. Immune system stimulation
4. Regulation of cell cycle and apoptosis
5. Inhibition of angiogenesis
6. Regulation of the redox state of the cell thereby altering activity of 
transcription factors, cell cycle regulatory proteins, signal transduction 
molecules and cell apoptosis.
7. ER stress response activator
8. Inactivation of protein kinase C
9. Alteration in DNA methylation
10. Induction of phase II conjugating enzymes
11. Increase in tumour-suppressor p53
Selenite administered in high concentrations induces oxidative stress (Figure 6) with 
which healthy cells can cope better (Bandura et al 2005; Husbeck et al. 2006; 
Husbeck et al. 2006) demonstrating an important property of Se i.e. that it affects 
cancer cells more than normal cells (Menter et al. 2000; Husbeck et al. 2005).
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Figure 6. Redox cycling of selenocompounds generating superoxide and 
hydrogen peroxide after (Chaudiere et al. 1992).
Sodium selenite is in general the preferred Se supplement for in vitro work as it dose- 
and time-dependently inhibits cell proliferation and induces cell death (S phase 
growth arrest) more effectively than selenomethionine (Redman et al 1998; Menter et 
al. 2000). It can induce single strand breaks with a concentration of 5-10 pM causing 
necrosis and acute cell lysis while a concentration of 10-50 pM of methylated Se 
compounds is needed to induce apoptosis (Letavayova et al 2006). However, 
selenomethionine induces G2-M cell cycle phase arrest (Menter et al 2000; Husbeck 
et al 2006) together with higher Poly (ADP-ribose) polymerase (PARP) expression 
and cleavage (Redman et al 1998; Menter et al 2000) indicating caspase activated 
apoptosis.
Se-methylselenocysteine (MSeC) does not use the trans-selenation pathway to 
produce monomethylated species as selenomethionine does but is instead degraded by 
a p-lyase (Figure 3). It is more efficient than sodium selenite in inducing apoptosis 
and less toxic making it a better candidate for use in human chemoprevention (Kim et 
al 2001).
25
Chapter 1 - Introduction
Methylseleninic acid (MSeA) is a synthetic selenocompound resembling MSeC but 
without an amino acid moiety. It was developed for in vitro use as a precursor of 
MSeC (Ip et al 2000). The fact that it directly reacts with reduced glutathione 
intracellularly to form methylselenol has been associated with its highly effective 
activity (higher than selenomethionine, sodium selenite and MSeC) in reducing cell 
growth and inducing apoptosis (Ip and Ganther 1990; Ip et al 1991; Ip et al 2000).
When all four compounds (MSeA, MSeC, selenomethionine and sodium selenite) 
were compared for their tumour inhibitory efficacy in two human prostate cancer 
xenograft models (DU 145 and PC-3), MSeA demonstrated the greatest tumour 
suppressor activity over selenomethionine and sodium selenite. MSeC together with 
MSeA also exerted a dose-dependent effect on the DU145 but not on the PC-3 model 
(Li et al 2008).
The effect Se compounds have on cancer cells depends on whether they enter the 
hydrogen selenide pool before being methylated to methylselenol or whether they 
generate the methyl Se compound (methylselenol) without first being metabolised to 
hydrogen selenide. G1 arrest and caspase-mediated apoptosis seem to be unique to 
compounds that directly generate methyl selenol (Kaeck et al 1997; Jiang et al 2001; 
Wang et al 2001; Wang et al 2002) while S/G2-M phase arrest and single strand 
breakages are characteristic of the necrosis processes with compounds that must first 
be converted to hydrogen selenide (Lu et al 1996; Kaeck et al 1997; Jiang et al 
2001; Kim et al 2001; Husbeck et al 2006). MSeA and methylselenol generally 
seem to exert the same effects on cancer cells although some inconsistencies have 
been found e.g. firstly, both Tissue Inhibitor of Metalloproteinase 1 and 2 (TIMP-1
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and 2) are inhibited by methylselenol but not by MSeA (Park et al 2006; Zeng et al
2006). Secondly, lower concentrations of compounds that can directly convert to 
methylselenol are needed thereby decreasing the risk of toxicity significantly.
1.2.10 Selenoprotein synthesis in eukaryotes 
Introduction
Selenoproteins are produced through the specific incorporation of Se as 
selenocysteine into proteins via the TGA codon, which led to the designation of 
selenocysteine as the 21st amino acid. Selenocysteine (Sec) has a similar structure to 
cysteine with a Se atom taking the place of a sulphur atom; Se is exceptional in being 
the only trace element having a codon coding for its incorporation into a polypeptide. 
TGA also codes for termination of translation and a complex of proteins ensures the 
incorporation of Se when appropriate. The incorporation of selenocysteine into a 
protein requires a set of cis and trans-acting factors and the process starts with the 
production of the selenocysteyl-tRNA[Ser| Sec.
Selenocysteine incorporation complex
Elemental Se produced by selenocysteine lyase is converted to selenide with 
monoselenophosphate as a product. This selenophosphate serves as a substrate for the 
modification of seryl-tRNA [ser] sec into selenocysteyl-tRNA [Serl Sec. The tRNA 
contains the anticodon UCA for the selenocysteine codon UGA and is responsible for 
the incorporation of selenocysteine in the protein (Figure 7).
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Figure 7. Bovine liver tRNASec nucleotide sequence. Taken from (Stadtman 1996).
The mRNA synthesized from a selenoprotein gene has a secondary structure called 
selenocysteine insertion sequence (SECIS) element, which is located somewhere 
between 1 and 4.5 kb downstream of the UGA codon in the 3' untranslated region.
that it can incorporate the selenocysteine into the protein sequence. Several other cis-
(SecisBP2) is responsible for bringing the whole complex of elongation factor, tRNA 
and selenoprotein mRNA together and it competes with ribosomal protein L30 to bind 
to the SECIS element.
Selenoprotein expression under low Se conditions is dictated through a hierarchy, 
which might depend on the binding affinity of SecisBP2 with SECIS elements of 
selenoproteins (Low et al. 2000). The elongation factor, termed EFsec or mSELB is 
specific for sec-tRNA[Ser]Sec and binds to the SecisBP2 holding the tRNA in place for 
the decoding and incorporation of selenocysteine into the growing selenoprotein
This structure holds the selenocysteyl-tRNA[Ser]Sec close to the ribosome complex so
and trans-acting factors are involved in this process. The Secis Binding Protein 2
(Figure 8).
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Figure 8. Selenoprotein synthesis. Taken from (Kohrle et al. 2005).
1.2.11 Individual selenoproteins
The biological roles of most selenoproteins are still under investigation although some 
are fairly well understood. The iodothyronine deiodinases are responsible for the 
production of active thyroid hormones (Kohrle et al 2005) and thioredoxin reductases 
are involved in the control of the cell-redox status (Rayman 2002). Phospholipid 
glutathione peroxidase (GPx4) acts as an antioxidant enzyme to protect developing 
sperm cells and serves as a structural protein in the mitochondrial capsule of mature 
sperm (Ursini et al. 1999). An overview of the currently know human selenoproteins 
is given in Figure 9.
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Figure 9. Karyotype with human selenoproteins indicated.
Glutathione peroxidase (GPx)
Humans have five different selenoprotein glutathione peroxidases, GPx 1-4 and 6, 
which differ in their localization and substrate specificity. The substrate for GPx is 
hydrogen peroxide (H2 O2 ) or an organic hydroperoxide, which GPx converts into 
water or alcohol while oxidising glutathione (Valko et al. 2006). By reducing these 
peroxides, it protects cells from oxidative damage.
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R00H(H20 2) +2GSH — — — ► R0H(H20) + H20  + GSSG 
Reaction 1. Reduction of peroxides by glutathione peroxidases.
Iodothyronine Deiodinases (DIO)
Three types of deiodinases are currently known, which differ in their tissue 
distribution and function although they are all catalysts for the activation or 
inactivation of the thyroid hormones (Kohrle et al. 2005).
Thioredoxin Reductases (TxnrD)
TrxRl and TrxR2 are ubiquitously expressed in mammalian tissues but are 
predominantly located in the cytoplasm and mitochondria respectively. Testes- 
specific glutathione reductase (TGR) is mainly present in the testes (Brigelius-Flohe 
and Banning 2006). They catalyse the NADPH-dependent reduction of oxidized 
thioredoxin, which is a central factor in cellular redox regulation of transcription 
factors.
Selenophosphate Synthetase 2 (SPS2)
SPS2 catalyses the reaction of selenide with AMP to produce selenophosphate, which 
can then be used as a Se donor for the biosynthesis of selenocysteine (Behne and 
Kyriakopoulos 2001).
Selenoprotein P (SEPP1)
SEPP1 constitutes over 70% of Se in plasma and has been widely recognized as a Se 
transporter protein although recently it has also been shown to protect the
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extracellular fluid by reducing lipid hydroperoxides (Saito et al. 1999). It is the only 
selenoprotein, which contains 10 selenocysteine residues with the first selenocysteine 
as the active redox site while the remaining nine residues function as a Se supplier 
(Saito et al. 2004). SEPP1 is mainly expressed in the liver but is also expressed in 
lower amounts in other tissues.
Selenoprotein 15 kDa (SEP15)
The biological function of SEP 15 is still unknown but it has been located in the 
cytoplasm complexed to UDP-glucose:glycoprotein glucosyltransferase (UGTR) 
where UGTR is known to play a role in the quality-control of protein folding 
(Korotkov et al. 2001).
Selenoprotein N  (SEPN1)
Selenoprotein N is a membrane glycoprotein, which localizes in the endoplasmatic 
reticulum (Allamand et al. 2006) and was the first selenoprotein shown to be 
responsible for a genetic disorder associated with muscle formation (Moghadaszadeh 
et al. 2001; Petit et al. 2003).
Methionine sulfoxide reductase (MsrBl)
Methionine sulfoxide reductase or SELR (also known as SelX) was the first 
selenoprotein identified using bioinformatics methods. MsrB2 and MsrB3 contain 
cysteine and not selenocysteine and are thus not selenoproteins. The function of 
MsrBl is to reduce oxidised methionine sulfoxide residues back to methionine in the 
presence of thioredoxin or dithiothreitol. This process protects the cell from oxidative 
stress and can regulate protein function (Levine et al. 2000).
32
Chapter 1 - Introduction
Selenoprotein S (SELS)
SELS plays an important regulatory role in the production of inflammatory cytokines 
and its expression is induced by endoplasmatic reticulum stress (Gao et al. 2006; Kim 
et al. 2007) and after stimulation with proinflammatory cytokines (Seiderer et al. 
2007). A SNP located in the promoter region of SELS (A105G) has been associated 
with TNF-alpha and IL-1 beta levels and the A allele is a risk factor for pre-eclampsia 
(Moses et al. 2008). Martinez and colleagues, however, did not find any association 
of 6 SNPs located throughout SELS with autoimmune inflammatory disease 
(Martinez et al. 2008).
Other selenoproteins
Other human selenoproteins, the biological functions of which remain unknown up to 
this point, may have a role in redox reactions. SELT is a transmembrane protein 
localised to the ER regulates Ca2+ homeostasis in differentiating neuroendocrine cells 
(Anouar et al. 2006). SEPW1 has been shown to exert an antioxidative function 
during myoblast growth and differentiation (Loflin et al. 2006).
1.2.11 Selenoproteins and cancer
A number of papers have implicated selenoproteins in cancer, (i) Irons and colleagues 
developed a mouse model where the tRNA specific for selenocysteine was knocked 
out, resulting in an overall selenoprotein knock-out. Using this model they showed 
that sec-tRNA[SerlSec knock-out (KO) mice had more azoxymethane-induced aberrant 
crypt formation in the colon and that Se supplementation decreased the number of 
aberrant crypts in both KO and wild type mice (Irons et al. 2006). (ii) Glutathione 
peroxidases are responsible for the reduction of lipid hydroperoxides and hydrogen
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peroxide undergo loss of heterozygosity (LOH) in lung tumours (Moscow et al. 1994) 
and have subsequently lowered expression (Hardie et al 2000); (iii) SNPs in GPxl (a 
cytosolic GPx) and SEP 15 have been associated with lung cancer risk (Gresner et al.
2007). (iv) SEPP1 deficiency, a plasma Se transporter protein with redox capabilities, 
increased cancer formation in APC KO mice (Schomburg 2006).
A number of selenoproteins have been shown to be downregulated in cancer:
1. GPx2 is downregulated in prostate cancer although the reason for the decrease 
has not yet been elucidated (Rebsch et al. 2006);
2. GPx3 is downregulated by hypermethylation in prostate cancer cell lines, 
primary prostate tissue (Lodygin et al. 2005) and Barrett’s oesophagus (Lee et 
al. 2005);
3. SEP 15 is downregulated in prostate cancer and hepatocarcinoma cell lines 
(Kumaraswamy et al. 2000);
4. SEPP1 is downregulated in prostate cancer cell lines and tissue (Calvo et al. 
2002);
5. Selenoprotein H (SELH), a newly discovered thioredoxin-like protein, is over­
expressed in human prostate cancer (LnCAP) and mouse lung cancer (LCC1) 
cells (Novoselov et al. 2007).
6. Up-regulation of GPxl by 5-azacytidine suggests it might be aberrantly 
methylated in lung cancer (Shames et al. 2006).
In cancer cells, gene-specific expression can be affected in a number of ways: tumour- 
specific mutations can positively or negatively affect the function of the protein; 
genes can be deleted resulting in loss of heterozygosity or amplified resulting in
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overexpression; or genes can be silenced by hypermethylation of their promoter 
region. It is the last mechanism of specific interest because of its involvement in 
selenoprotein gene expression silencing and its promising role in cancer aetiology.
1.3 Epigenetics
1.3.1 Introduction
Epigenetics can be defined as the mechanisms of heritable gene imprinting without 
changing the actual DNA sequence. It literally means “on top o f’ or “in addition to” 
genetics and takes the form of chromatin and DNA modifications, which affect gene 
expression (D'Alessio and Szyf 2006). The key processes include DNA methylation 
and histone acetylation and methylation. Other known histone modification processes 
such as phosphorylation, ubiquitinylation and sumoylation have not been associated 
with DNA methylation and will therefore not be discussed in this chapter.
DNA methylation by DNA methyltransferases (DNMTs) involves the covalent 
addition of a methyl group from the methyl donor SAM to the 5 carbon of a cytosine 
residue. Methylated cytosines are primarily found next to guanine bases forming so 
called CpG dinucleotides. CpGs are underrepresented in the global gene body but 
they are concentrated in promoter regions in about half of all genes of the human 
genome. When the frequency of these CpGs exceeds the expected number of 0.6 and 
(G+C)-content of 55% for a minimum of 500 bases they can be defined as ‘CpG 
islands’ (Takai and Jones 2002). About 80% of the CpGs in the bulk of the genome 
are methylated while CpG islands in promoter and 5' regions are normally 
unmethylated.
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Changes in CpG DNA methylation have been associated with ageing, cancer 
development and vascular disease (Herrmann 2005). Hypermethylation and 
hypomethylation are two processes that are commonly seen in cancer-related genes 
(Figure 10). Hypermethylation results in chromatin condensation resembling 
heterochromatin together with silencing of tumour suppresser and other genes while 
hypomethylation can increase or activate the expression of oncogenes and result in 
destabilization of the DNA sequence. This destabilization can take the form of 
aneuploidy, transposon relocation and gene amplifications i.e. processes commonly 
encountered in cancer cells (Baylin and Ohm 2006).
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Figure 10. Representation of aberrant DNA methylation and consequences for 
mRNA transcription. In a normal cell CpGs located within the regulatory region of a 
gene are unmethylated (white circles) while the CpGs in the remainder of the gene 
and intergenic regions are normally methylated (black circles). When the promoter 
region is unmethylated the transcription factors can bind to the DNA sequence and 
start the process of transcription. In cancer cells the CpGs in the promoter region can 
become hypermethylated by de novo methyltransferases. These attract Methyl- 
Binding Proteins that can block the transcription machinery of binding to the DNA 
sequence. The final result is the prevention of mRNA transcription. The CpGs in the 
gene body can become hypomethylated and cause genome instability.
1.3.2 Normal function of methylation
DNA methylation plays a key role in several biological processes. Knocking out 
DNMT1, a maintenance methyltransferase with an affinity for hemi-methylated DNA, 
is embryonically lethal in mice and suggests a vital role for DNA methylation in 
mammalian development (Lei et al. 1996). The expression of genes on the inactive X 
chromosome in females is repressed by DNA methylation imprinting and the same 
mechanism suppresses the expression of propagating repetitive elements such as Short 
Interspersed Nuclear Elements (SINEs) and Long Interspersed Nuclear Elements
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(LINEs). CpG islands in promoter regions on the other hand are in general 
unmethylated with the exception of tissue- and germline specific expressed genes and 
parental imprinted genes.
1.3.3 Hypermethylation
The classic two-hit model of Knudson describes the inactivation of a tumour 
suppressor in cancer by a mutation in one of the alleles (first hit) and the subsequent 
inactivation of the second allele by a deletion event (second hit) (Knudson 1971). 
The second event may be replaced by DNA hypermethylation of the promoter of the 
non-mutated allele resulting in gene silencing of both alleles. The inactivation of a 
tumour suppressor by mutations in both alleles is a rare event in contrast to DNA 
methylation silencing, which in contrast occurs frequently on both alleles (Chen and 
Baylin 2005). DNA hypermethylation in a 3' CpG island instead of the 5' CpG 
island of genes has been associated with an increase in mRNA expression in 
colorectal cancer tissues indicating that hypermethylation can have a uni-directional 
effect (Smith et al. 2007).
1.3.4 Repressor complex
Methylated CpG islands are mostly bound by methyl-CpG binding proteins (MBD: 
MeCP2, KAISO, MBD1, MBD2, MBD3, and MBD4) and repress transcription 
through the recruitment of histone deacetylases (HDAC). Methyl-CpG binding 
proteins form a complex with HDACs and directly inhibit transcription factors 
binding to the promoter (Fuks et al. 2003). HDACs remove acetyl groups from 
histone tails thereby increasing the ability of the histones to bind the DNA (chromatin
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condensation) and inhibit transcription. DNMTs are also able to recruit HDACs and 
both methyl-binding proteins and DNMTs can recruit histone methyltransferases, 
which catalyze a reaction whereby one to three methyl groups are transferred to lysine 
or arginine residues of histones resulting in tighter binding of the histones to the DNA 
and preventing transcription. A certain histone code has been observed to correlate 
with promoter hypermethylation in cancer cells and consists of deacetylation of 
histones H3 and H4, loss of histone H3K4 trimethylation, hypermethylation of H3K9 
and H3K27 (Fahmer et al 2002; Esteller 2007). This histone code of histone 
acetylation and dimethylation of five residues in histones H3 and H4 can be used to 
predict clinical outcome in prostate cancer patients (Seligson et al 2005). CpG 
islands are also hot-spots for mutations as methylated cytosines are mutagenic and 
undergo deamination to cause C>T transitions. This process has been held 
responsible for over 50% of all inactivating point mutations in the coding region of 
TP53 (Rideout et al 1990).
The list of hypermethylated genes in cancer is growing on a daily basis and becomes 
more complex as an increasing number of subtypes of cancer are being analysed. 
Genes affected by hypermethylation belong to a number of pathways including cell 
adhesion, DNA repair, immune response and cell cycle (Esteller et al 2002).
1.3.5 Restoring gene expression with demethylation
The reactivation of hypermethylated tumour suppressors by DNA demethylation in in 
vitro and in vivo (Herman et al 1998; Al-Romaih et al 2007) models can restore the 
function of the demethylated gene and with it its anti-tumourigenic property. 
Common demethylating agents such as azacytidine and decitabine can restore gene
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expression of hypermethylated genes by inhibiting DNA methyltransferases. 
Decitabine is a deoxy derivative of 5-azacytydine, a drug approved by the FDA in 
2004 for the treatment of all subtypes of myelodisplastic syndrome (Kaminskas et al 
2005). In three clinical trials treatment with 5-azacytydine had an overall response 
rate (normalisation of blood cell count and bone morphology) of 16%. HD AC 
inhibitors have been used in in vitro studies as well but only after cells were treated 
with a demethylating agent. The reason for this is that Trichostatin A (TSA; a 
common HD AC inhibitor) often does not result in the return of H3K9 acetylation 
(Cameron et al 1999; Lodygin et al 2005), which is associated with gene expression. 
Only after cells were treated with azacytidine did acetylation return (Cameron et al 
1999) suggesting that DNA methylation plays a greater role in suppressing gene 
expression than histone acetylation.
1.3.6 DNA Methylation analysis of prostate cancer as a diagnostic, 
prognostic and therapeutic tool
Diagnosis
Since 1992 PSA has been used as a serum tumour marker although there are several 
limitations to its use. Its poor specificity means that up to two-thirds of men with a 
PSA over 4 ng/ml have normal histology while one-third of the men with prostate 
cancer and prostate-specific antigen (PSA) levels below 4 ng/ml would not be 
identified by the PSA test. On top of this, biopsies could also miss tumour sites and 
give a false negative result (Perry et al 2006). These limitations make clear the need 
for a better and more specific screening test for prostate cancer. Methylation pattern 
analysis could provide a method that can help with the diagnosis, prognosis and 
therapeutics of prostate cancer. Data on the methylation patterns of genes in prostate
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cancer varies as different CpG sites and techniques can be used to measure 
methylation status. A review by Bastian and colleagues (Bastian et al. 2004) 
summarized the literature published on hypermethylated genes in renal, bladder and 
prostate cancer and they suggest that a specific methylprofile can be obtained for each 
type of cancer. A search on PubMeth in June 2008 (Ongenaert et al. 2008), a cancer 
methylation database based on published literature, revealed 80 genes to be 
hypermethylated in prostate cancer (Table 3).
Table 3. PubMeth list of hypermethylated genes in prostate cancer.
Hypermethylated genes in prostate cancer
ABCB1 DKK3 LOC728412 RBMY1A1
APC DLC1 MGMT RBMY1H
AR EDNRB MME RBP1
BCL2 ESR1 MT1G RUNX3
CAV1 ESR2 NAB2 S100A2
CCND2 FAS NEUROG1 S100A6
CD44 FHIT NKX3-1 SCGB3A1
CDC6 FOLH1 NULL SFN
CDH1 GPX3 PCQAP SFRP1
CDH13 GREM1 PDLIM4 SRY
CDKN1A GSTP1 PGR SVIL
CDKN1B HIC1 PRDM2 TGFBR2
CDKN1C HLTF PRIM A1 THBS1
CDKN2A HPGD PRY TIMP2
CTNNB1 HPP1 PTGS2 TIMP3
CVY IGFBP7 PYCARD TMEFF2
CYP1A1 INHA RARB TNFRSF10C
DAPK1 LAMA3 RARRES1 TNFRSF10D
DAZ1 LAMB3 RASSF1 TUSC3
DDB2 LAMC2 RBI WRN
41
Chapter 1 - Introduction
By increasing the number of markers, the specificity of the markers for a given cancer 
dramatically increases. Studies have revealed a set of genes that are repressed by 
hypermethylation in prostate cancer tumours and by using the methylation profiles 
were able to identify prostate cancer with high sensitivity and specificity using tumour 
tissue (Vanaja et al. 2006), urine (Hoque et al 2005), ejaculate (Suh et al 2000) and 
plasma samples (Chuang et al 2007).
Therapeutics
The identification of hypermethylated genes can be used in two types of therapeutics:
1. Discriminating between tumours that are responsive to certain chemo­
therapies.
2. Demethylation/reacetylation of hypermethylated tumour suppressors in cancer 
patients.
Azacytidine was the first drug to be approved by the FDA for the treatment of 
myelodysplastic syndromes (Baylin 2004)) and phase III clinical trials have shown a 
complete and partial response (15%) to the drug. The use of HD AC inhibitor agents 
proved beneficial for patients with response rates of 17-49% (Oki and Issa 2006). 
Other phase II and III trials are ongoing with new agents and a combination of 
demethylating and HD AC inhibitors.
The alkylation of the DNA base guanine at its 06 position by carcinogens such as 
nitrosamines (Abdulnur and Flurry 1976) has several implications from which its 
tendency to pair with thymine resulting in the point mutation G:C>A:T is a hallmark 
(Snow and Mitra 1988). This lesion can be repaired by 06-methylguanine-DNA
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methyltransferase (MGMT) and the number of MGMT molecules is directly 
correlated with its protective effect (Jacinto and Esteller 2007). Because 
hypermethylation of the MGMT promoter occurs in a sub set of tumours making them 
sensitive to alkylating chemotherapeutic drugs a test was developed to screen for 
MGMT hypermethylation. It is therefore likely that other genes can be used for the 
same type of therapeutic screening as MGMT.
Prognosis
Gleason grade, tumour stage and PSA value can correlate with hypermethylation of a 
number of specific genes suggesting that methylation status of DNA obtained from 
prostate cancer tissue biopsies can be used to predict the outcome of the cancer 
(Bastian et al. 2004; Enokida et al. 2005; Ellinger et al. 2008). A general consensus 
is that sensitivity and specificity is increased when multiple markers are investigated 
in combination.
1.3.7 Methylation patterns of selenoprotein genes
GPx3
Recently GPx3 was shown to be hypermethylated in LnCAP (lymph node metastasis) 
and PC-3 (bone metastasis) prostate cancer cell lines and in 93% of primary prostate 
cancer tumours (Lodygin et al. 2005). Yu (Yu et al. 2007) not only confirmed the 
hypermethylated state of the GPx3 promoter in prostate cancer tissues (90% of all 
cases) but also stated that the inactivation of GPx3 in prostate cancer correlated with 
poor clinical outcome. Deletions of GPx3 occurred in 39% of samples and 
overexpression of GPx3 reduced colony formation and independent-anchorage growth 
of the prostate cancer cell lines. A reduction in mortality and tumour volume was
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observed when GPx3 was expressed in PC-3 xenograft mice suggesting a tumour 
suppressor role for the antioxidant enzyme (Yu et al. 2007).
GPx3 was also shown to be hypermethylated in 62% of Barrett’s metaplasia, 82% of 
dysplasia and in 88% Barrett’s adenoma samples (Lee et al 2005). GPx3 mRNA was 
reduced in 91% of Barrett’s adenocarcinomas (BA). Monoallelic methylation was 
associated with partial loss of GPx3 expression in metaplasia while biallelic 
methylation and severe loss of GPx3 expression was seen in all BA samples. The 
authors suggested that the epigenetic inactivation of GPx3 indicates that the 
regulation of glutathione might be critical in the development and progression of 
Barrett’s oesophagus (Lee et al 2005).
MsrBl
Methionine sulfoxide reductase 1, MsrBl, is highly expressed in the weakly 
metastatic breast carcinoma cell line MCF7 but poorly expressed in the high 
metastatic cell line MDA-MB231. The promoter of this selenoprotein is regulated by 
epigenetic modification as evidenced by the upregulation of the gene transcript after 
treatment with 5-aza-2 '-deoxycytidine (5-AZA) (De Luca et al 2007). A CpG site 
within the Spl consensus site located 46 bp upstream of the transcription start site was 
found to be hypermethylated in the highly metastatic cell line suggesting a possible 
cause for the repression of transcription.
From the results of these four studies and the potential anti-carcinogenic role of 
selenoproteins we can hypothesise that other selenoproteins are likely targets for 
hypermethylation in cancerous tissues.
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1.3.8 Hypomethylation
Focal and global hypomethylation
Hypomethylation largely affects the intergenic and intronic regions of the genome and 
in particular repeat sequences and transposable elements. Long Terminal Repeats 
retrotranspo sons, LINEs and SINEs can all be demethylated and account for the 
majority of reduction in DNA methylation levels (Wilson et al 2007).
There are approximately 1.4 million (10% of the human genome) Alu repeats 
(sequences recognized by the action of the Alu restriction endonuclease) and half a 
million (18% of the human genome) LINE-1 sequences within the human genome 
that are normally heavily methylated (Cho et al. 2007). It is estimated that about a 
third of methylated cytosines are located in repetitive sequences, therefore 
methylation levels in LINEs and Alu elements can both be used as surrogate markers 
to measure global hypomethylation (Yang et al 2004). A 10-50% reduction in DNA 
methylation levels is frequently observed in cancer cells compared to normal tissue 
(Wilson et al 2007).
Besides global demethylation, regional hypomethylation or demethylation of 
individual genes are both possible and are responsible for the re-expression of 
epigenetically silenced genes. The aberrant expression of oncogenes [CMYC 
(Sharrard et al 1992)] [MAGE (Kim et al 2006)] and imprinted genes [IGF2 (Ito et 
al 2008)] can all be induced by hypomethylation of their respective promoters and 
lead to tumour growth support.
Genome-wide mapping of hypomethylated sites combined with gene expression data 
found a positive correlation between hypomethylated promoters and gene expression
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but an inverse correlation between hypomethylated intragenic and 3' UTR regions 
with gene expression (Shann et al 2008).
Cause of hypomethylation
The expression of DNA methyltransferase enzymes has not been directly linked with 
hypomethylation. They interact with a large number of proteins and a disruption in 
any of the pathways might be responsible for loss of global methylation levels. Other 
possible causes have been suggested such as transcription of antisense RNA (Wilson 
et al 2007), the repair of strand breaks that may result in the replacement of 
methylated cytosines with unmethylated cytosines (Suzuki et al 2006) or the 
dysregulation of the cell cycle whereby DNA methyltransferase activity is disturbed 
and out of sync with DNA replication (Hoffmann and Schulz 2005).
Consequences of DNA hypomethylation
A recent review by Wilson and colleagues (Wilson et al 2007) describes the effect of 
global hypomethylation on the genome and gives a good overview of the possible 
consequences of DNA hypomethylation. The transcription of repeat elements can be 
initiated by demethylation of the promoter leading to a product that could influence 
RNA transcription/translation, protein binding by competition or initiate the 
expression of oncogenes. Chromosomal aberrations caused by DNA demethylation 
of transposable elements has been well documented and can include insertional 
mutagenesis and recombination of the genome. Both events can lead to altered 
expression or disruption of gene sequences and recombination of demethylated simple 
tandem repeats can lead to karyotype abnormalities.
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DNA hypomethylation has been linked with immunodeficiency, centromeric region 
instability, and facial anomalies syndrome, which is the only disease linked to a 
mutation in a methyltransferase enzyme (DNMT3B, (Ehrlich et al 2008)). The 
disease is diagnosed by immunoglobulin deficiency, chromosomal rearrangements 
and facial anomalies. DNA hypomethylation at specific chromosomal locations is 
also a common event in facial anomalies syndrome and it has been proposed that it 
might be causing the dysregulation of genes in the lymphoblasts of patients by 
interfering with transcription factors, changing nuclear architecture, or the expression 
of noncoding RNAs (Ehrlich et al 2008).
Hypomethylation in prostate cancer
Hypomethylation in prostate cancer was first described by Bedford and van Helden in 
1987 (Bedford and van Helden 1987) where they observed a significantly lower level 
of DNA methylation measured by high performance liquid chromatography (HPLC) 
in prostates with benign prostatic hyperplasia and metastatic tumours compared to 
normal prostate. After this initial publication only six other research papers have been 
published on the subject of global hypomethylation in prostate cancer compared to the 
hundreds published on hypermethylated genes thereby proving the lack of 
interest/research within this specific area of epigenetics. Typing the words 
‘hypomethylation’ or ‘hypermethylation’ with ‘prostate cancer’ returns 40 or 227 
papers respectively in PubMed (http://www.ncbi.nlm.nih.gov/pubmed/; Accessed 
20/06/08), again demonstrating the low interest in the subject.
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In general all studies show a global decrease of methylation in prostate cancer versus 
normal tissue but some have compared different parameters within their study that are 
worth mentioning.
Three papers investigated the relationship between focal hypermethylation and global 
hypomethylation. All three papers agree that hypomethylation of LINE-1 is 
correlated with tumour stage and that hypermethylation and hypomethylation 
contribute towards cancer progression. LINE-1 [and Alu sequences as well according 
to Cho and colleagues (Cho et al. 2007)] methylation levels were found to be 
significantly lower in prostates with hypermethylated genes suggesting they are 
mechanistically linked. Florl and colleagues (Florl et al 2004) go further by stating 
that prostate cancer could fall into three classes: cancer with few DNA methylation 
changes, with frequent hypermethylation, or with additional LINE-1 
hypomethylation. This classification system resembles the CpG island methylator 
phenotype (CIMP) in colorectal cancer where a subset of cancers has a much larger 
number of hypermethylated genes (Toyota et al 1999).
A paper published by Schulz’ research group investigated the association between 
hypomethylation and chromosomal aberrations (Schulz et al 2002). They identified a 
specific region on the small arm of chromosome 8, which is subject to frequent gain 
or loss in prostate cancer. The aberrations seemed to correlate with DNA 
hypomethylation (LINE-1) suggesting there might be a direct relationship between 
them. This hypothesis was refuted by the same group in a later paper where new 
results pointed towards contributions to prostate cancer progression by both 
chromosomal aberrations and hypomethylation brought about by independent causes
48
Chapter 1 - Introduction
(Schulz et al 2007). Gene ontology (GO) analysis identified genes related to innate 
immunity, cytoskeletal organization and cell adhesion as targets of both types of 
alterations.
1.3.9 Selenium and DNA methylation
Because Se seems to have a role in one-carbon metabolism and global DNA 
methylation it is conceivable to think that it might influence gene-specific methylation 
levels too. Two papers have been published on the subject and show some very 
interesting results.
Davis and colleagues (Davis et al. 2000) reported that colorectal cancer Caco-2 cells 
showed promoter hypomethylation of the tumour suppressor p53 when grown in Se- 
free medium. On the other hand no change in methylation levels of the promoter 
region of p i6 was observed in the same circumstances suggesting that DNA 
hypomethylation induced by Se deficiency can be gene-specific.
Ramachandran and colleagues (Ramachandran et al. 2007) did not observe any 
change in promoter methylation levels of both glutathione S-transferase pi (GSTP1) 
and Ras association (RalGDS/AF-6) domain family member 1 (RASSF1A), two 
commonly hypermethylated genes in prostate cancer, when prostate cancer and 
cervical cancer cell lines were supplemented with 10 pM sodium selenite or 150 pM 
selenomethionine for 96 hours. Large and obvious differences (such as treatment 
versus no treatment, different genes and techniques used to measure DNA 
methylation) exist between the two studies, which point out the gap in knowledge 
within this specific area of Se research and the need for further investigation.
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In the same study (Davis et al 2000) but also in other follow-up studies (Davis and 
Uthus 2002; Uthus et al 2002; Davis and Uthus 2003) global DNA methylation levels 
were reduced when a colon cancer cell line and rats were subjected to Se-deficient 
conditions, again pointing towards a role for Se in DNA methylation reactions. 
Treatment of the cells with 5-AZA also resulted in significant DNA hypomethylation 
but no interactive effects were observed between 5-AZA and Se (Davis and Uthus 
2002). DNMT1 activity and protein expression levels were higher in cells cultured 
without Se, suggesting that Se can have an impact on DNA methylation without 
interfering with one-carbon metabolism. These results seem to contradict each other 
as DNMTl’s role is to methylate DNA but its increased expression is associated with 
global hypomethylation. Other research groups have obtained similar results (Cox 
1985; Cox and Goorha 1986; Fiala et al 1998) and a possible molecular explanation 
is provided by Slack and colleagues (Slack et al 1999). They showed that an AP-1 
regulatory site of DNMT1 is hypomethylated in a mouse adrenal carcinoma cell line 
that overexpresses DNMT1 compared to normal somatic tissues or a mouse 
embryonic cell line where the AP-1 site is hypermethylated (Slack et al 1999). This 
results in a larger amount of DNMT1 when AP-1 is hypomethylated caused by global 
hypomethylation. This however would not account for selenium’s anti-carcinogenic 
properties as DNMT1 is not a de novo but a maintenance methyltransferase 
methylating the hemi-methylated strand during cell division. Another hypothesis 
provided by Davis and colleagues states that selenite in its turn, which has been 
shown to be able to inhibit binding of AP-1 to DNA (Handel et al 1995), could 
inhibit AP-1 binding to the regulatory region of DNMT1 and prevent its expression 
(Davis and Uthus 2002).
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1.4 Summary of the literature review
One-carbon metabolism is a vital process in the human body but can become 
deregulated in disease resulting in excess concentrations of Hey and aberrant 
methylation patterns of the human genome.
The role of Se in one-carbon metabolism seems to differ between species and the 
exact nature of the influence it exerts on the pathway is still controversial. 
Highlighted in the literature review are studies that aimed to shed some light on the 
issue but a carefully controlled intervention trial with Se where besides Hey also 
folate, vitamins B12 and B6 are measured would help to clarify the interactions 
between the nutrients.
Se became a very hot topic in the field of cancer research after Larry Clark published 
his findings in 1996 on the NPC trial in which Se supplementation decreased prostate 
cancer risk with 63% (Clark et al. 1996). Its specific incorporation as the 21st amino 
acid, in the form of selenocysteine, proves it is an essential trace mineral with some 
very important roles within the human body. Published data implicates both 
selenoproteins and low molecular weight selenocompounds in cancer prevention but 
conclusive evidence by means of functional human assays and intervention trials is 
still scarce.
A number of SNPs located within or near selenoproteins have been associated with 
cancer risk but more convincing is the silencing of MsRBl and GPx3 through 
hypermethylation. Because of their role within the human body, it is very likely that 
other selenoprotein genes are silenced in cancer as well and that GPx3 and MsrBl are
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silenced in different cancers besides breast and prostate cancer as has been published. 
In addition to this, it is not unreasonable to hypothesise that other Se responsive 
genes, besides selenoproteins, are hypermethylated in cancer providing a clonal 
advantage for tumour cells. A genome-wide microarray based analysis incorporating 
both gene expression and DNA methylation pattern analysis of cancer cell lines and 
tissues would aid in the identification of such genes, selenoproteins or not.
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1.5 Aims of the thesis
1.5.1 Hypothesis
Se influences the availability of one-carbon units that are ultimately available for 
DNA methylation thereby influencing cancer aetiology.
1.5.2 Aims
To investigate the influence of Se on one-carbon metabolism Se, folate, Hey, vitamins 
B12 and B6 will be measured in a randomized double-blind, placebo controlled trial 
with a Se supplement intervention. The interactions between the measured nutrients 
will be analysed with multivariate statistical techniques.
Whole genome gene expression microarray analysis will be carried out using prostate 
cell line RNA and healthy and cancerous human prostate tissue RNA to determine 
basic gene expression. The effect of Se and/or a demethylating agent will be 
determined in the same prostate cell lines, which will identify Se responsive genes, 
hypermethylated genes and hypermethylated genes that are Se responsive in an 
unmethylated state.
Methylated DNA will be identified with a technique called Methylated DNA 
Immunoprecipitation in combination with promoter tiling arrays. Prostate cell line 
and healthy prostate tissue DNA will be used to validate the results generated by the 
gene expression microarray for the prostate cells treated with the demethylating agent.
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Chapter 2 General Reagents and Methods
2.1 Nutrition Study Reagents & Methods
2.1.1 Study D esign
The UK pilot study for the planned international PRECISE (Prevention of Cancer by 
Intervention with Selenium) trial was set up to assess the viability of conducting the 
main trial in the UK. It was carried out in four general practices of the Medical 
Research Council General Practice Research Framework from UK areas with 
differing demographic characteristics: Guisborough and Linthorpe (North East), 
Bromsgrove (West Midlands) and Bungay (East Anglia). No formal power 
calculations were performed for the pilot study and the target accrual (510 subjects in 
12 months) was chosen to give sufficient subjects from which to be able to draw 
reasonable inferences about recruitment, compliance and loss-to-follow-up, while 
keeping costs within reasonable bounds.
2.1.2 Subjects and recruitment
Between June 2000 and July 2001, research nurses recruited similar numbers of male 
and female volunteers from each of three age-bands: 60-64, 65-69 and 70-74 years. 
Exclusion criteria were: i) a Southwest Oncology Group performance status score >1 
(i.e. incapable of carrying out light housework or office work); ii) active liver or 
kidney disease; iii) prior diagnosis of cancer (excluding non-melanoma skin cancer); 
iv) diagnosed HIV infection; v) on immunosuppressive therapy; vi) diminished 
mental capacity; vii) supplementing with >50 pg/d of Se in the previous six months
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(by patient report). The study had approval from the appropriate UK Local Research 
Ethics Committees and participants provided written informed consent to participate.
2.1.3 Protocol
Following a four-week placebo run-in, 501 volunteers were randomly assigned to one 
of four treatment regimens: placebo, 100, 200 or 300 pg of Se/d for a minimum of six 
months. The intervention agent was high-Se yeast, SelenoPrecise™ (Pharma Nord, 
Vejle, Denmark) or a placebo yeast, identical except for Se-content. Central 
randomization was by computer-generated permuted blocks stratified by GP practice, 
gender and age group. Research nurses telephoned the independent randomization 
service at the Clinical Trials and Statistics Unit, Institute of Cancer Research, to 
obtain an anonymous code for each volunteer. Participants collected their 
corresponding pre-labelled tablets from the research nurses. Participants and general 
practice personnel were blinded to study treatment. Participants provided a blood 
sample at both baseline and six months (when visiting the GP practices for the 
purpose of the PRECISE pilot study). Heparinised plasma was prepared and frozen at 
the practices. Plasma samples were transferred to the University of Surrey where they 
were stored at -80 °C. All transfer of samples between centres was carried out on dry 
ice.
2.1.4 Measurements
Baseline and six-month plasma samples from the placebo, 100 and 300 pg/d groups 
were analysed for Se, tHcy, folate, vitamin B12, PLP and PA. For reasons of cost, B 
vitamins and tHcy were not measured in follow-up samples from the 200 pg/d group. 
Lithium-heparin plasma was analysed for Se at Central Science Laboratory, Sand
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Hutton, UK, by hydride-generation Inductively-Coupled-Plasma Mass Spectrometry. 
Weighed plasma samples were prepared by microwave digestion (Multiwave, Perkin- 
Elmer, Bucks, UK) and reduced to Se (IV), before being made up to volume for 
analysis. All reagents were "Analar" grade (or better) and the water used was 
Millipore-grade (18 MQ). Quality-control procedures were accredited under the UK 
Accreditation Scheme. Accuracy was assured by analysis of certified reference 
materials namely: Seronorm Serum, mean value (10 determinations) 85.5 ng/g, RSD 
12.7% (certified 86 ng/g); NIST 1598 Bovine Serum, mean value (16 determinations)
43.5 ng/g, RSD 6.2% (certified 42.4 ±3.5 ng/g). The Limit of Detection was 5 ng/g 
and the Mean Recovery 108% (12 determinations). Plasma folate and vitamin B-12 
were measured by Dr Molloy at Trinity College Dublin using microbiological assays 
as previously described (Kelleher and Broin 1991; Molloy and Scott 1997). Inter and 
intra- assay coefficients of variation (CVs) were <8.2% for plasma folate and <10.4% 
for vitamin B12. Plasma tHcy was measured by Dr Molloy at Trinity College Dublin 
by fluorescence polarization using an Abbott IMX instrument (Leino 1999). Inter- 
and intra-assay CVs were <2.5%. Plasma PLP (the main active form of vitamin B6) 
and PA (a catabolic B6 form) concentrations were determined by reverse-phase 
HPLC with fluorescence detection according to the method of Bates and colleagues 
(Bates et al. 1999) and were measured by Dr Pentieva and Dr Helene McNulty at 
Ulster University. Inter-assay CVs were 3.7% and 4.2% for PLP and PA, 
respectively.
2.1.5 Statistical analysis
Data analyses were performed using SPSS version 14.0. Data are generally expressed 
as means ± SD. Variables not normally distributed were log transformed. ANOVA,
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ANCOVA, independent samples t test, Pearson’s correlations and linear regression 
were used to test the relationships among the different variables as appropriate. 
P<0.05 was taken as the criterion of statistical significance. Baseline linear regression 
analyses were adjusted for age owing to the known relationship between age, kidney 
function and tHcy. Baseline and age were included as covariates in the ANCOVA 
analyses of follow-up values. Statistical parameters presented are (3 (standardized 
regression coefficient), R (coefficient of multiple determination) and r (Pearson 
correlation coefficient).
2.2 Molecular Genetics Reagents and Methods
2.2.1 Cell Lines
Four different prostate cell lines and one liver cancer cell line were used in the 
experiments.
1. RWPE-1, a nontumourigenic human epithelial prostate cell line immortalized 
with HPV18 (donated by Dr Campbell, University of Birmingham).
2. DU 145, a human prostate carcinoma derived from a brain metastasis 
purchased from the American Tissue Culture Collection (ATCC)
3. PC-3, a grade IV human prostate adenocarcinoma derived from a bone 
metastasis purchased from ATCC
4. LnCAP, a human prostate carcinoma derived from a left supraclavicular 
lymph node metastasis purchased from ATCC
5. Hep G2, a hepatocellular carcinoma cell line derived from the liver tissue of a 
15 year old Caucasian male with a well differentiated hepatocellular 
carcinoma. The cells were originally purchased from ATCC.
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2.1.1 Cell Culture and Growth Media
DU 145 cells were grown in Eagle’s Minimum Essential Medium with Earl’s 
Balanced Salt solution and 2 mM L-glutamine supplemented with 10% foetal bovine 
serum FBS, 1.0 mM sodium pyruvate, 0.1 mM nonessential amino acids and 1.5 g/L 
sodium bicarbonate. RWPE-1 cells were cultured in defined keratinocyte serum-free 
medium supplemented with pituitary bovine extract). PC-3 cells were grown in 
Kaighn’s modification of Ham’s FI2 medium with 2 mM L-glutamine, 1.5 g/L 
sodium bicarbonate and 10% FBS. LnCAP cells were grown in RPMI 1640 medium 
with 2 mM L-glutamine supplemented with 10 mM 4-(2-hydroxyethyl)-l- 
piperazineethanesulfonic acid (HEPES), 1 mM sodium pyruvate, 4.5 g/L glucose, 1.5 
g/L sodium bicarbonate and 10% FBS. Hep G2 cells were cultured in Eagle's 
Minimum Essential Medium supplemented with 10% foetal bovine serum FBS. All 
media was supplemented with 1% penicillin (50 IU/mL) and 1% streptomycin (50 
pg/mL) and pre-warmed to 37 °C before use. All reagents were purchased from 
Invitrogen (Carlsbad, California, USA).
2.1.2 M aintenance o f cell Lines
All cell lines were routinely cultured in 5% CO2 air atmosphere at 37 °C in either 25 
cm2 (T25), 75cm2 (T75) or 175 cm2 (T175) vented tissue culture flasks. All cell lines 
are adherent cell lines and need to be passaged before reaching confluency. When 
cells were first taken from storage (stored as 1 million cells/mL in vapour phase of 
liquid nitrogen storage tank) they were thawed rapidly in a circulating water bath at 
37 °C until defrosted. Immediately after defrosting they were resuspended in a T25 
containing 5 ml of pre-warmed medium.
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Before reaching confluency, cells were washed twice with warm (37 °C) sterile 
phosphate buffered saline (pH 7.2; PBS; Invitrogen, Carlsbad, California, USA) and 
trypsinised in 0.05% trypsin (Invitrogen; Carlsbad, California, USA) until cells 
detached from the flask. The cells were transferred to a 15 mL falcon tube and an 
equal volume of growth medium containing FBS was added to neutralise the trypsin 
enzymes. The cells were centrifuged at 250 g for 5 min (Fisherbrand 3R, Fisher 
Scientific UK, Loughborough, UK) and the supernatant was removed. The cells were 
then resuspended in growth medium for cell counting and viability determination. 
Twenty pL of cell suspension was mixed with 20 pL of trypan blue solution (0.4% 
solution; Invitrogen; Carlsbad, California, USA). Ten pL was loaded onto a 
haemocytometer (Neubauer) and clear (viable) and blue (non viable) cells were 
counted for each of the 4 comers. This was repeated for all comers of the 
haemocytometer and the average number of viable cells was determined by averaging 
the ratio of viable cells over the total number of cells. The total number of cells was 
calculated by multiplying the number of viable cells with the dilution factor and by 
multiplying that number by lx l04.
Cells were stored in the vapour phase of a liquid nitrogen cell bank for long term 
storage. Trypsinised cells were resuspended in normal growth medium supplemented 
with 10% dimethyl sulfoxide (DMSO; Sigma, UK). One mL aliquots (1 million/mL) 
were transferred in 1.5 mL cryovials (Nunc™, Fisher Scientific, UK) and frozen 
overnight at -80 °C in a Cryo 1 °C freezing vessel (Nalge (Europe) Ltd, Hereford, 
UK) containing propan-2-ol. The next day the vials were transferred to the tissue 
culture bank containing liquid nitrogen. All vials were stored in the vapour phase.
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2.1.3 Cell culture preparation to determ ine d o se -r e sp o n se  curve o f  
5-aza-2'-deoxycytid ine
The ‘normal’ RWPE-1 prostate cells were cultured until near confluency, washed, 
trypsinised and counted as described in section 2.1.2. A total of 7500 cells/cm2 were 
seeded in T75 tissue culture flasks in 15 ml growth medium. All cells were incubated 
for 24h to acclimatise and adhere to the bottom of the tissue culture flask. At the start 
of the experiment (0 hours) growth media was renewed with media supplemented 
with either 0, 1, 5 or 10 pM 5-AZA dissolved in DMSO with a final concentration of 
0.438% in sterile PBS. The cells were left to grow for 4 consecutive days with media 
renewal every 24h. Growth media for control cells was supplemented with an equal 
volume of PBS (250 pL) supplemented with 0.438% DMSO. The experiment was 
performed with single replicates for each condition.
After four days the media was decanted and cells were washed twice with pre­
warmed sterile PBS. The cells were trypsinised and centrifuged as described in 
section 2.1.2. DNA and RNA were extracted according to the protocol with the 
QIAGEN® AllPrep DNA/RNA mini kit (Qiagen; Hilden, Germany). A denaturing 
Buffer RLT Plus containing guanidine-isothiocyanate supplemented with P- 
mercaptoethanol (1%) deactivated DNases and RNases, lysed the cells and denatured 
proteins. The lysate was transferred into a Qiageshredder spin column for further 
disruption and homogenisation of the cellular material. Silicon spin columns 
selectively captured the DNA with a high salt buffer while the flow-through was 
mixed with ethanol to allow binding of RNA to an RNA spin column. DNA and 
RNA were eluted with a tris-EDTA buffer and RNase-free water respectively.
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Both DNA and RNA samples were quantified with the Agilent Nanodrop 
Spectrophotometer (Agilent Technologies, Stockport, UK). For quantification 1.5 pL 
was pipetted on the Nanodrop platform. The Nanodrop software calculates DNA and 
RNA quantities by applying a modified Beer-Lambert equation. DNA was stored 
long term at 4 °C while RNA was diluted with RNAse-free water to 1 pg and 10 ng 
aliquots and stored at -80 °C.
2.1.4 Cell culture preparation to determ ine sod ium  se len ite  
treatm ent e ffec tiv en ess
Hep G2 liver cancer cells were cultured until near confluency, washed, trypsinised 
and counted as described in section 2.1.2. 2x105 cells were seeded in 6 T25 flasks 
and left overnight to attach and acclimatise. After 24h the growth media was 
refreshed for 3 of the flasks while the remaining 3 were given growth media 
supplemented with 100 nM sodium selenite. All cells were left to grow for another 
48h after which the media was decanted and the cells were washed twice with pre­
warmed sterile PBS. The cells were trypsinised and centrifuged as described in 
section 2.1.2. RNA was extracted using the RNeasy kit (Qiagen; Hilden, Germany), 
which works in a similar way as the AllPrep DNA/RNA kit described in chapter 
2.1.3. Extracted RNA was diluted to 1 pg and 10 ng aliquots and stored at -80 °C.
2.1.5 Cell culture preparation for g en e  exp ression  and prom oter  
tiling microarray
All prostate cell lines were cultured until near confluency, washed, trypsinised and 
counted as described in section 2.1.2. The appropriate numbers of cells were seeded
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in T75 tissue culture flasks in 15 mL growth medium. Cell density varied according 
to condition (Table 4). Sodium selenite was reconstituted in sterile PBS.
Table 4. Gene re-expression experimental set-up.
Cell Line Sample a 5-AZA
(pM)
Sodium selenite 
(nM)
Cell Densityb 
k/cm2
RWPE-1 M 0 5.0
A 10 7.5
S 0 100 5.0
B 10 100 7.5
DU 145 M 0 5.0
A 10 7.5
S 0 100 5.0
B 10 100 7.5
LnCAP M 0 5.0
A 10 7.5
S 0 100 5.0
B 10 100 7.5
PC-3 M 0 5.0
A 10 7.5
S 0 100 5.0
B 10 100 7.5
aM= Media; A=5-aza-2 '-deoxycytidine; S=sodium selenite; B=5-aza-2'- 
deoxycytidine + sodium selenite. 
b Cell density depended on condition.
All prostate cells were incubated for 24h to acclimatise and adhere to the bottom of 
the tissue culture flask except for the LnCAP prostate cancer cell line, which was 
given 48h. The experiment was performed with quadruplicates for each condition per 
cell line giving a total of 64 samples.
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Figure 11. Gene expression microarray experimental set-up. M=Media, A=5- 
AZA, S=Se, B=5-AZA + Se; Red triangle=DNA/RNA extraction for samples M and 
A, Yellow triangle= DNA/RNA extraction for samples S and B.
Growth media for samples A and B were supplemented with 10 pM 5-AZA (Figure 
11). The prostate cells were grown for 4 consecutive days with growth media renewal 
every 24h. Growth medium for control cells was supplemented with an equal volume 
of PBS (250 pL) and 0.438% DMSO. After 4 days, growth media for samples S and 
B was replaced with growth media supplemented with 100 nM sodium selenite made 
up in sterile PBS while DNA/RNA was extracted, quantitated and stored from 
samples M and A according to the protocol described in section 2.1.3. After two days 
of additional growth in Se supplemented medium, samples S and B had their DNA 
and RNA extracted, quantitated and stored according to the QIAGEN® AllPrep 
DNA/RNA mini kit (Qiagen; Hilden, Germany) protocol described in section 2.1.3.
The RNA quality for microarray experiments needs to be of superior quality for the 
best binding conditions to the probes on the array. The RNA was qualitated with the 
Agilent Bioanalyser (Agilent Technologies, Stockport, UK) and the RNA 6000 Nano 
Assay. The RNA 6000 Nano Assay uses electrophoresis to measure the integrity of 
the 28S and 18S subunits of ribosomal RNA present in the sample. Twenty ng of 
each sample was run on an RNA 6000 Nano Assay chip together with a denatured 
RNA ladder. The quality is expressed as an RNA Integrity number (RIN), which is
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calculated from the ratio of 28S over 18S. The large majority of samples had RINs 
over 9 out of 10 (Figure 12).
Sample 9
RIN:10
h
I---------1-------- 1---------1-------- 1-----
20 30 40 50 60
Figure 12. Example of an electropherogram from an RNA sample with a RIN of
10.
2.7 Prostate Tissue Samples
Two healthy prostates tissue samples (called ProsF and ProsP) preserved in 
RNALater® (Ambion, Applied Biosystems; Foster City, California, USA) from 
different individuals were donated by Dr Giuseppe Corruba (Palermo, Sicily). Both 
samples originated from bladder cancer patients who underwent cystoprostatectomy 
and were histologically cleared of prostate cancer by a histopathologist.
Six prostate cancer RNA samples were donated by Dr Giuseppe Corruba (Palermo, 
Sicily). The samples originated from three prostate cancer patients. Each patient had 
donated a prostate biopsy for the left and right prostate lobe. Characteristics per 
patient are described in Table 5. The quantity of RNA present in the sample was 
assessed by Nanodrop (Agilent Technologies, Stockport, UK).
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Table 5. Prostate cancer samples characteristics obtained from Dr Corruba.
Sample
Number
PSA Pathology Age Gleason
Grade
Notes
FM002 33.5 Prostate Cancer 58 8 Multifocal
FM007 18.3 Prostate Cancer 68 8 Right Lobe: Cancer; 
Left Lobe: Atypical 
Hyperplasia
FM008 500 Prostate Cancer 89 8 Bone Metastasis
Six prostate cancer DNA samples (2 pg each) from 5 different individuals were 
donated by Prof Colin Cooper (Table 6). Samples 10643#1 and 10643#2 came from 
the same patient. DNA concentrations were quantified with the Agilent Nanodrop 
Spectrophotometer (Agilent Technologies, Stockport, UK).
Table 6. Prostate cancer samples characteristics obtained from Prof Cooper.
Sample Number Label PSA Pathology Stage Age Gleason
Grade
10643#1 and #2 CaPla and lb 9.8 2 65 7
2211#1 CaP2 10.3 2 57 6
10376#1 CaP3 6.9 2 58 7
3128#1 CaP4 10.7 2 58 6
9134#2 CaP5 6.1 2 69 7
2.2 RNA/DNA Extraction from prostate tissues
Both RNA and DNA were extracted simultaneously from the healthy prostate tissues. 
Approximately 30 mg was cut off using sterile disposable scalpels (Fisher Scientific, 
UK) and transferred into a 1.5 mL tube containing 600 pL of RLT Plus buffer
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(Qiagen; Hilden, Germany) supplemented with 6 pL P-mercaptoethanol to facilitate 
cell lysis and protein denaturation. The sample was disrupted in the TissueLyser 
(Qiagen; Hilden, Germany) for 2x2 minutes and DNA and RNA was extracted using 
the QIAGEN® AllPrep DNA/RNA mini kit (Qiagen; Hilden, Germany) protocol 
described in section 2.1.3. DNA and RNA were quantified with the Agilent 
Nanodrop Spectrophotometer (Agilent Technologies, Stockport, UK).
2.3 Gene Expression Microarray
4x44k human whole genome two-colour expression microarrays produced by (Agilent 
Technologies, Stockport, UK) contain 45,220 probes of which 6,301 are available for 
customization. 288 extra probes covering 96 genes of interest and neighbouring 
genes with 3 extra probes per gene were added onto the array filling it for 86.07%. 
The 60-mer probes were designed by the eArray software available online on 
Agilent’s website (http://www.chem.agilent.com).
For each of the four conditions per cell line, three biological replicates were 
fluorescently labelled amounting to a total of 48 arrays. With the two healthy and 6 
cancerous prostate tissue RNA samples this came to a total of 56 arrays. Universal 
Reference RNA (URR; Stratagene, Agilent Technologies, Stockport, UK) is a 
collection of pooled DNase-treated total RNA originating from 10 human cell lines 
and was chosen as an internal reference.
All samples were labelled with the Low RNA Input Linear Amplification Kit Plus 
(Agilent Technologies, Stockport, UK). The protocol is available online 
(http://www.chem.agilent.com) and is briefly explained below. A spike-in mix (Two-
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Color RNA Spike-In Mix; Agilent Technologies, Stockport, UK) was added to each 
sample comprising of 10 in vitro synthesised, polyadenylated transcripts in 
predetermined ratios. These transcripts specifically hybridise to control probes on the 
arrays and the expected versus observed log ratios can be used to monitor the quality 
of the microarrays for linearity, sensitivity and accuracy. Five hundred ng of target 
sample and the universal reference RNA was reverse transcribed into cDNA and 
labelled with Cy3 and Cy5 using a T7 RNA polymerase, which amplifies the cDNA 
at least 100-fold and incorporates the fluorescent dyes at the same time. RNase 
inhibitors were used throughout the protocol to reduce RNA degradation. Labelled 
cRNA was purified with the RNeasy Mini Kit (Qiagen; Hilden, Germany) and 
quantitated using Nanodrop. Cy dye activity was determined using the following 
formula: (concentration of Cy3 or Cy5) / (concentrations of cRNA) x 1000 = pmol Cy 
dye incorporation per pg cRNA. The lowest activity for any sample obtained was 
10.69 pmol/pg cRNA.
A total of 825 ng of each labelled sample and URR were co-hybridized onto the gene 
expression arrays and incubated at 65 °C for 16 hours. After washing the arrays were 
scanned on the Agilent Microarray Scanner (Agilent Technologies, Stockport, UK) at 
a resolution of 5 pM and the data was digitized with Agilent’s Feature Extraction 
software (Agilent Technologies, Stockport, UK) and the appropriate design files for 
the arrays.
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2.4 Gene Expression Microarray Analysis
Data preparation, normalization and t-test/rank test analyses on the gene expression 
microarray data was performed by a collaborating bioinformatician, Dr Emma Laing.
2.4.1 Norm alisation and p ro cessin g  o f the g en e  exp ression  
microarrays
Arrays were imported into the statistical package R (version 2.5.0) fhttp://www.R- 
proiect.org, R Development Core Team) and global median normalised using the 
LIMMA package (Smyth and Speed 2003; Gentleman et al. 2004). The data 
distribution across all arrays was checked and across-array normalisation was 
performed such that the Median Absolute Deviation was the same for each array 
(scale method in the LIMMA package (Smyth and Speed 2003)).
Spots (probes) on each array were flagged as poor quality if at least one of the four 
Feature Extraction variables for each channel on the array had the value 1; thus if a 
spot did not have a good signal (as determined by Feature extraction software) in both 
channels (Universal Human RNA reference and sample) then that spot was assigned 
NA.
The value assigned to each gene under a particular condition/replicate (single array) 
for downstream analysis (e.g. differential expression) was the average log2 
cDNA/human reference RNA across all probes that target that gene; where a gene did 
not have at least one good probe (=NA) the gene was assigned NA. Genes that did 
not have an average log2 cDNA/human reference RNA in at least two biological
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replicates for each condition was filtered out of the data set. A total of 23,117 genes 
remained after filtering for analysis.
2.4.2 A nalysis o f the data
A two fold threshold for up- or down-regulation was maintained throughout the study 
(DeRisi et al. 1996). A Welch t-test with Benjamini and Hochberg (Benjamini and 
Hochberg 1995) false discovery rate correction (applied as 5% of a large data set are 
expected to give rise to a large T value (equal to small p-value) and therefore classed 
as significantly different by chance)) was used increase the stringency to investigate 
significant differences between tissue samples. Normalized data was explored, 
visualized and clustered with GeneSpring GX (Agilent Technologies, Stockport, UK).
Processes were identified using statistical overrepresentation in MetaCore (GeneGo, 
St. Joseph, MI). MetaCore is an integrated systems biology web-based platform for 
the functional analysis of experimental data. The program uses annotation databases 
and creates a list of gene ontology processes that are ranked according to their P 
value. Networks are calculated through a hypergeometric distribution in which the P 
value represents the probability of particular mapping arising by chance, given the 
numbers of genes in the set of all genes on maps/networks/processes, genes on a 
particular map/network/process, and genes in the experiment.
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2.5 Quantitative Real-Time PCR
2.5.1 RNA Quantitative PCR
Gene expression profiles obtained with the gene expression microarrays were 
validated with quantitative real-time PCR (QPCR) using a real-time PCR machine 
(Applied Biosystems 7500) and SYBR green technology (QuanTitect SYBR Green 
PCR Kit Qiagen; Hilden, Germany). Primer sequences for most genes are unknown 
as they are proprietary to Qiagen. A list of genes is given in Table 7.
Table 7. List of genes for RNA microarray validation with QPCR and their 
corresponding Qiagen catalogue number.
Gene Qiagen Catalogue Number
GPxl QT00203392
GPx2 QT00200039
GPx3 QT00062279
GPx4 QT00067165
GSTP1 QT00086401
SelS QT00008169
DIOl QT00046032
DI03 QT01155462
C19orf53 QT00035616
RPS18 QT00248682
GAPDH QT01192646
Primers for BHMT and BHMT2 were generated using Primer3 (Rozen and Skaletsky 
2000). Primers were picked that crossed exon boundaries for RNA amplification 
specificity. All annealing temperatures were at 60 °C.
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Table 8 . BHMT and BHMT2 primer sequences and amplicon lengths.
Gene Sequence Amplicon length
BHMT FP GC AGTT C AC ACC AAT GAT GG
93 bp
BHMTRP ATT GGCCC AGAAGGAGATTT
BHMT2 FP AGAAAGCTGCCATCTCCAAT
86 bp
BHMT2RP CAT GGCACCT GCTGGAC
Each biological replicate was assayed in triplicate giving 9 replicates (3 biological x 3 
technical replicates) per cell condition and per cell line. Only primer sets that 
produced standard curves with an R of over 0.99 were used in the experiment. RNA 
from the standard curve consisted of universal reference RNA diluted to 10, 1 and 0.1 
ng of RNA per p L .  A serial dilution of the standard curve was aliquotted out and kept 
at -80 °C ensuring high inter-plate reproducibility. Per reaction 30 ng (3 p L  of a 10 
ng dilution) of RNA, 6.25 p L  SYBR Green mastermix, 0.16 p L  reverse transcriptase 
mix and 1.25 p L  of pre-made primer mix was used. The reaction volume was 
adjusted to 12.5 p L  with RNAse-free water. The plates were prepared on StarChill 
PCR racks (StarLab; Ahrensburg, Germany), sealed with Absolute QPCR seals 
(ABgene, UK) and centrifuged for 3 min at 3000 rpm on a 4K15C centrifuge (Qiagen; 
Hilden, Germany).
PCR parameters for each of the RNA QPCR reactions were as follows: reverse 
transcription of 30 min at 50 °C, 95 °C initial denaturation for 5 min, 95 °C 
denaturation for 30 sec followed by annealing at 60 °C and extension at 72 °C for 30 
sec. The final three steps were repeated for 40 cycles in total.
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Every QPCR plate was subjected to melting curve analysis after the PCR over an 
increasing temperature range of 65 °C to 95 °C to determine the specificity of the 
amplicons generated. The relative expression of the target samples was calculated 
using the linear regression derived from the standard curve and plotted in Excel 
(Microsoft; Redmond, Washington, USA) and GraphPad (La Jolla, California, USA). 
ANOVA tests with correction for multiple testing (Bonferroni) tested for significant 
differences between the conditions.
2.5.2 DNA Quantitative PCR
DNA QPCR primers were designed to amplify the region of DNA corresponding to 
the region investigated for DNA methylation.
Table 9 . DNA QPCR primers and annealing temperatures (Tm).
Primer Name Primer sequence Tm
SELS_QPCR_FP 1 GT CAT GGAACGCC AAGAGG
57
SELSQPCRRP1 GGACGACCCACCCATCAT
GSTP1QPCRFP1 
GSTP1QPCRRP1
AGGCCTTCGCT GGAGTTT C 
GAGCTCTGAGCCCCATCC
56
Per reaction 9 ng DNA was amplified with 6.25 pL SYBR Green mastermix, 7.5 
pmol of each primer in a 12.5 pL reaction. PCR parameters were as follows: initial 
denaturation at 95 °C for 10 min, 95 °C for 30 sec, Tm (Table 9) for 30 sec, final 
extension at 72 °C for 30 sec. The final three steps were repeated for 40 cycles.
Fold enrichment was calculated using the standard curve method outlined in chapter 
2.5.1. Paired and unpaired two-tailed t-tests were performed with GraphPad (La Jolla, 
California, USA). P values below 0.05 were considered significant.
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2.6 Methylated DNA ImmunoPrecipitation
Methylated DNA ImmunoPrecipitation or MeDIP is a technique devised for the 
specific enrichment of methylated DNA during immunoprecipitation. Briefly, a 
monoclonal mouse anti 5-methylcytosine antibody, which recognises methylated CpG 
sites is mixed with a sonicated DNA sample. Both input (total DNA) and output 
(enriched, methylated DNA) are labelled with fluorescent Cy dyes and hybridised 
onto whole genome human promoter tiling arrays (Figure 13).
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Figure 13. Methylation analysis by MeDIP. Sonicated DNA is denatured into single 
strands and methylated DNA is enriched through immunoprecipitation with an 
antibody raised against methylated cytosines. Input and enriched fractions are 
differentially labelled and hybridised onto promoter tiling arrays. Promoter 
methylation levels were calculated from probes located between -700 and +200 bp 
relative to the transcription start site (Weber et al. 2005; Weber et al. 2007). The ratio 
of output over input DNA for a cancer sample compared to the same ratio in a normal 
sample provides data about the enriched, hypermethylated areas within the cancer 
genome.
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2.6.1 Validation o f the MeDIP protocol
Five microgram of DNA was diluted in 350 pL of TE buffer and sonicated using a 
Sonics Vibra Cell sonicator (Sonics; Newtown, Connecticut, USA) with microtip. 
Ten times 20 second bursts on power level 30 with 40 second rests on ice in between 
bursts sheared the DNA into fragments between 300-800 bp in length. Four 
microgram of the sonicated DNA was diluted into 450 pL of TE buffer. The 
remaining 1 pg was left untreated to serve as input control. Sonicated DNA was 
denatured for 10 minutes on a heating block at 100 °C and left to cool on ice for 
another 10 minutes. To this 51 pL of 10X IP buffer (100 mM Na-Phosphate pH 7.0, 
1.4 M NaCl, 0.5% Triton X-100) and 10 pL of antibody (10 mg/ml; AbD Serotec) 
was added and incubated for 2 hours at 4 °C with overhead shaking. To reduce noise 
from unspecific binding to the magnetic beads, 40 pL of sheep anti-mouse IgG 
Dynabeads (Invitrogen; Carlsbad, California, USA) were pre-washed with 800 pL 
PBS-0.1% BSA (NEB; Ipswich, Massachusetts, USA) for 5 minutes at room 
temperature with shaking to prevent sedimentation of the beads. They were collected 
with a magnetic rack, resuspended in 40 pL of IX IP buffer and added to the sample. 
The sample with the beads was incubated for 2 hours at 4 °C with overhead shaking 
to let the beads bind the antibody-methylated DNA complex. The whole complex 
was collected with a magnetic rack and washed three times with 700 pL of IX IP 
buffer for 10 minutes at room temperature with shaking. The complex was collected 
with a magnetic rack and resuspended in 250 pL proteinase K digestion buffer (50 
mM Tris pH 8.0, 10 mM EDTA, 0.5% SDS) to which 7 pL of proteinase K (10 
mg/ml; Promega; Madison, Wisconsin, USA) was added. The proteinase K removed 
the beads from the antibody-methylated DNA complex during a 3 hour incubation at 
50 °C with shaking. DNA was purified using MinElute columns (Qiagen; Hilden,
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Germany), which uses silica-membrane spin columns and a high-salt buffer to bind 
the DNA. Purified DNA was eluted with 2X 10 pL of a low-salt buffer. DNA 
concentrations were measured with Nanodrop.
2.7 Whole Genome Amplification
The whole genome amplification process is based on Multiple Displacement 
Amplification (MDA) technology and was performed with the Repli-G kit (Qiagen; 
Hilden, Germany). Ten ng of DNA was denatured at 65 °C for 5 min and incubated 
with a cp29 DNA polymerase and random primers for lOh at 30 °C. During the 
incubation the polymerase moves along the DNA template strand while displacing the 
complementary strand. This DNA strand serves as a template for replication allowing 
high yields of high-molecular-weight DNA to be generated. The enzyme was heat- 
inactivated for 3 min at 65 °C. The DNA generated is unmethylated and can be used 
as a negative control in methylation reactions.
2.8 Sss1 treatment of DNA
In vitro DNA methylation was performed with Sssl methylase. The reaction 
contained 2.1 pg of untreated control DNA, 2.2 pL lOx NEBuffer, 1.2 pL of a 1600 
pM S-adenosyl methionine solution and 1 pL of Sssl methylase (4 U/pL). All 
reagents were purchased from New England Biolabs (Ipswich, Massachusetts, USA). 
After an initial incubation of 2 hours at 37 °C, the same amount of SAM and Sssl as 
in the initial reaction were added to the sample and incubated for another 2 hours at 
37 °C to ensure complete cytosine methylation. The samples were purified with the 
QIAquick PCR Purification Kit (Qiagen; Hilden, Germany), which binds DNA to the
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silicon membrane of a spin column in a high-salt buffer. The DNA is eluted under 
low-salt conditions and stored at -20 °C. The DNA produced is methylated and can 
be used as a positive control for methylation analysis reactions.
2.9 Human Promoter Tiling Array
Human Promoter ChlP-on-ChIP tiling arrays (Agilent Technologies, Stockport, UK) 
cover -5.5 kb upstream to +2.5 kb downstream of the transcriptional start sites with a 
total of over 488k probes and represent approximately 17,000 of the best defined 
human transcripts by RefSeq.
Table 10. Sample list with incorporated dyes indicated. ProsF and ProsB are two 
healthy prostate tissue samples. R=RWPE-1, D=DU145, L=LnCAP, P=PC-3. 
Samples A and B represent the two pooled DNA samples.
Sample Cy3 Cy5 Sample Cy3 Cy5
ProsF DIP X ProsB DIP X
ProsF SON X ProsB SON X
RADIP X RB DIP x
RA SON X RB SON X
DA DIP X DB DIP X
DA SON X DB SON X
LA DIP X LB DIP X
LA SON X LB SON X
PA DIP X PB DIP X
PA SON X PB SON X
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Samples were labelled using the BioPrime kit (Invitrogen; Carlsbad, California, 
USA), which employs a Klenow enzyme to attach the Cy5 or Cy3 dye to the DNA. A 
maximum of 20 pL of enriched methylated DNA was labelled overnight at room 
temperature. If the volume was less than 20 pL it was made up to 20 pL with sterile 
deionised water. An equal volume of 2.5x Random Primers and 0.5 pL of MilliQ 
were added to the reaction. The sample was denatured at 94 °C for 3 min after which 
5 pL of dNTP mix, 3.75 pL of Cy dye and 1.5 pL of Klenow enzyme were added. 
The reaction was incubated overnight at 37 °C. The reactions were purified using 
MinElute PCR Purification Kit (Qiagen; Hilden, Germany) and eluted in 2x 10 pL TE 
buffer. The quality of dye incorporation was checked with Nanodrop as described in 
chapter 2.3. A dye swap of pre-MeDIP (total DNA) and post-MeDIP (enriched 
methylated DNA) between biological replicates allowed adjustment for dye 
incorporation bias.
The addition of highly repetitive human placental Cot-1 DNA (Invitrogen; Carlsbad, 
California, USA) was used to block non-specific hybridization. Samples were 
hybridized for 60 hours at 65 °C to the slides (two slides per sample) and washed 
using comparative genomic hybridisation-specific wash buffers (Agilent 
Technologies, Stockport, UK). The arrays were scanned and data extracted as 
previously mentioned (Chapter 2.3) but with array specific design files.
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2.10 Human Promoter Tiling Array Analysis
2.10.1 Norm alisation and p rocess in g  o f all arrays
Normalisation methods make the assumption that the bulk of probes on the array 
should have a signal in both channels. As the methylation status of all promoters 
represented on the array is unknown (and therefore signals of the probes targeting 
those promoters) normalisation was not applied to the MeDIP arrays. The outlier 
parameters of the microarray scanning Feature Extraction software (Agilent 
Technologies, Stockport, UK) described in Section 2.4.1 were once again used to 
check spot quality. Probes that did not have at least 2 good values in each of the 
conditions tested were filtered out; 457,951 probes that target the upstream regions of 
genes (700 bp upstream of the annotated start and 200 bp downstream of the 
annotated start) passed filtering/quality checks and were used for further analysis. 
Data was dye swapped and visualised with ChIP Analytics (Agilent Technologies, 
Stockport, UK) and the University of California Santa Cruz (UCSC) genome browser.
2.10.2 Statistical an a lysis
Differentially methylated probes between normal and cancerous samples (e.g. healthy 
prostate tissues versus prostate cancer PC-3 cell line) were determined by the non- 
parametric t-test in the statistical package R (version 2.5.0) (http://www.R-proiect.org. 
R Development Core Team) using the multi-test package of bioconductor (Gentleman 
et al, 2004). Resultant P-values were corrected using the Benjamini and Hochberg 
false discovery rate correction (Benjamini and Hochberg 1995) and probes that had a 
corrected P-value of < 0.05 were classed as significantly differentially methylated 
between conditions.
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2.11 Methylation pattern analysis
2.11.1 Restriction D igestions
Generally, about 4 jixg of cell line genomic DNA was used in a single 100 pL reaction 
with 10X 4-Core Buffer, 100X BSA and 25 units of ECORV enzyme. This enzyme 
has the recognition sequence GAT/ATC. Digests were left overnight at 37 °C and the 
enzyme was inactivated with a final incubation at 60 °C for 20 minutes.
2.11.2 Bisulphite con version
The bisulphite conversion can be used to distinguish between methylated and 
unmethylated cytosines whereby DNA is treated with sodium bisulphite to convert 
unmethylated cytosines to uracil in single stranded DNA. Downstream PCR 
translates uracil into thymine and can be used to distinguish between the different 
bases (Figure 14).
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Figure 14. Outline of the bisulphite conversion process. Unmethylated cytosines 
are deaminated into uracils while the methylated cytosines are protected from such 
reaction.
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Five hundred ng of sonicated/enzyme digested input DNA was converted using the 
EZ DNA Methylation kit from Zymo Research. DNA is denatured at 98 °C for 10 
minutes and incubated with sodium bisulphite for 2.5 h at 65 °C. Desulphonation of 
uracil-6-sulphonate to uracil and washing of the sample with ethanol is performed on 
a spin column. The converted DNA is eluted with 11 pL elution buffer providing 
enough sample for 5 PCR reactions.
2.11.3 Methylation Seq u en cin g
There are a number of ways to investigate methylation patterns of promoter regions of 
genes. Two techniques were used during this project: Methylation Sanger Sequencing 
and Methylation Pyrosequencing.
2.11.3.1 Methylation Sanger Sequencing
The analysis of methylation patterns with conventional Sanger sequencing requires 
cloning of the fragment of interest to generate a high quality and quantity product. 
The technique relies on the incorporation of fluorescently labelled dinucleotides 
during the PCR process. The labelled amplicons are separated according to size and 
the fluorescent labels are detected by a CCD camera at the end of the electrophoresis 
capillary. The average methylation percentage of a gene is determined by sequencing 
at least 10 clones.
PCR reaction
Bisulphite converted DNA cannot be reliably quantitated due to the degradation of the 
DNA during the conversion. Two pL was the standard recommended amount used in 
all reactions. A typical 50 pL reaction would therefore contain 2 pL bisulphite
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converted DNA, 10 pmol forward and reverse primer, 1.25 units of HotStarTaq DNA 
polymerase, 200 pM of each dNTP (Qiagen) and 10X PCR buffer. Non-template 
controls were used in all experiments. PCR parameters are described in Table 11.
Table 11. Nested and semi-nested PCR parameters.
Temperature in °C Time in minutes
95 5
94 1
Tm (See Table 13) 2 X5
72 3
94 0.5
Tm (See Table 13) 1 X25
72 1.5
72 10
4 00
For the second round of PCR, the final extension at 72 °C was increased to 20 
minutes. This extra time enables the taq polymerase to add an extra adenosine at the 
end of each amplicon. The extra adenosine allowed for TA cloning, which makes it 
possible for the direct transfection of a PCR product in a vector with single 3’-T 
overhangs.
Cloning
The T4 DNA Ligase Blue/White Cloning (Promega; Madison, Wisconsin, USA) was 
used for DNA ligation into a vector. A typical 10 pL reaction would contain 2X 
ligation buffer, 100 ng of vector DNA (pGEM), 3 units of T4 DNA Ligase (Weiss 
units) and 2 pL of PCR product. The reaction was incubated overnight at 4 °C. A
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positive control provided by the kit was included in the experiment. The following 
day 2 pL of ligation product was mixed with competent JM109 cells (Promega; 
Madison, Wisconsin, USA) and placed on ice for 20 minutes. For transformation the 
reaction was placed in a water bath at 42 °C for 50 seconds to allow the vector to 
enter the cell and placed back on ice for 2 minutes. SOC medium (Super Optimal 
Catabolic Repression; recipe in Appendix 1) was added to a volume of 1 mL and 
placed in an incubator at 37 °C while shaking. Hundred pL of the sample after 
incubation was plated out on agar plates supplemented with XGal, IPTG and 
ampicillin (recipes in Appendix 1). After 10 minutes of rest on the lab bench to 
prevent evaporation of the samples, the plates were incubated at 37 °C for 16-24 
hours.
Checking o f the inserted amplicon
To check the cells for the correct insert, white (positive insert) colonies were picked 
using a loop or needle that was shaken in 20 pL H2O to release a small amount of 
cells and then plated out on a new agar plate containing ampicillin. Heat lysis of at 
least 20 individual colonies using a boiling water bath for 2 minutes released the DNA 
from the cells that was purified with the Wizard Plus SV Minipreps (Promega; 
Madison, Wisconsin, USA). Cells were centrifuged at room temperature for 1 minute 
and lysed in 250 pL cell lysis solution (0.2 NaOH and 1% SDS), 10 pL alkaline 
protease solution and 250 pL cell resuspension solution (50 mM Tris-HCl pH 7.5, 10 
mM EDTA, 100 pg/ml RNase A). After 4 times inversion the reaction was stopped 
with 350 pL of neutralization solution (4.09 M guanidine hydrochloride, 0.759 M 
potassium acetate and 2.12 M glacial acetic acid) and centrifuged for 15 minutes at 
room temperature. The lysate was decanted into the spin column and centrifuged at
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top speed for 1 minute at room temperature. The column was washed three times 
with wash buffer (162.8 mM potassium acetate, 22.6 mM Tris-HCl pH 7.5, 0.109 mM 
EDTA pH 8.0) after which the purified DNA was eluted with TE buffer.
A PCR was set up with universal primer M l3 and the internal reverse primer used in 
the original nested PCR to check whether the insert had the correct size. The 
reactions contained 5 pL sample, 10 pmol of each primer and 10 pL RedTaq (Sigma) 
mastermix and were subjected to an initial denaturing step at 94 °C for 3 minutes, 40 
cycles of 94 °C, 51 °C and 72 °C each for 1 min and a final extension step at 72 °C 
for 10 minutes. Negative controls with water instead of DNA ensured the reagents 
were contamination-free. Ten pL of the PCR products was checked on a 2 % 
ethidium bromide-agarose gel run in IX TBE. Approximately 50% of the clones 
would contain the correct insert.
Sequencing
DNA from the positive colonies was harvested using the Wizard Plus SV Minipreps 
(Promega; Madison, Wisconsin, USA) and their concentration checked by Nanodrop. 
DNA was heat denatured before used in sequencing reactions by incubation at 96 °C 
for 1 minute. Fifty ng of sample DNA was mixed with 2 pL of DCTS Quickstart kit 
Dye Terminator Cycle Sequencing mix (Beckman Coulter; Fullerton, California, 
USA), 10 pmol universal primer M l3 or M l3 reverse, 1.5 pL Reducing Mix and 
made up to 20 pL with H2O. Thermal cycling parameters were as follow: 40 cycles 
of 96 °C for 20 seconds, 50 °C for 20 seconds and 60 °C for 4 minutes. The reactions 
were stopped by adding 2 pL 3 M sodium acetate, 2 pL 100 mM sodium-EDTA and 1 
pL of 20 ng/ml glycogen (Roche; Basel, Switzerland).
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DNA was precipitated using a standard ethanol precipitation protocol. Sixty pL of 
96% ethanol was added and vortexed. The sample was subsequently centrifuged at 4 
°C for 20 minutes at full speed. The supernatant was removed by decanting the tube 
over a paper towel and the pellet was washed twice with 200 pL ice-cold 70% 
ethanol. The DNA was dried on a heating block at 60 °C for 10 minutes or until all 
ethanol had evaporated. The sample was resuspended with 40 pL sample loading 
solution (Beckman Coulter; Fullerton, California, USA) and left for 30 minutes at 
room temperature shielded from light. After a brief vortex and centrifugation the 
sample was loaded onto a plate and one drop of mineral oil was added on top of the 
sample. On a separate wash plate 200 pL of running buffer was added for each 
respective well. All samples were sequenced on a CEQ 2000XL DNA Analyzer 
System (Beckman Coulter; Fullerton, California, USA).
The sequences were visualized using CEQ2000 software (Beckman Coulter; 
Fullerton, California, USA) and quality checked. Correct inserts were aligned with 
the reference sequence from NCBI in which all CG dinucleotides in the sequence 
were changed into YG dinucleotides for CpG recognition and submitted to MethTools 
(http://genome.imb-iena.de/methtools/) for visualization of the data.
2.11.3.2 Methylation Pyrosequencing
Methylation pyrosequencing is a sequencing-by-synthesis method that uses purified 
single strand DNA to synthesise its complementary sequence. The 4 dNTPs are 
dispensed according to a pre-set dispensation order according to the sequence. The 
incorporation of the correct number of dNTPs by a DNA polymerase releases 
pyrophosphate stoichiometrically that is converted to adenosine triphosphate (ATP)
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by ATP sulphurylase. ATP drives the luciferase mediated light-generating reaction 
whereby luciferin is converted into oxyluciferin. The amount of light generated by 
this reaction is proportional to the number of nucleotides incorporate into the 
sequence. The generated light is digitally translated into peaks that are used as a 
measure of average methylation percentage.
PCR reactions were performed in a 50 pL volume with 2 pL converted DNA, 10 
pmol of each primer, with/without 3.5 mM MgCh depending on the primer set, 1.25 
U HotStarTaq and 200 pM of each dNTP. PCR parameters are given in Table 12.
Table 12 . PCR parameters for a PSQ sample.
Temperature in °C Time in minutes
95 5
94 0.5 C
Tm (See Table 14) 0.5 X50
72 0.5
72 10
4 00
For global methylation analysis a tag primer design within a nested PCR was 
employed. Primer sequences (Table 14) were taken from a paper published by Yang 
and colleagues (Yang, 2004). Standard PSQ-PCR conditions applied: first 2 pL of 
bisulphite converted DNA was amplified using the forward and reverse primers with 
an annealing temperature of 43 °C but all denaturing, annealing and extension steps 
were held for 1.5, 1 and 2 min respectively. The second round of PCR used 3 pL of 
the 1st round amplicon together with the biotinylated tag primer and the 
complementary forward primer (see Table 14). During this PCR the annealing
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temperature was higher at 55 °C and all denaturing, annealing and extension steps 
were held for 30 seconds.
The DNA strand with the biotinylated primer is captured with 3 pL streptavidin beads 
(Invitrogen; Carlsbad, California, USA) and 37 pL binding buffer (10 mM Tris-HCl, 
2M NaCl, 1 mM EDTA, 0.1% Tween 20). The sample is shaken vigorously for 10 
minutes on a vortex to allow the binding between the streptavidin beads and biotin 
molecules. A vacuum prep tool (Biotage; Upsala, Sweden) sucks up the streptavidin 
beads, washes the sample in 70% ethanol, denatures it in 2 M NaOH, washes it in 
PSQ wash buffer (10 mM Tris-Acetate) and RO water. The beads are released in a 96 
well plate containing 45 pmol sequencing primer mixed with 40.5 pL annealing 
buffer (20 mM Tris-Acetate, 2 mM MgAc2). The samples are denatured at 80 °C for 
2 minutes and allowed to cool to room temperature to allow the sequencing primer 
bind to the DNA strand before they are placed in the pyrosequencer. The amount of 
enzyme, substrate and dNTPs added to the dispensation tool depends on the 
dispensation order and is automatically calculated by the pyrosequencing software 
(Biotage; Upsala, Sweden).
Negative and positive PCR and pyrosequencing controls were included with each 
experiment. To determine whether the primers on their own generated background 
noise they were added in separate reactions without the addition of PCR product. 
Pyro Q CpG, a program designed by Biotage (Biotage; Upsala, Sweden) for 
evaluating methylation patterns with pyrosequencing, was used to determine the 
average methylation percentage across all CpGs sequenced per reaction and 
individual methylation percentages per individual CpG. Data generated by Pyro Q
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CpG was used to plot graphs with GraphPad (La Jolla, California, USA). All samples 
were analysed on a PSQ MA (Biotage; Upsala, Sweden).
2.11.4 PCR Primer D esign
CpG islands were identified with MethPrimer, a free web-based program 
fhttp://www.uro gene. or g/methprimer/index 1.htmli using the limits set out by 
Gardiner-Garden and Frommer (1987). These limits define a CpG island as a region 
of at least 200 bp long with a GC content >60% and an observed/expected ratio of 
CpG dinucleotides >0.6. PCR primers were designed to amplify a region within the 
CpG islands and as close to the transcription start site as possible.
2.9.4.1 Sanger sequencing primer design
For Sanger sequencing the strategy of nested PCR was adopted in order to increase 
the specificity of the PCR reactions. Semi-nested PCR was found to be most 
successful and was adopted for the majority of amplicons. Conventional primer 
length of ±20 bp was increased to approximately 27-28 bp in order to increase 
specificity and decrease mispriming. Primers were not allowed to overlap CpG 
dinucleotides as it would introduce bias into the amplification of methylated alleles 
and PCR gradients were used to find the best annealing temperature and magnesium 
concentration. The amplicons were tested on a 2% agarose gel first to check whether 
the predicted amplicon length matched the observed length. Primer combinations that 
showed only one band of the right length were used for downstream cloning and 
sequencing.
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Table 13. Primer sequences for GPx3, Sepl5, GPx4, GSTP1 and the universal
primer M13.
Primer Name Sequence Annealing Temperature (°C)
GPx3_Fl GTTTTTTT GTTTT GGTTGT AATG GA GAT “
50
GPx3_Rl CTAAAAACTTACACAACCCACCCAAA
50 -
GPx3_F2
GPx3_R3
TTT GG AGTT AA AA GA GG AA GG GAT 
AC AA AA AA AATTC AA AA AATC TCT 50
54.5 " 50
GPx3_F5 AGAGATTTTTT GAATTTTTTTTGT -
GPx3_F3 TTTT GTTT GTTTTTTTT GTTTTT GGT -
Sep 15_F1 TTT GAT ATT GTTAGGGTTTTTTGTAA -
50
Sep 15_R2 AAACTAAATAAAAAACTAAACTACCC - —
60.6Sepl5_F2 GGGTT ATTTTTT G GTT AG GG AA G _
GPx4_F 5 
GPx4_R5
GGTGGA GGTTGT AGTGAGTTGA GAT AG 
CAAAAAAATATCCCCAACTCTTAT ] 50
GPx4_F6 GTT ATTT AG GA GGTTG AGTTA GG AG AAT - 50
GPx4_R6 CAAACCAAACAACCTAAAAATACTA -
GSTPl_Ext_F TTATGT AATAAATTT GT ATATTTTGTATATG -
50GSTPl_Ext_R AAAAAACCTTTCCCTCTTTCCCAAATCCC
GSTPl_Int_F TGT AG ATT ATTT AA GGTTA GG AGTT — 50
GSTPl_Int_R AAACC TA AA AA AT AA AC A AAC A AC AA A -
Universal primer M13 GTAAAACGACGGCCAGT
2.11.4.2 Pyrosequencing Primer design
Primers for methylation pyrosequencing were designed with PSQ Assay Design 
software (Biotage; Upsala, Sweden) after the sequences were converted in silico and 
CpGs were identified as C (methylated)/T (unmethylated) single nucleotide 
polymorphisms (SNPs). Pyrosequencing primers were designed for GSTP1, GPx2, 
GPx3, SelS, DIOl, DIOS, BHMT, BHMT2, USP4, OPRK1, ESD, PPP1R3C, SIM1, 
CDKN2A IS01 and CDKN2A IS04. Table 14 lists the primer sequences with the 
required magnesium concentrations, annealing temperatures and sequences to analyse. 
All amplicons were checked on agarose gels to verify the predicted length and only 
single band primer combinations were used for downstream PSQ analysis.
VS
u
53
03u
&
E
-M
wo
S3
4>aa
03
T3
S3A
vsa
o
•  pH-M
03U-+*avw
S3Ow
E
33
•» hvs<D
S3
OX
03s
4)o
S3«
33
c rV
vs
s-0)
a•p^
Pm
O'
CZ3
Pm
2
03
H
5  OH e .
OX) ^
ox)
•i *S3 *2 CD OX) 
33 <Dcr(U H_l
Cf l
S3
O rS /-N  
^ 3  OX) CM 
f t f l  A
a w  
c
1)O
S3<d
csorCD
GO
0)
i
z
«
?H
CM
co
v din
in(N
co
(N ^
co
co
o \CO
H
H 
O 
Ha  
<d
o  <
< IS
< SH <
^h 2 5H ^  r h
H H ^
H < 5°  ^
^  <  fc
8  2  £
8  h  ^
C <  H
O <  H
O  A  <
o  2  o
O B  O
Ph H Ph
fei I w io  o o
GO GO GOOh, ^  a,|
r*H H r~H
Oh Cm cm
H H H
g o  c/3  c/3
O O O
H
H
O
O
t*o
O
<Ho
<
o
o
2
H
2
O
H
H
H
Ho<
H
o
H
O
H
O
H
H
Ho<ooH
Ho
H
H
H
H
O
O
< cg o 
g o 
n g  
9  h9 P<  H 
O  Ho o
H O
Dvs
'a
§
CDO
g
§■<uC/3
CM
HC/3
o
muo
in(N
co
o oOs O
r —I (N
+ +
<NO(N
o
o
H
< H
2 <
rO —^lO  o  
O  O
a  <  
o  u
< u  
o  o
g 8
o
2
H <H 
H
O _
H PB
<<<<
H
H<H
H
<J<H
C
H
O
O<
o
H
H
H
H
O
CM
m
o  o  o
C/3 CO C/3
fc fc A,
(N (N <NX X X  
Cm Cm Cmo o a
o
H
H
H
H
H
H
H
H
oo
H
H
H
H
H
o
o
Hoo
H
H
H
o
o
o<H
H
H
H
H
H
H
O
H
O
H
<
2
O
H
H
O<
o
C<H
H
H
O
<H
H
H
<
H
H
H
H
<
O
Oo
D
vs
> *
'a
s
<DO
S3(U
33c r<D
C/3
<N
X
Oh
O
CO
vd
in(N
o(N
H 
<  <  c  o  
p  <H H 
H H H H
V  o  
2  h  
^  h  u  h
t  <  ^
H <  t
S 8 gH 8 EO H 
H
O
<H
PQ O
CM
O
GO
^1CO
X
CM
O
H  CM
I ^1o o
C/3 C/3
O h  Cm I ICO CO 
X  X  
CM CM
o  o
<<<
OH
H
H
H
Ho
H
H
O
o
Ho
c
<
Ho
oo<o
H
o
ooo
Hoo
<doo
o
o
<ooo
H
H
Ho
H
O
H
H
c
H Ho o
h  ;* 
< h
H O
fc <H  f-HO H 
H H 
H H
a>
vs
> ?
§
<uo
S3CD
S3
cr1CD
GO
CO
X
CM
O
in
o^  <N 
in  o  o  ^
?  +
C<
U<
u
uc
c  h
<  2
o ^ o  
o  ^  <
h  5  H
h  ^  oH U <m
O U H9 8 °<  9  o
9 ^ o  o  2  h
^  b  h
H  ^  H
H <  H
H A ^
2  5  0
<  PQ O
1—i H
Oh H CM
S l
C/3 11o a o
C/3 GO GO
* 11
GO G3 GO13 13 IS
GO GO C/3
in
in
o
H
H
Ho
H
H
H
H
H
HO
H
H
O
O
>*
H
H
Oo
>Ho
oo
H
H
H
H
H
H
H
£o
IX
Ho
< 3o
o
o
>H
H
H
H
H
Hoo
< 3oo
>ho
o
H  
H  E—' 
H  
<3 
O  
O  Ix 
H  
H
CD
CDo
§
&
<d
CO
CO
13
CO
o
^  CO 
T—I 0 0  
CN CN
¥  +
O
VO
Ph
Ph.
Ph
CO
Ia  a  c/
CO C/5 CO
* ' * ' ^  
o o oHH h—I HH
Q Q Q
CD<Z)
*<3
§
CDo
a
<d
p
c rCD
CO
oH-1
Q
00
CNm
5
00 ,-T
Ph
Ph.
P h
CO
a  a  a
C/5 C/5 C/5
Cl  Cp CpI I I
CO CO CO
o o oHH HH HH
Q Q Q
H
O
2
O
H
H
H0
1
H
Ho
H
H
H
3
H
H
HO
Ooo
H
H
c
H
c
H
O
O
<3
H
H
H
H
H
H<3
<3
H
HO3x
HO
>H
H
H
H
<3
H
H
O
CDC/3
P *13
s
CDopCDPcrCD
C/5
COo
min
ov
+
O
H->
vo
VO
l>
P h
& ,
r-H
Ph
CO1
O ' a a
CO CO CO
* 1 * 1
E-h E-h E-h
s s s
ffi K ffi
PQ PQ PQ
H
H
O
HO
>«
H
H
£o
H
HO
O
>H
Ha
<3
H
H
Ho
>*
H
H
Oa
3ooa
JHo
<3
Ho
><O
H
HOaoo
H
O  .
o ^
2 o 
H  P  
H  £  <3 H
£  5
£  H  >* HO  HH  <3
H H
CDC/3
s
CDOaCDPScrCDco
H
ffi
PQ
i"-m
<3H<3
<3
H  ^
g  < Ho  <j e-h
<  h  gO  H  <3
H U OO  <3 H
O <3 O
<3 <3 O
<3 <3O  O
< 3  U  0
<3 uH  C!
HO
O
O
H
H
ooo  w  o
p  P i pfa a  <»
O ' O ' O '
CO CO CO
fa fa, fa,
(N (N MH H H
S  S  S
ffi ffi K
PQ PP PQ
U
<3
<3OO0
1
u
o
H
Ops3O
H<3
<3
O
U
ps3O
<3tH
<3
<3
<3
<3
CDO)
§
CDo
S
§•CD
CO
CNH
K
PQ
inin
vo
ovo(N
<3
<OH
<3H
O
<3HHHO
<3H
O
<3
<3H
OOH
E-h
E-h
OH
E-h
O
O
CP
H
E-h
<3
<3O
$oOoO
<3O
E-hOE-hH
<3
E-h
E-h
o
<3
E-ho
U
y °E-h O
E- 1 E-h
E-J H <3 E-h
rH
Ph P i P h
S |
CO1
a a a
CO CO CO
* 1 V
P h P h Ph
CO CO CO
p p p
oov
in
in
<D
§
CD
O
a
CD
p
CT
CD
GO
P h
co
D
-2 vo
<N
m  ’—' 
CN
N -
<N
U
o
o  2
g &
g %
P h
W .
H
g B 2
h  O o
s § s
3 S so  a  ^
O  
<  8  
°  g
8 „
3 3O  ■
H  
H
H PQ H
Ph
C/5
o o o
CO GO GO
g1 g1 g's i i
Ph Ph P h
O O O
coooo
<ooHHoooo
>«oHHH
O
<
o
>*
oao
> hHooo
o
2
o
2
O
8 o
>H O
£  2  
h  H
O  ^  
H  ^o  oH  Oa oH  O  
O  H  O  H
>H Oo o
O  <3
<  O H  O  H  O
< H 
O  Ho o  © o  © o
>H O  
H  >ho o o > h
<d
00
13
a
C3
aj
o
a
<d
scr
<d
CO
Ph
O
in
in
o
<<
o
Hoo
H  
H  
O  
H  
H  
O  
E—1
PQ
mo
CN
vo
in
CN
H
c
O
a
H
O  U  
O  H  
H
H  ^
fc O
H
H
U
a
H
O
H
H
a
H
O
H
H
O
<
u<
H
H
<
O
c
Uc
H
H
H
O
U
P h P i P h
^1 I 5/31o ' a  a
C/5 GO CO
°i *i 
Q Q Q
CO CO GOW W W
2
U
2
H
<
2
2
2
O
H
O
2
U
H
H
H
P4
O
P i
o
u
u
P i
u
H
H
u
<J
2
O
o
H
O
3
u
u
H
u
u
u
u
0  
P i
u
c
1
p^
o
P i
u
u
■H
u
u
<
c
u
<L)
13§
o
o
c
(U
c r
<uGO
Q
co
W
in
in
o^
 ^t- co m 
in  cn
+ +
vooCN
O
o
E-h 
H  
E-h
<
p BE-h 
E-h
o  <
O
P <
o
o
H E-h
E-h
H  
H
o  
P o
o
o 
o  <
<E-h ^
o  e-h P H
a  o  
o  A
PQ
o  o
H  H
H
O
<oE-h
Ph W  P h* 2 «
a  o ' c /GO GO GOa, a, P,
o o om m ro
g  P4 P h
P h Ph Ph
P h Ph Ph
P h Ph P h
E-h
o
2
E-h
E-h
E-h
O
> h
Oooooo
E-h
E-ho
<
$
o
o
o
e-ho
E-h
o
2
O
o
>-<
$
o
o
o
2
2
fc o
<D
O
a<D
P
CT1
<D
CO
O
m
P4 So ’—1 >•* 
Ph 13 
Ph f i  
Ph c3
in
in
-2 CN
OCN ^  
CO
(N
CN
o
o
o
2
o
<
e-hh <fc ^E-h o
^ p
2 < hP  <d ^2 < <2  o q
H  <  
H  
H
Ph
^ 1
a
CO
P h .
CO
s .
E-h E-h
E-h 
E-h
O 
E-h
< . , •< u  o
s  ^  <P  < HO U C
< < <2 <i <P  < 2
o  ^  <m o o
CQ O O
P h
CO
O' O
CO CO 
Ph Ph I ^1 
1—<
S 2HH MGO C/J
<
E-h
E-h
E-h
E-h
Eh
<
E-h
E-h
Eh
<c
2
Eh
E-h
E-h
P4
o
<
<uVI
13§
0)
o
C
<u
Pcr
<D
GO
CO
O n
m
in
o^ in
' s f  ON 
00 CN
+ +
in
CN
(N
o
o
o
<o
<<o
H<
<  O  
^  <  
fS £
o  < j
*  s
O  h  
o  a
H
o
H
H
o  
a
H  
H  
H  
H  
. H  
H  O
o
H
O
H  
H  
E-h 
H  
H  
< !
H ^  p  
O c. . E-h 
PQ O
Ph
C/3
Ia  a  a
C/3 C/3 00
*i * i fci
^  T j-
O O O
C/3 C/3 C/3
<  <
(N  CN CN
§ a I
Q Q QO O O
O
O
>H
<H
E-h O
b  < 
o  5  o  P  
>H o  
o  <
> H  o
< 2s fc
P  H
fc P
O  h  
P  H
<J E-h
o  o
E-h O
O  H
<  o
H b
s?>H O
o  PH o
o  o
JH  <
o o
^  o  
o  §
o  g
H  °
H  P< p
o o
p g
<13o
SP
13
O
c r
(13
C/3
O
O -S2
C/3 0J3 
■—'. C
< £
9  «  
§ £Q g
O  8
ovo
(N
C">
O  O
o  h
O  ^
<  2  
h  c
<  e-h 
o  o
O  E-h
o  o
< yo  h
E-h O
P  Ooo
o  <
O  <1  
<  p0  P
1  OE-h hh 
E-h PQ
o
o
<
E-h
<
o
o
o<
o
H
E-h
E-h
<
o
o
c
1— f i— f
P h & P h
S l
C / 3 1
a
1
a
1
a
C / 3 C / 3 C / 3
* 1 1 1 11—H
o o o
C / 3 C / 3 C / 3M 1 •— ‘ i
< < <
CN CN CN
Q Q Q
O O O
E-h
o
o
E-h
E-h
o
o
o
o<
o
o
<
0  <
1 
i
o
< c
o
o
H
<
o
ES
o
H
E-h
E-h
E-h
E-h
E-h
o
o
o
o
o
$
o
E-h
o
13o
c
03
c r
13
C/3 ^
O  • ri
C/3 t i
' o
V " 3Ol
CN
Q g 
O  §
in
in
inin+
o
(N
t" -+
O
Hj-
E-h
o
< P
E-h
E-h
<<<
<
E-h 1
E-h <
O  b
< E-h O
b  P  E-h
2
< o
< p
P o 
C
E-h 
E-h
< P
. o
s  <
ri °  P  O
E-h
H
E-h
E-h
O
H
OIo
HH
PQ
O
O<E-h
O
o<
o
e-h
e-h
e-h
<
o
o
<
, H o
P 4 & < PLh
S l C / 3 1
a c x
1
a
1
a
C / 3 C / 3 C / 3 C / 3
* 1P ' P ' P ' P
P P P
< c < <
ooo
p ^o
coo
<o
03w
§
13
O
Ch
13
ocr
13
C / 3
Dh-1
c
(N
O n
Chapter 3 -  PRECISE pilot study
Chapter 3 Effects of Se status and supplementation on 
plasma homocysteine and the interaction of these 
effects with nutritional factors involved in one-carbon 
metabolism
3.1 Introduction
A number of human studies (Bates, 2002; Gonzalez, 2004; Klapcinska, 2005; 
Belanger, 2006) have linked Se status with tHcy concentrations and found an inverse 
correlation between the two. This correlation was not observed in a New-Zealand 
study (Venn, 2002). In that same study, supplementation with 200 pg Se/day did not 
influence tHcy concentrations. The results of the human studies are in contrast to 
those in rats and mice where Se supplementation increased tHcy levels (Uthus, 2002 
etc.).
Given the conflicting reports described above, the effect of Se supplementation on 
plasma tHcy was investigated. A further aim was to observe to what extent B-vitamin 
status might affect the interaction, particularly given the known requirement for PLP 
in selenoamino-acid metabolism (Figure 1; Soda, 1999).
For this purpose, plasma samples were used that had been generated in the UK 
PRECISE Pilot Study (Rayman, 2006). This was a double-blind, placebo controlled 
trial in which 501 UK volunteers aged 60-74 were randomly allocated to receive 100, 
200 or 300 pg Se/d as high-Se yeast or a placebo yeast. Blood was collected at 
baseline and six months, enabling plasma Se, tHcy, folate, vitamin B12 and PLP to be
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measured at these time points in a selection of samples. As it is considered good 
practice to use more than one index for evaluation of vitamin B6 status (Leklem, 
1990), plasma 4-pyridoxic acid (PA) was also measured, a catabolite of PLP, which 
gives a complementary measurement of vitamin B6 status (Bates, 1999).
3.2 Participants
Five hundred and one participants were recruited between June 2000 and July 2001. 
All variables were measured in the baseline samples but owing to financial 
constraints, only samples from the placebo, 100 and 300 pg groups were analysed for 
all variables at follow-up. Figure 15 (overleaf) shows the flow of participants through 
the study from which it can be seen that 374 participants in total were allocated to the 
placebo, 100 and 300 pg groups and that 83, 85 and 81 samples respectively were 
analysed for all variables at follow-up.
3.3 Compliance with treatment
Three hundred and sixty one of the 374 participants (96.4%) randomized to the 
placebo, 100 and 300 pg/d groups were compliant (missed less than 10% of the total 
number of tablets they should have taken) according to pill count. Non-protocol use 
of over-the-counter Se (“drop-ins”) was assessed by inspection of the distribution of 
plasma Se concentrations in the placebo group at six months. 103 out of 114 
participants on placebo had follow-up Se measurements; of these, two (1.9%) had a 
Se status at follow-up more than two standard deviations above the mean, consistent 
with the 2.5% expected for a population approximating a normal distribution. We 
have made the assumption therefore, that "drop-ins” were rare.
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Randomised (n = 501)
Missing at least one 
measurement (n = 31)
Missing at least one 
measurement (n = 32)
Missing at least one  
measurement (n = 33)
Analysed
(n = 0)
A ssessed  for eligibility
(n =2140)
Missing all
measurements except 
Se (n = 122)
Analysed
(n = 83)
Men (n = 43) 
Women (n = 40)
Analysed
(n = 85)
Men (n = 45) 
Women (n = 40)
Analysed
(n = 81)
Men (n = 41) 
Women (n = 40)
Allocated to placebo
(n = 121)
Received allocation 
(n = 121)
Allocated to 300 pg/d
(n = 126)
Received allocation 
(n = 126)
Allocated to 200 pg/d
(n = 127)
Received allocation 
(n = 127)
Allocated to 100 pg/d 
(n = 127)
Received allocation 
(n = 127)
Excluded (n = 1639)
Not meeting inclusion criteria (n = 780) 
Refused to participate (n = 826)
Failed to complete placebo run-in (n = 33)
Withdrawals from 
treatment (missing 6- 
month blood sample)
(n = 5)
Reasons:
Adverse events (n=1) 
Non compliance (n=0) 
Failed to attend (n=1) 
Serious medical event 
(n=0)
Other health problems 
(n=0)
Wishes to take selenium 
(n=0)
Other personal (n=3) 
Died (n=0)
Withdrawals from 
treatment (missing 6- 
month blood sample)
(n = 12)
Reasons:
Adverse events (n=8) 
Non compliance (n=1) 
Failed to attend (n=1) 
Serious medical event 
(n=0)
Other health problems 
(n=1)
Wishes to take selenium 
(n=1)
Other personal (n=0) 
Died (n=0)
Withdrawals from 
treatment (missing 6- 
month blood sample)
(n = 10)
Reasons:
Adverse events (n=2) 
Non compliance (n=0) 
Failed to attend (n=2) 
Serious medical event 
(n=1)
Other health problems 
(n=1)
Wishes to take selenium 
(n=0)
Other personal (n=3) 
Died (n=1)
Withdrawals from 
treatment (missing 6- 
month blood sample)
(n = 7)
Reasons:
Adverse events (n=2) 
Non compliance (n=0) 
Failed to attend (n=0) 
Serious medical event 
(n=1)
Other health problems 
(n=1)
Wishes to take selenium 
(n=1)
Other personal (n=2) 
Died (n=0)
Figure 15. Participant flow through the study. * Insufficient sample. J 200 pg 
group follow-up samples were not analysed owing to limited resources
3.4 Withdrawals
Thirty-four of the initial 501 participants (7%) withdrew from the study within the 
first six months, five of whom had been allocated to the 200 pg group. Thus there 
were 29 withdrawals from the 374 participants that were randomized to the placebo,
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100 and 300 jig groups, i.e. 8% of the total. There was no significant difference in 
numbers of participants withdrawing from treatment in the different groups (7, 10, 
and 12 in the placebo, 100 and 300 pg groups respectively: X2=1.2, df=2, P=0.57). 
Of these, 12 withdrew because of adverse events, six of which were 
abdominal/stomach problems. Other reasons for discontinuation appeared unrelated to 
treatment.
3.5 Stability of measured parameters over time
Self-correlation tests between measurements on the placebo group at baseline and at 
six months were performed. The linear regression line with its R value can be used 
as an indirect measure of the reproducibility of the measurements over a six-month 
period. Scatter plots were constructed from placebo cases with a measurement value 
for both baseline and at six months were entered in scatter plots and linear regression 
lines were fitted (Figure 16). R values for the different factors were 0.529 for Se, 
0.806 for tHcy, 0.380 for folate, 0.285 for PLP, 0.059 for PA and 0.709 for vitamin 
B12.
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Figure 16. Self-correlation scatter plots for placebo samples at baseline and after 
six months. Se: Selenium; tHcy: homocysteine; PLP: Pyridoxal 5'-phosphate; PA: 4- 
pyridoxic acid.
3.6 Baseline data
Table 15 shows the mean concentrations of the different factors assayed prior to 
treatment. Men had significantly higher total plasma tHcy (11.50 ± 4.19vs. 10.17 ± 
3.64; P0.001) but lower plasma folate (11.51 ±7.47 vs. 13.28 ± 8.86; P=0.023) and 
vitamin B12 (340.76 ±100.34 vs. 369.83 ±130.80; P=0.009) values compared to
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women. Age was inversely correlated (both sexes combined) with Se (r = -0.176, 
PO.OOOl) and positively correlated with tHcy (r = 0.220, P<0.0001).
Table 15. Baseline study population characteristics by sex, and P values for 
differences between men and women.
Variables Na Menb Womenb P
Age,y 265/236 67.05 ±4.01 66.64 ±4.17 0.269
Plasma Se, ng/g 254/229 88.09 ±17.78 91.28 ±20.23 0.066
Plasma tHcy, pmol/l 239/215 11.50 ±4.19 10.17 ±3.64 <0.001
Plasma Folate, ng/ml 239/216 11.51 ±7.47 13.28 ±8.86 0.023
Plasma PLP, nmol/l 238/211 51.17 ±27.28 49.40 ±27.08 0.493
Plasma PA, nmol/l 238/211 18.79 ±14.34 16.65 ±15.23 0.125
Plasma B12, pg/ml 235/215 340.76 ±100.34 369.83 ±130.80 0.009
a Number of participants who had each measurement at baseline (males/females). 
Values are means ± SD
A correlation matrix was set up (Table 16), which revealed that tHcy was significantly 
inversely correlated with all variables though only in males in the case of Se (r=-.138, 
P=.034), PLP (r=-.178, P=.006) and PA (r=-.161, P=.014). tHcy correlated in both 
males and females with folate (r=-.297, P<.001; r=-.258, P<.001) and vitamin B12 
(r=-.363, P<.001; r=-.311, P<.001). Se was also significantly correlated with PLP 
(r=.144, P=.027) but again, only in males. Folate was significantly correlated in both 
males and females with PLP (r=.288, P<.001; r=.428, P<.001) and PA (r=.433, 
P<.001; r=.437, P<.001) while folate was only correlated with vitamin B12 in females 
(r=-.311, P<.001). PLP and PA correlated very strongly with each other in males 
(r=.525, P<.001) and in females (r=.385, P<.001). Vitamin B12 correlated in both 
genders with PLP (r=.174, P=.008; r=.228, P=.001) and PA (r=.195, P=.003; 
r=.147,P=.035).
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Chapter 3 -  PRECISE pilot study
Linear regression identified factors that significantly influenced tHcy concentration at 
baseline (Table 17). The tests were performed separately in men and women as there 
were marked differences between the sexes. All variables from Table 15 were 
entered into the stepwise linear regression model. Plasma Se concentration was found 
to have a significant influence on tHcy concentration in males, accounting for 1.8% of 
the variance, though the effect was considerably smaller than that of folate (17.6%) 
and vitamin B12 (13.1%); in females, there was no effect of plasma Se, folate having 
by far the largest effect (29.2%).
Table 17. Linear regression of the baseline values using tHcy as the dependent 
variable.
Independent
variableb,c
P coefficient Significance
R2 change 
in %
Men (n =225)a Folate - 0.355 < 0.0001 17.6
B12 -0.361 <0.0001 13.1
Se -0.137 = 0.013 1.8
Women (n =204)a Folate - 0.487 <0.0001 29.2
B12 -0.169 = 0.004 2.6
a Number of men or women who had measurements of Se, tHcy, folate, PA, vitamin 
B12 and B6 at baseline.
•L
Values were adjusted for age. 
c Variables were logarithmically transformed.
There were significant differences in tHcy concentrations between the lowest (<78 
ng/g) and highest (>94.01 ng/g) Se tertiles in males (11.73 ±3.37 vs 10.91 ±4.97 
pmol/1 respectively, P<0.05, independent t-test) consistent with linear regression and 
Pearson correlation results. Female subjects with folate concentrations in the top
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tertile (>14.16 ng/ml) had lower tHcy concentrations (8.04 ±1.56 vs 10.67 ±5.92 
pmol/1, P<0.01, independent t-test) when their Se concentrations were also in the top 
tertile (>100.01 ng/g) compared to the lowest Se tertile (<80 ng/g). This also became 
evident when linear regressions were compared between the different correlation sets 
(Figure 17). As shown above, Se and tHcy data points correlate significantly only in 
males (Figure 17a) and not in females (Figure 17b), but when female cases were 
selected with folate concentrations in the top tertile, the linear regression line was 
significantly different from zero as well (Figure 17c; P=.038). The initial correlation 
between Se and tHcy disappeared when males only were selected who had folate 
concentrations in the top tertile (Figure 17d).
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Figure 17. Scatter plots with correlations between Se and tHcy at baseline, a: All
male cases at baseline; b: All female cases at baseline; c: Female cases with folate 
concentrations in the top tertile only (>14.16 ng/ml); d: Male cases with folate 
concentrations in the top tertile only (>13.26 ng/ml).
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Concentrations of tHcy were lowest in those subjects with high folate (>13.25 ng/ml), 
PLP (>56.21 nmol/l) or vitamin B12 (>390 pg/ml) who also had high Se (>98 ng/g) 
(Figure 18).
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Figure 18. 3D Bar Charts showing the interaction of Se, folate, PLP and vitamin 
B12 on tHcy concentrations at baseline. A: Se and folate tertiles; B: Se and PLP; 
C: Se and vitamin B12. (Asterisks indicate significantly different from the lowest 
tertile of the X-axis variable by ANOVA, *P<0.05).
3.7 Se status
Overall mean plasma Se in the 483 participants who had Se measurements at baseline 
was 89.6 (SD ±19.0) ng/g {equivalent to 92.0 (SD ±19.5) pg/L (Lide and Raton 1993- 
1994)}. Four hundred twenty one participants had plasma Se measurements at 
follow-up from which it could be seen that Se supplementation significantly elevated 
Se concentrations in all treatment groups except the placebo group (Table 18).
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Table 18. Plasma Se at baseline and after 6-months supplementation and P value 
for difference.
Treatment
Baseline Se 
ng/g1
Six months Se 
ng/g1
P
Placebo (n=103) 89.98 91.36 0.738
100 pg (n =107) 87.85 144.49 < 0.0001
200 pg (n=110) 89.41 191.16 <0.0001
300 pg (n =101) 91.33 226.71 < 0.0001
Plasma Se measurements can be converted from ng/g to pg/L by
multiplying by 1.027, the density of plasma (Lide, 1993).
A visual representation of the Se intervention data is given in figure 19.
I | Baseline 
M  Six Months
Figure 19. Plasma Se at baseline and after 6-months supplementation. Selenium 
status was significantly altered by supplementation with 100, 200 and 300 pg Se/d (all 
P0.001, paired t-tests). Data are means and 95% CIs at baseline (open square), and 
six month follow-up (filled square), for the four intervention doses.
"3j 400*
300
200<
100
Chapter 3 -  PRECISE pilot study
3.8 Effect of the intervention on plasma tHcy
Concentrations of plasma tHcy at baseline and after six-months are shown separately 
for males and females in the three treatment groups (Table 19). At baseline, there was 
no evidence of any difference in tHcy levels between groups (P=0.741, ANOVA). 
When follow-up plasma tHcy concentrations (adjusted for baseline tHcy 
concentration and age) in the different treatment groups were compared to that of the 
placebo group, there was no evidence of an effect of Se intervention on plasma tHcy 
in either males, females (Table 19) or both sexes combined (data not shown).
Table 19. tHcy at baseline and after six-months supplementation, and P  value 
for difference.
Sex Na
Treatment
Group
tHcy at Baseline 
(±SD) 
pmol/1
tHcy at Six months 
(±SD) 
pmol/1
P  value 
(ANCOVA) b’c
Males 45 Placebo 10.94 (±3.56) 11.30 (±3.77) -
48 100 pg Se 11.64 (±4.02) 12.12 (±4.06) 1.000
50 300 pg Se 11.42 (±3.17) 12.00 (± 3.36) 0.482
Females 41 Placebo 10.42 (±3.72) 10.07 (±3.47) -
42 100 pg Se 10.32 (±2.86) 10.14 (±3.07) 0.526
44 300 pg Se 9.56 (± 2.37) 9.51 (±2.26) 1.000
a Number of participants who had a tHcy measurements at both baseline and follow-up. 
b tHcy at BL (pmol/1) as dependent variable 
c Values were adjusted for age
When subjects were grouped according to tertile of plasma Se attained at six months, 
no significant differences were found in tHcy concentrations between tertiles (P=.992, 
ANOVA). Even subjects in the top quartile of tHcy at baseline, who might have been
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expected to show tHcy lowering on Se supplementation, did not benefit from Se 
treatment (P= 558, ANOVA).
A stepwise linear regression model containing all the variables in Table 15 was 
generated to assess which, if any, of the variables affected tHcy concentration at 
follow-up. The only variable influencing tHcy concentration in all treatment groups 
at follow-up was folate, except in the 100 pg/d female group where PA had a larger 
effect (Table 20).
Table 20. Linear regression analysis of the impact follow-up variables on follow- 
up tHcy.
Na Treatment Independent
variable
p  coefficient Significance R2 change 
in %b
Men 51 Placebo Folate - 0.256 <0.01 5.7
47 100 pg Se Folate -0.178 <0.05 2.4
46 300 pg Se Folate -0.162 <0.05 2.3
Females 39 Placebo Folate - 0.368 <0.001 10.5
46 100 pg Se PA - 0.220 <0.05 4.6
41 300 pg Se Folate -0.231 <0.01 5.0
a Number of men or women who had measurements of Se, tHcy, folate, PA, vitamin 
B12 and B6 at follow-up. 
b Values were adjusted for age.
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Chapter 3 Discussion: The PRECISE pilot Study
One-carbon metabolism is responsible for the production of methyl groups that are 
used in a large number of biological processes ranging from the detoxification of 
metabolites to DNA methylation. Diet is an important modifiable determinant for the 
pathway as the remethylation reactions depend on the availability of folate, choline, 
methionine and vitamins B2, B6 and B12. The nutrients are either co-factors of the 
enzymes involved in the pathway or, as in the case of folate and choline, they are the 
methyl group donors for the enzymes. Deficiency of any of these dietary factors can 
result in a flux change translating itself into methyl group deficiency or inappropriate 
accumulation of toxic metabolites such as tHcy. An important process depending on 
the end-product of one-carbon metabolism, DNA methylation, has been associated 
with folate concentrations and cancer susceptibility, providing evidence for a link 
between diet, one-carbon metabolism and cancer risk.
Recently, Se too was shown in a number of studies to play a role in one carbon 
metabolism and DNA methylation. Se and tHcy plasma concentrations in humans 
were found to be inversely correlated in Spanish, Polish, UK and Inuit populations. 
However, an intervention with 200 pg/d Se in New-Zealanders did not affect plasma 
tHcy.
The aim of the study was to investigate the effect of Se supplementation on plasma 
tHcy concentration taking into account the other nutritional factors involved in one- 
carbon metabolism. For this purpose Se, tHcy, folate and vitamins B6 and B12 were 
measured in plasma samples from the PRECISE pilot trial.
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Studies within different age groups have suggested that Se concentrations decrease 
with age while tHcy increases (Bates et al. 2002). The results of this study clearly 
corroborate these conclusions. A clear difference between sexes was noted for 
concentrations of the nutritional factors. Females appeared to have better nutritional 
status than males, as shown by higher concentrations of folate and vitamin B12 and 
lower tHcy concentrations at baseline. Males in our study had 12% higher mean tHcy 
concentrations than females. Similar differences between the sexes have been 
observed in other studies: tHcy was 9% higher in males than in females in the NDNS 
(Bates et al 2002) and 15% higher in the British Regional Heart Study (Dekou et al 
2001). In the latter study, folate was not significantly different between the sexes but 
vitamin B12 was higher in females compared to males (14%) (Dekou et al 2001) as it 
was in our study (9%).
The UK NDNS provides a suitable reference group with which to compare our values 
as it also investigated nutrient concentrations in elderly men and women (Finch et al 
1998; Bates et al 2002). Compared to NDNS subjects, participants in the PRECISE 
study had higher concentrations of all nutrients investigated, while tHcy was lower. 
Specifically, mean plasma Se in the healthy volunteers was 89.6 ng/g (equivalent to 
92.0 pg/L) compared to 78.17 pg/L in NDNS subjects (Bates et al 2002). In the past, 
maximum activity of plasma glutathione peroxidase has been taken as a measure of 
Se adequacy. By this criterion, the mean status of the study population was borderline 
adequate (Duffield et al 1999) though given the median value of 91.4 pg/L, this 
suggests that almost 50% may not have achieved adequacy.
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Despite optimistic predictions from observational human studies (Bates et al 2002; 
Gonzalez et al 2004; Klapcinska et al 2005; Belanger et al 2006), no effect was 
found of supplementation with 100 or 300 pg/d high-Se yeast on plasma tHcy 
concentration in the double-blind placebo-controlled trial. The results are in 
accordance with a study from New Zealand that found no effect of supplementation 
with 200 pg/d Se as selenomethionine on tHcy concentration (Venn et al 2002). The 
increase in tHcy that might have been predicted by studies in rats (Uthus and Ross 
2007) was not found in this study though this may be because comparisons are made 
with states of Se deficiency in animals that are not seen in humans. It may also be 
relevant that species-specific differences have been seen in the response of Hey to Se 
supplementation. Such a difference between species was observed in rats and mice 
where Se deficiency decreased tHcy concentrations in both species but enzymes 
involved in the pathway were affected differently between species (Uthus and Ross
2007). This indicates that the effect of Se on one-carbon metabolism is species- 
specific and provides an alternative explanation to the effects observed in this human 
study compared to previous animal studies.
Though no effect of the intervention was observed, significant associations between 
plasma concentrations of Se, tHcy and B vitamins were found at baseline. Notably, 
low Se status was significantly associated with high tHcy concentration at baseline, 
though only in men. In women, ANOVA showed that those with significantly lower 
tHcy were in the top tertile both of plasma folate and plasma Se.
Linear regression analysis in males at baseline revealed that plasma Se was associated 
with 1.8% of the variation in tHcy while folate, at 17.6%, had the largest effect. This
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is in contrast to the results of Gonzalez and colleagues (Gonzalez et al. 2004) who 
reported that for both sexes together, serum folate explained a smaller proportion of 
plasma tHcy variation than did serum Se (2.2% vs. 5.8%), with serum vitamin B12 
accounting for very little of the variance (0.6%). Though PLP was shown by Bates 
and colleagues (Bates et al. 1999) to affect tHcy concentration, it did not have a 
significant effect in this study, although it did correlate with tHcy in males at baseline.
The British Regional Heart Study (Dekou et al. 2001) showed equally strong negative 
and highly significant correlations between tHcy, folate and vitamin B12 as did our 
study. The inverse relationship between Se and tHcy that we observed at baseline has 
previously been observed by other groups (Gonzalez et al. 2004; Klapcinska et al. 
2005; Belanger et al. 2006) although they did not separate the sexes in their analysis, 
nor did they take account of any possible confounding by B-vitamin status. In the 
NDNS study of the UK elderly, folate, PLP and vitamin B12 were also measured 
(Bates et al. 2002). After adjustment for serum folate, PLP and vitamin B12, the 
inverse correlation between plasma Se and tHcy seen in the free-living NDNS 
population became non-significant (Bates 2005). It is possible that had the B vitamins 
been measured in the other studies, the relationship between Se and tHcy would have 
disappeared or have been attenuated. This is unlikely to be the whole explanation for 
the relationship between Se and Hey seen in the Spanish study however, as both folate 
and vitamin B12 were taken into account in the analysis.
Another possible explanation for the finding of an inverse association between plasma 
Se and tHcy is that we were seeing an effect of protein intake. Protein is the main 
dietary carrier of Se and its intake is inversely correlated with tHcy (Stolzenberg-
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Solomon et al. 1999). However, Gonzalez and colleagues found that the correlation 
they saw between tHcy and protein intake became non-significant after Se was 
included in the model, suggesting that Se is driving the effect of protein on Hey 
concentration (Gonzalez et al. 2004). This is therefore an unlikely explanation.
Though the B vitamins were measured and could therefore account for their effects, 
creatinine was not measured, an indicator of kidney function that in turn is linked to 
plasma homocysteine homeostasis (Refsum et al. 2006). In the elderly NDNS, 
plasma creatinine was significantly inversely associated with plasma Se (n=700, 
F=15.3, PO.OOOl, ANOVA) (Bates et al. 2002). It is therefore possible that the 
inverse association between Se and tHcy is an effect of kidney function, where low Se 
is secondary to failing kidneys (Sabe et al. 2002). This is unlikely to be the whole 
story, however, as Gonzalez and colleagues measured serum creatinine and though 
they used it as a covariate in their analysis, were still unable to account fully for the 
association between Se and tHcy.
Perhaps a more likely explanation for the PRECISE results and those of Gonzalez and 
colleagues relates to a primary effect of pro-inflammatory cytokines on the levels of 
both plasma/serum Se and tHcy. In both acute (Nichol et al. 1998) and chronic 
illnesses (Sattar et al. 1997), Se plasma concentrations are decreased in proportion to 
the magnitude of the inflammatory response (Nichol et al. 1998). Three different 
cytokines have been shown in in vitro studies to have a negative effect on SEPP1 
expression: TGF- p (Mostert et al. 1999), IL1-P and IFN-y (Hesse-Bahr et al. 2000). 
SEPP1 and plasma GPx make a major contribution to the concentration of Se in 
plasma but during the acute phase response the expression of SEPP1 and other
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selenoproteins could be reduced by the previously mentioned pro-inflammatory 
cytokines.
In addition, Se can be redistributed during the acute phase response from blood and 
liver to muscle tissue causing a redistribution of Se over the body possibly resulting in 
inaccurate whole body Se determinations from plasma (Drain et al 2006). Se (as 
selenomethionine) is also incorporated into plasma albumin, a negative acute-phase 
protein. Together with the decreased selenoprotein expression that occurs with 
inflammation, lower albumin synthesis in an inflammatory state might account for the 
lower plasma Se concentration observed in such states (Drain et al 2006).
By contrast, the concentration of tHcy has been positively correlated with pro- 
inflammatory cytokines [IL-lra and IL-6 (Gori et al 2005)]. In vitro studies have 
shown that homocysteine can stimulate IL-6, IL-ip and TNF-a production in human 
endothelial cell and monocytes via nuclear transcription factor activation (Dalai, 
2003). If this increase in cytokines stimulates a state of inflammation it could 
decrease Se concentrations by (1) negatively influencing SEPP1 and plasma GPx 
expression and (2) by decreasing albumin concentrations in plasma.
Thus a hypothesis can be generated that the more prevalent inflammation is in a 
population, the stronger the inverse correlation between Se and tHcy might be 
expected to be. In an elderly population, levels of inflammatory mediators such as 
cytokines and acute phase proteins are two- to four-fold higher than in younger 
groups (Vasto et al 2007). Given that the Spanish study population consisted of 
nursing-home residents of mean age 75y, it is likely that inflammation was more
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prevalent than in our free-living, healthy volunteers of mean age 67y. The fact that 
tHcy concentrations were higher (by 17% and 26% in males and females respectively) 
in the Spanish study population than in the subjects from the PRESICE study supports 
that conclusion. It is therefore likely that inflammation explains the inverse 
correlation observed between Se and tHcy, and that the degree of inflammation in any 
given population will predict the strength of such a correlation.
If Se and tHcy concentrations are influenced by the acute phase response and are 
responsible for the inverse correlation between Se and tHcy observed in this study, a 
marker of acute phase response such as C-reactive protein should be included in 
future studies to distinguish true correlations between nutrients from inflammation 
effects.
While this may be the most likely explanation for the baseline associations observed 
in the current study, the small correlation of Se status with tHcy concentration could 
also be an independent effect. Uthus and colleagues (Uthus et al 2002; Uthus and 
Ross 2007) found that Se deficiency affected the activity of BHMT, GNMT and GCL 
enzymes involved in one-carbon metabolism. It is know that Se can react with 
cysteine-rich regions present within the catalytic domain of enzymes such as protein 
kinase C where it may induce oxidation of cysteines (Gopalakrishna et al. 1997). As 
BHMT is a zinc-dependent cysteine-rich enzyme, an altered thiol redox status could 
influence its activity (Uthus et al 2002) in much the same way as for protein kinase 
C. Though the volunteers were not classed as Se-deficient, it is possible that those of 
higher baseline Se status were better able to use BHMT to catalyse the transfer of a 
methyl group from betaine to homocysteine for its remethylation back to methionine.
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In summary, in the PRECISE study population, baseline Se status (mean 89.6 ± 19.0, 
range 49-177 ng/g) was significantly inversely associated with plasma tHcy 
concentration, though the magnitude of the association was small amounting only to 
1.8% of the variance observed. However, no effect was observed of supplementation 
with Se at 100 or 300 pg/d for six months on plasma tHcy concentration in a 
randomised, double-blind placebo-controlled trial.
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Chapter 4 Gene expression and DNA methylation 
analysis of prostate cells
4.1 Introduction
Aberrant DNA methylation can be associated with either gene activation or gene 
silencing. As covered in the literature review (Chapter 1.3), both gene activation and 
silencing can result from DNA hypermethylation depending on the region of 
methylation. DNA hypomethylation has only been associated with gene activation 
either through a direct mechanism by allowing activating transcription factors to bind 
or an indirect mechanism through the translocation of DNA fragments, which can e.g. 
initiate expression of oncogenes.
Demethylation with a chemical compound is a commonly used technique to 
investigate whether promoter hypermethylation is the cause of gene silencing. This 
demethylating agent inhibits DNA methylation by covalently trapping DNA 
methyltransferases and results in an increased number of RNA transcripts of genes 
whose promoters are potentially hypermethylated. Gene expression microarrays can 
then identify which transcripts are significantly up-regulated on a whole genome 
scale. Downstream DNA methylation profiling techniques can afterwards identify 
whether promoter hypermethylation really is the cause behind the gene silencing.
A few papers have identified two selenoproteins to be hypermethylated in cancer. 
GPx3 was found to be hypermethylated in prostate (Lodygin et al 2005; Peng et al
2008) and oesophageal cancer (Lee et al 2005) while SelR or MsrBl was
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hypermethylated in highly metastatic compared to low metastatic breast cancer cells 
(De Luca et al 2007). Whether these selenoproteins are innocent bystanders of a long 
range hypermethylation effect or whether they play an active role as tumour 
suppressor genes is unclear, but it does suggest that other selenoproteins or genes that 
also respond to Se supplementation might be hypermethylated.
4.1.1 Aim
The aim of this project was to identify hypermethylated genes that are Se-responsive 
in an unmethylated state by supplementing cell lines with (i) a demethylating agent to 
restore gene expression; (ii) extra Se after demethylation to stimulate an additional 
increase of RNA expression. This approach allowed the identification of 
hypermethylated genes on a whole genome scale that would be Se-responsive if they 
had not been hypermethylated.
4.2 Methylation pattern analysis of cancer cell lines
The promoter methylation status of GSTP1, GPx3, GPx4 and SEP 15 was investigated 
in DU 145, LnCAP and RWPE-1 prostate cell lines and in an acute monocytic 
leukemia cell line, THP1. DNA extracted from the cell lines was bisulphite converted 
after restriction digestion and amplified with different PCR primer sets according to 
the methods outlined in Chapter 2 to check for primer binding specificity (Table 21).
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Table 21. Optimised PCR amplicons for GSTP1, GPx3, GPx4 and Sepl5.
Gene
CpG sites 
relative to TSS
Location 
relative to TSS (bp)
GSTP1 -56 to -36 -1024 to -567
GPx3 (amplicon 1 and 2) +1 to +54 +19 to +758
GPx4 amplicon 1 -42 to -30 -700 to -322
GPx4 amplicon 2 -26 to +38 -245 to +261
Sep 15 -90 to -75 -1245 to -1063
Examples of PCR optimisation and clone selection using gel electrophoresis can be 
found in Appendix 2 as Figures 1-4. The PCR fragments were cloned into plasmids, 
grown in bacteria and extracted plasmid DNA was sequenced using Sanger 
sequencing with the reverse primer. Sequences were put into MethTools 
rhttp://genome.imb-i ena.de/methtools/1 to visualise the ratio of methylated vs 
unmethylated CpG sites (Figure 20).
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Most CpGs of the alu sequence of GSTP1 were methylated (Figure 20). The sequence 
downstream of the [ATAA] repeat was not methylated in any of the clones. CpG -55 
was the only CpG site to be methylated in all 5 clones in this THP-1 monocyte-like 
human cell line. The methylation profile of GSTP1 was in complete accordance with 
the results published by Millar and colleagues (Millar et al 2000) and validated the use 
of bisulphite sequencing for the investigation of promoter methylation patterns.
None of the CpG sites were methylated in any of the prostate cell lines for the SEP 15 
amplicon. GPx3 was methylated in LnCAP cells but not in the ‘normal’ prostate 
epithelial RWPE-1 cell line. Two CpG sites at +35 and +50 (9/10) were consistently 
not methylated in the LnCAP clones, while only one CpG site, +34, was methylated in 9 
out 10 of the DU 145 clones. This CpG site is part of a putative SP1 binding site 
[CCCCGCC] and may play a role in gene expression regulation by diminishing the 
DNA-binding activity of the transcription factor (Alikhani-Koopaei et al 2004).
In the RWPE-1 cells the first amplicon of GPx4 was 56.3% methylated, in DU145 cells 
it was 30.1% methylated and in LnCAP cells it was 64.6% methylated. CpG site -32 
was the only CpG that was hypermethylated in DU 145 (5/10 CpGs) and LnCAP (10/10 
CpGs) cells compared to RWPE-1 cells (0/10 CpGs). CpG site -30 was almost 
completely unmethylated in all cell lines compared to the rest of the amplicon. Almost 
no CpG sites were methylated for any of the cell lines in the second GPx4 amplicon 
covering the transcriptional start site. The large difference in methylation between the 
two amplicons of GPx4 could be due to their location. Amplicon 1 is located within a 
CpG poor region and amplicon 2, incorporating the transcriptional start site, within a 
CpG rich region whereby CpG site -30 functions as the first CpG site located within the
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CpG island. These results are in accordance with gene expression data from NCBI 
(UniGene Hs.433951), which shows that GPx4 is expressed in normal prostate and 
prostate cancer tissues.
4.3 Validation of methylation pyrosequencing
Pyrosequencing is a quick and cheap method to sequence short regions of DNA and can 
be used on PCR-amplified, bisulphite-converted DNA to determine the proportion of 
methylated vs unmethylated CpGs. This technique was validated by analysing the 
promoter methylation status of a control gene, GSTP1. Primer sets for methylation 
profiling were designed and tested for primer binding specificity as described in section 
4.2. The validity of the technique was tested with two dilutions made from a 
combination of whole genome methylated DNA and Sssl treated/methylated DNA (1/1 
and 3.5/1.5), a positive (Sssl treated DNA) and a negative control (whole genome 
amplified DNA). Results are represented in Figure 21.
GSTP1 PSQ validation
100n
♦  W G A  
S s s l  
P C -3
1 .5 /3 .5  Mix 
■ *- 1/1 m ix
80 -
J8 60-
20 -
0 1 2 3 4  5 6 7 8 9 10 11 12 13 14
C pG  S ite
Figure 21. Methylation pyrosequencing validation with Sssl methylated DNA and 
whole genome amplified DNA. Results were obtained from a single experiment. 
WGA: whole genome amplified DNA; Sssl: DNA methylase treated DNA.
119
Chapter 4 -  Gene re-expression
As expected, whole genome amplified DNA had the lowest average methylation score 
of 7% and Sssl methylated DNA the highest score with 94% while the positive control, 
PC-3 cells, had 67%. The two dilutions had a score of 72% and 26%, for the 1/1 and 
3.3/1 dilution respectively. The results confirm methylation pyrosequencing as a valid 
tool to investigate DNA methylation analysis.
4A Validation of the Se treatment
Hep G2 cells were used to validate the Se treatment necessary to up-regulate the RNA 
expression of Se-responsive genes. Cells in triplicate were given either control medium 
(with PBS) or medium with 100 nM sodium selenite for 48 h (Pers. Comm. Dr 
Brigelius-Flohe). QPCR was performed for a putative control (unaltered by Se) gene 
RPS18 (=18S rRNA) and selenoproteins GPxl, GPx3 and GPx4. Sodium selenite was 
the preferred source of Se as selenite was shown to induce GPx activity more rapidly 
than selenomethionine (Rebsch et al. 2006; Zeng et al. 2008). Results are displayed in 
Figure 22.
GPx1 GPx3 GPx4
Figure 22. Gene expression analysis of GPxl, GPx3 and GPx4 before and after Se 
treatment. Expression values were normalised against housekeeping gene (HKG) 
RPS18. **P<.01, ***P<.001, paired t-test, error bars are SD. Results obtained from 3 
technical replicates for each of 3 biological replicates for both conditions in a single 
experiment.
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RNA levels of RPS18 were not significantly altered by Se treatment (data not shown) 
and was chosen as a suitable control gene. Levels of GPxl and GPx3 RNA, however, 
were significantly increased (P<.01 and P<.001 respectively) after treatment. GPxl 
RNA increased 2.4 fold while GPx3 RNA increased by 1.5 fold but GPx4 RNA levels 
did not change significantly. This is according to the selenoprotein hierarchy shown by 
Hill and colleagues (Hill et al 1992) and as predicted by Squires and colleagues 
(Squires et al. 2007) due to their sensitivity to nonsense-mediated decay. 100 nM 
sodium selenite was therefore chosen as a suitable concentration and source of Se for 
the microarray gene re-expression experiment.
4.5 Dose-response to demethylation with 5-aza-2 -dexycytidine
Methylation patterns of both GPx3 and GSTP1 were investigated with DNA 
methylation pyrosequencing to validate them as positive controls for this experiment 
(Figure 23). GPx3 was found to be hypermethylated in the PC-3 and LnCAP prostate 
cell lines compared to the ‘normal’ RWPE-1 cell line and normal prostate tissues. The 
analysed region of GPx3 was found not to be hypermethylated in the DU 145 cell line, 
which is in accordance with the bisulphite Sanger sequencing results presented in 
Figure 20. GSTP1 was hypermethylated in all prostate cancer cell lines compared to the 
‘normal’ RWPE-1 prostate cell line and normal prostate tissues. The results confirm 
both genes as useful positive controls.
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Figure 23. Promoter methylation profiles for GPx3 and GSTP1. All samples were 
analysed once for each gene (n=l) by methylation PSQ.
The appropriate dose of 5-AZA for the prostate cell line RWPE-1 was investigated by 
treating the cells with either 0, 1, 5 or 10 pM 5-AZA for four days. Methylation 
patterns of the GPx3 promoter were determined by PSQ and RNA levels for both genes 
including the control gene GAPDH were measured by QPCR (Figure 24).
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GPx3 RWPE-1
* \  ^  
5-AZA (pM)
Figure 24. DNA methylation (left y-axis) and gene expression (right y-axis) results 
for GPx3 in RWPE-1 cells before and after treatment with either 0,1, 5 or 10 pM 
5-AZA. The expression values were normalised against GAPDH control gene. Clear 
bars are average methylation % (n=l). Filled bars are QPCR expression averages (n=3) 
with SD error bars. [There are no error bars for the average methylation levels as the 
experiment was performed only once.]
Average methylation of GPx3 decreased 21% at 10 pM 5-AZA while gene expression 
increased gradually with increasing 5-AZA concentrations up to a maximum of 12 fold 
compared to control cells. Because of these results and previously published data in the 
same cell lines (Dunn et al 2005; Turley et al 2007), a concentration of 10 pM 5-AZA 
was chosen to demethylate hypermethylated genes in the gene re-expression 
experiment.
4A Global gene expression in prostate cancer cell lines and 
tissues
Prostate cell lines RWPE-1, DU 145, PC-3 and LnCAP cells were either untreated, or 
treated with 5-AZA for four days, 100 nM sodium selenite for two days or 5-AZA for 
four days followed by 100 nM sodium selenite for an additional 48 hours. DNA and
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RNA were harvested from all samples. Cell line RNA was co-hybridised with universal 
reference RNA on whole genome customised 4x44k gene expression arrays. RNA 
extracted from the two healthy prostates (ProsF and ProsP) and 6 prostate cancer 
samples (FM002 SX, FM002 DX, FM007 SX, FM007 DX, FM008 SX, FM008 DX 
renamed CaPla-CaP6) were cy dye labelled and co-hybridised with universal reference 
RNA on the same type of arrays. After inter-array normalisation and removal of 
problem probes, the probes present on the array were averaged for each gene and a total 
of 23,117 genes were used for downstream analyses.
4.4.1 Conditional clustering an a lysis
In order to assess the quality and reproducibility of the protocol, the data generated by 
the biological replicates was averaged and clustered (Pearson correlation) by condition 
in GeneSpring (Figure 25 overleaf).
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Bram  Analysis (Default Interpreta.
-----------------  i-----------------1 i-----------------1 i-----------------1 w
RWPE-1 DU145 PC-3 LnCAP O
Figure 25. Conditional cluster of all gene expression arrays. Gene list included all 
genes that past filtering (n=23,117). Each sample represents three biological replicates 
except for the prostate tissues.
Clustering revealed an initial separation between cell lines and tissues and healthy and 
cancerous prostates each clustered on a separate branch. The DU 145 and PC-3 cell 
lines clustered together while LnCAP and RWPE-1 cell lines clustered separately from 
the other two cells lines. For each cell line separately, 5-AZA and 5-AZA+Se samples 
clustered together as did the Se and control samples. This tree shows that the individual 
treatments had an effect on gene expression as they were all separated on different 
branches. All biological replicates correlated with a Pearson correlation coefficient of 
at least 0.88 for the cell lines and 0.83 for the replicates of the tissues. The good
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agreement between the replicates illustrates a high level of reproducibility of the gene 
re-expression protocol.
4.4.2 Validation o f microarray g en e  exp ression  profiles with QPCR
In order to validate the microarray gene re-expression data, 8 genes were chosen to be 
analysed by QPCR: GPx3, GSTP1, BHMT, BHMT2, SelS, DIOl, DI03 and GPx2. 
Control genes that did not vary among conditions were chosen based on the microarray 
data: RPS18 for RWPE-1, DU 145 and PC-3 cell lines. RPS18 RNA expression varied 
significantly between conditions in the LnCAP cell line and therefore a different control 
gene, C19orf53, was chosen. On average (excluding GTSP1 in the PC-3 cell line due to 
missing data points in the microarray data) the Spearman correlation between the 
microarray data and the QPCR data was r=0.86.
4.4.3 Correlation betw een g en e  ex p ress io n  and DNA m ethylation  
resu lts for the g e n e s  o f interest
Methylation patterns were determined for the promoters of 8 genes in each cell line and 
for the healthy prostate tissues to determine the relationship between gene expression 
and methylation profiles. GPx3 and GSTP1 are two genes known to be 
hypermethylated to a high degree in prostate cancer and were chosen as positive 
controls. DI03 is a putative imprinted gene and BHMT, BHMT2, SelS, DIOl and 
GPx2 were identified through the microarray data as interesting genes. There was no 
DNA available for the cancerous prostate samples used in the gene expression 
microarrays but additional samples provided by Prof Colin Cooper (see Section 2.1, 
Table 6) were analysed instead. Statistical analyses (unpaired t-test) identified
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differences in methylation between individual samples by averaging the CpG 
methylation scores per sample. Statistical analysis for gene expression data was based 
on three technical replicates for each of three biological replicates.
GPx3 RWPE-1
GPx3LnCAP
GPx3 DU145
5n
GPx3 PC3
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Figure 26. Gene expression (A) and DNA methylation (B) results for GPx3. (A) 
***P<.001. ANOVA with Bonferroni multiple test correction. Error bars are SD, n=3 
(B) Black spots represent CpG sites. The bar is the average methylation %, n=l.
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Control levels of RNA in the cell lines were inversely related with DNA methylation 
scores as would be predicted if methylation was acting to silence gene expression. In 
the RWPE-1, LnCAP and PC-3 prostate cell lines gene expression increased after 
treatment with 5-AZA (P<001; Figure 26A). This is in accordance with DNA 
methylation profiles for these cell lines, which show that GPx3 is hypermethylated in all 
cell lines except DU145 cells (Figure 26B). The average methylation score for GPx3 of 
the RWPE-1 cell line lies in between the lower score of the DU 145 cell line and the 
higher scores for the LnCAP and PC-3 cell lines. This is also reflected in the gene 
expression value of the control RWPE-1 cell line, which is lower than control DU 145 
but higher than control LnCAP and PC-3 cell lines. Se supplementation on its own had 
no effect on gene expression but supplementation after demethylation did (P<.001) in 
LnCAP and PC-3 cells. These were also the cell lines with the highest values for 
promoter methylation, which indicates that gene expression values of completely 
silenced Se-responsive genes benefit from additional Se after demethylation. In the 
DU 145 cell line, gene expression only increased after supplementation with Se and 5- 
AZA (P<.001) but not with either of them alone. As GPx3 has very low methylation 
scores and associated high gene expression values in the DU145 control cells, 5-AZA 
and Se individually had no effect unless used together. GPx3 was hypermethylated in 
prostate cancer sample CaP4 with 24% average methylation (P<.01) compared to the 
two control prostate tissues (ProsF = 8%, ProsP = 6%; Figure 26B).
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Figure 27. Gene expression (A) and DNA methylation (B) results for GSTP1. (A)
*P<.05 ** P<.01 ***P<.001. ANOVA with Bonferroni multiple test correction. Error 
bars are SD, n=3. (B) Black spots represent CpG sites. The bar is the average 
methylation %, n=l.
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Control levels of RNA in the cell lines were inversely related with DNA methylation 
scores. In both the DU 145 and LnCAP cell lines, GSTP1 RNA was only increased after 
5-AZA supplementation (P<.05 and P<.001 respectively) whereas an increase was 
observed in the RWPE-1 and PC-3 cell lines only after Se supplementation. Each 
cancer tissue sample was significantly hypermethylated compared to RWPE-1 cell line 
and healthy prostate tissue samples (P<.001).
DI03 RNA expression was responsive to 5-AZA in each cell line, which can be 
explained by the overall high methylation scores (Figure 28 overleaf). The PC-3 and 
DU145 prostate cancer cell lines had higher DI03 methylation scores than ‘normal’ 
RWPE-1 cell line though RNA expression in the control cells between the cell lines was 
not significantly different. The increase with 5-AZA in the RWPE-1 and LnCAP cell 
lines was lower compared to the other cell lines reflecting their lower methylation 
scores. The addition of Se after demethylation in PC-3 and RWPE-1 cell lines caused 
an additional increase (P<.001) in DI03 RNA expression while it had the opposite 
effect in DU145 (P<.001) and LnCAP cell lines (P<.05). All tissue samples had high 
DI03 methylation scores and no cancer tissues were hypermethylated compared to 
normal tissue.
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Figure 28. Gene expression (A) and DNA methylation (B) results for DI03. (A)
*P<.05 ***P<.001. ANOVA with Bonferroni multiple test correction. Error bars are 
SD, n=3. (B) Black spots represent CpG sites. The bar is the average methylation %, 
n=l.
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Five more genes were chosen based on their microarray gene expression profiles: GPx2, 
SelS, BHMT and BHMT2 and DIOl (Figure 29).
GPx2
Conditio
Cancer
N orm al
SelS
Conditio
BHMT
C onditio
BHMT2
Conditio)
DIOl
Conditio
Figure 29. Microarray gene expression profiles for GPx2, SelS, BHMT, BHMT2
and DIOl. Gene expression values are relative to the universal reference RNA and 
grouped per cell line: R=RWPE-1; D=DU145, L=LnCAP, P=PC-3. Conditions are 
grouped per cell line: M: control; A=5-AZA; S=Se; B=5-AZA+Se. Normal=Healthy 
prostates tissues; Cancer=Cancerous prostates tissues.
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For each gene, QPCR confirmed the microarray gene expression results in one or more 
cell line and DNA methylation profiles were obtained with methylation pyrosequencing.
GPx2 RWPE-1 GPx2 LnCAP
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Figure 30. Gene expression (A) and DNA methylation (B) results for GPx2. (A)
*P<.05 ***P<.001. ANOVA with Bonferroni multiple test correction. Error bars are 
SD, n=3. (B) Black spots represent CpG sites. The bar is the average methylation %, 
n=l.
GPx2 profiles looked similar across all cell lines (Figure 30A) and therefore only two 
cell lines were analysed by QPCR: the ‘normal’ RWPE-1 cell line and the cancerous 
LnCAP cell line (Figure 30A). GPx2 RNA expression was increased (P<.001) in all 
samples after demethylation with 5-AZA even though only the cancer cell lines were 
hypermethylated compared to the RWPE-1 cell line (Figure 30B). Se did not have an
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additional effect before or after demethylation. Each individual cancer tissue sample 
was significantly hypermethylated compared to the RWPE-1 cell line and healthy 
prostate tissue samples (P<.01). According to gene expression data from the tissue 
samples used for the methylation analysis provided by Prof. Colin Cooper, GPx2 was 
significantly down-regulated in the cancerous tissues compared to three independent 
healthy prostate samples (P<.05). The microarray data from the present study confirms 
this with a 7.6 fold down-regulation of the cancer tissue samples compared to the two 
healthy prostates (Figure 29).
SelS RWPE-1 SelS PC-3
*
B
100-]
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Figure 31. Gene expression (A) and DNA methylation (B) results for SELS. (A) 
*P<.05 ***P<.001. ANOVA with Bonferroni multiple test correction. Error bars are 
SD, n=3. (B) Black spots represent CpG sites. The bar is the average methylation %, 
n=l.
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None of the cell lines were hypermethylated though 5-AZA did increase detection of 
SELS RNA transcripts in RWPE-1 and PC-3 cell lines (Figure 31A and 3IB; P<.01). 
Se supplementation after demethylation caused a significant decrease (P<001) of SelS 
transcripts although this was not observed in the microarray data. Healthy prostate F 
was methylated more than (P<.001) all other samples but this was only an average of 
13% methylation (Figure 3IB).
BHMT DU145BHMT PSQ
* * *
Figure 32. DNA methylation (A) and gene expression (B) results for BHMT. (A)
Black spots represent CpG sites. The bar is the average methylation %, n=l. (B) 
***P<.001. ANOVA with Bonferroni multiple test correction. Error bars are SD, n=3.
The microarray data shows that BHMT (Figure 29) is responsive to 5-AZA in the 
DU145 cell line only (P<.001), which was confirmed using QPCR (Figure 32B), 
although all of the cancer cell lines were hypermethylated compared to the RWPE-1 
cells (P<.01; Figure 32A). All cancer tissue samples were hypermethylated compared 
to healthy prostate P (P<.001) and two (CaPla and CaP2) were hypermethylated 
compared healthy prostate F (P<.01 and P<.05 respectively). The cancer tissue samples 
were 1.5 fold down-regulated compared to the healthy controls (Figure 29).
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Figure 33. DNA methylation (A) and gene expression (B) results for BHMT2. (A)
Black spots represent CpG sites. The bar is the average methylation %, n=l. (B) 
***P<.001. ANOYA with Bonferroni multiple test correction. Error bars are SD, n=3.
BHMT2 is responsive to 5-AZA in all cell lines (Figure 29) and this was confirmed 
with QPCR in the DU145 cell line (Figure 33B). In accordance with the gene 
expression results, BHMT2 was hypermethylated in all cancer cell lines (Figure 33A). 
Only cancer tissue sample CaPla was significantly hypermethylated (P<.01), though 
the other cancer tissue samples had higher methylation scores as well compared to both 
healthy prostate tissue samples. Compared to BHMT, BHMT2 had lower methylation 
scores for RWPE-1 (72% vs. 21%; P<.001). Even though only one cancer tissue 
sample was hypermethylated, RNA expression of BHMT2 was 3.3 fold lower in cancer 
tissues compared to healthy controls (Figure 29).
BHMT2 down-regulation seems to be caused by hypermethylation even though only 
one cancer tissue sample was significantly hypermethylated. BHMT was 
hypermethylated in the cancer samples but gene expression was not down-regulated to 
such an extent as BHMT2. This would indicate that both genes are differentially
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regulated and methylated in cancer even though they are located next to each other on 
5ql4.1.
DI01 LnCAP
Figure 34. DNA methylation (A) and gene expression (B) results for DIOl. (A)
Black spots represent CpG sites. The bar is the average methylation %, n=l. (B) 
***P<.001. ANOVA with Bonferroni multiple test correction. Error bars are SD, n=3.
The LnCAP cell line had the lowest methylation score for DIOl (RWPE-1 78%, DU 145 
93 %, LnCAP 62%, PC-3 91%; Figure 34A) and, consistent with this, was 
overexpressed (P=.0194) compared to the other cell lines (Figure 29). DIOl was also 
1.5 fold overexpressed in cancer tissue samples compared to healthy controls, although 
this difference did not reach statistical significance. Gene expression after 
demethylation slightly increased in the DU 145 and LnCAP cell lines but not in the 
RWPE-1 or PC-3 cell lines. Gene expression for the LnCAP cell line was confirmed by 
QPCR (Figure 34B). None of the cancer tissue samples were significantly
hypermethylated compared to healthy prostate tissue (Figure 34A).
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4.4.3 General g en e  exp ress ion  microarray resu lts
The influence of Se, 5-AZA and 5-AZA+Se on gene expression was investigated by 
analysing the gene expression differences between conditions per cell line. These 
differences were filtered with a threshold of two-fold up- or down-regulation.
4.4.3.1 Effect of Se treatment on gene expression
Se treatment caused both up- and down-regulation of specific sets of genes for each cell 
line.
Table 22. Gene expression changes after Se treatment for each cell line.
Direction Cell line N a GOb P value
Up DU 145 418 Cell adhesion
Positive regulation of apoptosis
4.80xl0'13 
3.07x1 O'06
LnCAP 161 Cell communication
Negative regulation of biological process
2.96xlO'20 
9.07x10‘13
PC-3 601 Extracellular structure organisation and 
biogenesis
Regulation of apoptosis
2.26x1 O’37 
1.08xl0'14
Down DU 145 221 Positive regulation of cell proliferation 1.02x1 O'06
LnCAP 573 Positive regulation of biological process 1.43x1 O'08
PC-3 321 Positive regulation of cellular process 1.52xl0'17
a Number of genes present in the gene list.
i .
Analysis was conducted with MetaCore software.
Network interaction analysis with MetaCore identified a number of cellular processes 
influenced by Se treatment that were very similar between the cell lines. The list 
containing genes up-regulated by Se was significantly enriched for genes involved in
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apoptosis, cell adhesion and cell communication, which are all biological processes that 
have been previously linked to hypermethylated genes. The ‘negative regulation of 
biological processes’ is represented by genes that function in the inhibition of cell 
proliferation, differentiation and migration while the genes involved in the ‘extracellular 
structure organization and biogenesis’ have a function in the signalling pathway 
between the basement membrane and the extracellular matrix.
The list containing genes down-regulated by Se was significantly enriched for genes 
involved in the positive regulation of cell proliferation or biological processes. These 
processes were represented by genes involved in mitogenesis and by oncogenes such as 
MYCN.
One gene was up-regulated by Se treatment in all cell lines: Cone-rod homeobox or 
CRX, which has a role in the differentiation of photoreceptor cells (Furukawa et al. 
1997). Three genes were down-regulated in all three cancer cell lines: glutamate 
receptor metabotropic 3 (GRM3) is a neurotransmitter receptor, cysteine/tyrosine-rich 1 
(CYYR1) has no known function and sulfotransferase family, cytosolic, 2A, 
dehydroepiandrosterone (DHEA)-preferring, member 1 (SULT2A1) sulfates steroids.
4.4.3.2 Effect of 5-AZA treatment on gene expression
Gene lists were compared between 5-AZA treated cells and control cells with a two fold 
threshold. To decrease the number of false positives such as imprinted genes, tissue- 
specific genes, stress-responsive genes etc., genes also up-regulated in the RWPE-1 cell 
line were removed from the comparison and only genes that were at least 2 fold down- 
regulated in prostate cancer tissue compared to healthy prostate tissue were kept in the
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gene lists. This resulted in lists containing genes that were potentially hypermethylated 
only in prostate cancer cell lines and were down-regulated in prostate cancer tissue.
The lists of genes significantly different in 5-AZA treated cells, i.e. those whose 
expression is suppressed by methylation, contained 193 genes for the DU 145 cell line, 
183 genes for LnCAP cell line and 112 genes for PC-3 cell line. Gene ontology 
analysis identified ‘apoptosis’ as a significantly enriched process in all prostate cancer 
cell lines (DU145 P=3.31x10'15; LnCAP P=3.66xl0'14; PC-3 P=3.65xl0‘15). In 
addition, the DU145 gene list was enriched for ‘negative regulation of cellular process’ 
(P=4.20xl0'6) and ‘cell communication’ (P=1.84xlO'10) while PC-3 gene list was also 
enriched for ‘DNA damage response’ (P=2.65xl0’6). The ‘negative regulation of 
cellular processes’ was represented by tumour suppressors such as PER2 and anti­
metastatic genes such as HP1 alpha.
Interestingly, the keratin gene family was strongly represented with 6 genes (KRT13-17 
and KRT27) in the DU 145 list of genes that were up-regulated after 5-AZA treatment, 
while there was only one in the LnCAP cell line (KRT15) and one in the PC-3 cell line 
(KRT17).
There were 14 genes up-regulated by 5-AZA in all prostate cancer cell lines that were 
also at least two fold down-regulated in prostate cancer compared with healthy prostate 
(Table 23).
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Table 23. Genes up-regulated in all cancer cell lines after 5-AZA treatment and 
also down-regulated in cancer tissues.
Gene Name Description Function if known
THC2650074 Unknown Unknown
ID4 inhibitor of DNA binding 4 Helix-loop-helix transcriptional 
regulator involved in development
VIT vitrin Unknown
S100A14 SI00 calcium binding protein 
A14
Unknown
VTCN1 V-set domain containing T cell 
activation inhibitor 1
T-cell costimulatory molecule
LM02 LIM domain only 2 Negative regulator of cell
(rhombotin-like 1) differentiation
BATF2 basic leucine zipper 
transcription factor, ATF-like 2
Unknown
SCN4B sodium channel, voltage-gated, 
type IV, beta
Cardiac channel regulatory protein
LYPD5 LY6/PLAUR domain 
containing 5
Unknown
DOK7 docking protein 7 Role in signalling downstream of 
receptor and non-receptor 
phosphotyrosine kinases
ARL9 ADP-ribosylation factor-like Small GTPase mediated signal
protein 9 transduction
WNT3A wingless-type MMTV 
integration site family, member 
3A
Wnt pathway activator
SAMD9 sterile alpha motif domain P-catenin stabilisation/negatively
containing 9 regulates cell proliferation
THBD thrombomodulin Regulates coagulation by binding 
to thrombin and activating the 
protein C system resulting in 
tumour growth inhibition and 
metastasis
Gene ontology analysis identified one process that was significantly enriched in this list 
of genes (Table 23): regulation of development (P=8.49xlO'H; represented by genes 
LM02, ID4, WNT3A and DOK7). This will be covered in greater depth in the 
discussion but briefly, the enrichment of genes involved in development supports the 
hypothesis of the stem cell origin of cancer (Clarke and Fuller 2006).
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The microarray gene expression profiles of two genes (S100A14 and thrombomodulin) 
from Table 23 are shown in Figure 35 below as examples. Both genes are down- 
regulated in the cancer cell lines compared to the normal RWPE-1 cell line and have 
lower expression values in the cancer tissues compared to the healthy tissues. 5-AZA 
treatment increased gene expression in all cancer cell lines suggesting they are 
hypermethylated genes.
Conditio!
Conditio
Figure 35. Microarray gene expression profile for S100A14 (top) and
thrombomodulin (bottom). Error bars are SD. Gene expression values are relative to 
the universal reference RNA and grouped per cell line: R=RWPE-1; D=DU145, 
L=LnCAP, P=PC-3. Conditions are grouped per cell line: M: control; A=5-AZA; 
S=Se; B=5-AZA+Se. Normal=Healthy prostates tissues; Cancer=Cancerous prostates 
tissues.
4.4.3.3 Effect of 5-AZA and Se treatment on gene expression
The selection of genes that were up-regulated with 5-AZA and Se only and not with 
either of them alone used the following filter process: (1) for each cell line, genes with 
gene expression at least 2 fold higher after 5-AZA and Se treatment than with Se or 5- 
AZA alone were selected; (2) genes regulated in common between cancer and RWPE-1 
cells were deducted to prevent false positives; (3) genes had to have at least 2 fold 
increased gene expression after treatment with 5-AZA and Se compared to control.
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Thirteen genes in DU145 (Table 24), twelve in LnCAP (Table 25) and 15 genes in PC-3 
cell lines (Table 26) were selected by this filtering process.
Table 24. Gene expression changes after Se and 5-AZA treatment for DU145 cells.
Gene Name Fold Description Function if known
Unknown 7.319 cDNA FLJ40020 fis Unknown
MTF1 2.985 metal-regulatory transcription 
factor 1
Transcription factor that 
induces expression of 
metallothioneins and other 
genes involved in metal 
homeostasis
PLA2G4A 2.818 phospholipase A2, group IVA 
(cytosolic, calcium-dependent)
Catalyzes the hydrolysis of 
membrane phospholipids
IFIT3 2.719 interferon-induced protein with 
tetratricopeptide repeats 3
Unknown
Unknown 2.502 cDNA clone CS0DF020YB09 
of Foetal brain of Homo sapiens
Unknown
APOL6 2.465 apolipoprotein L, 6 Affects movement or binding 
of lipids to organelles/induces 
mitochondria-mediated 
apoptosis
RIOK1 2.389 RIO kinase 1 (yeast), transcript 
variant 1
Unknown
GPR87 2.282 G protein-coupled receptor 87 Possible suppressor of LPA- 
dependent cell migration and 
invasion
C19orf40 2.139 Fanconi anemia-associated 
protein (FAAP24)
Required for normal levels of 
FANCD2 monoubiquitylation 
following DNA damage
PIK3R3 2.123 phosphoinositide-3 -kinase, 
regulatory subunit 3 (p55, 
gamma)
Binds Rb and induces cell 
cycle arrest
SETX 2.111 Senataxin DNA and RNA processing/ 
defence against oxidative DNA 
damage
FOXOIA 2.082 Forkhead box 01A 
(rhabdomyosarcoma)
Transcription factor required 
for SEPP1 expression
ACOT11 2.038 Acyl-CoA thioesterase 11, 
transcript variant 2
Temperature-responsive gene
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Table 25. Gene expression changes after Se and 5-AZA treatment for LnCAP cells.
Gene Name Fold Description Function if known
DPYD 5.887 dihydropyrimidine
dehydrogenase
Rate-limiting factor in the 
pathway of uracil and 
thymidine catabolism
SEMA3A 3.808 sema domain, 
immunoglobulin domain 
(Ig), short basic domain, 
secreted, (semaphorin) 3A
Suppresses VEGF- 
mediated angiogenesis
FAM83A 3.645 family with sequence 
similarity 83, member A, 
transcript variant 2
Unknown
NPAL2 3.156 NIPA-like domain 
containing 2
Unknown
BX640618 3.102 cDNA DKFZp779M0652 Unknown
CNTFR 2.689 ciliary neurotrophic factor 
receptor, transcript variant 
1
Stimulates gene 
expression, cell survival 
or differentiation through 
MAPK pathway
SPTBN1 2.467 spectrin, beta, non- 
erythrocytic 1, transcript 
variant 2
Role in actin crosslinking 
and molecular scaffold 
protein
VAV3 2.399 vav 3 oncogene, transcript 
variant 1
Activates pathways 
leading to actin 
cytoskeletal 
rearrangements
ANXA2 2.365 W7B_A Chain A, 
Annexin A2
Regulation of cellular 
growth and in signal 
transduction pathways
ENST00000242475 2.359 Unknown Unknown
SEMA3D 2.024 sema domain, 
immunoglobulin domain 
(Ig), short basic domain, 
secreted, (semaphorin) 3D
Exhibits anti-angiogenic 
activity
C19orf33 2.01 chromosome 19 open 
reading frame 33
Unknown
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Table 26. Gene expression changes after Se and 5-AZA treatment for PC-3 cells.
Gene Name Fold Description Function if known
PCDH7 4.572 BH-protocadherin (brain- 
heart), transcript variant c
Thought to function in 
cell-cell recognition and 
adhesion
PPAPDC3 3.879 phosphatidic acid 
phosphatase type 2 domain 
containing 3
Unknown
FAM46C 3.616 family with sequence 
similarity 46, member C
Unknown
CR595668 3.537 full-length cDNA clone 
CS0DB003YC18 of 
Neuroblastoma Cot 10- 
normalized of Homo 
sapiens
Unknown
SCUBE2 3.023 signal peptide, CUB 
domain, EGF-like 2
Unknown
BX433326 2.768 Homo sapiens cDNA clone 
CS0DM004YL09 3-PRIME
Unknown
GGT7 2.591 Gamma-glutamyltransferase 
4 precursor
Involved in both 
metabolism of 
glutathione and in 
transpeptidation of 
amino acids
NP1165618 2.535 cDNA DKFZp547I2016 Unknown
BDNF 2.505 brain-derived neurotrophic 
factor, transcript variant 1
May play a role in the 
regulation of stress 
response
SART2 2.419 squamous cell carcinoma 
antigen recognized by T 
cells 2
Tumour-rejection antigen
EMCN 2.395 endomucin Interferes with the 
assembly of focal 
adhesion complexes
FAM83A 2.296 family with sequence 
similarity 83, member A, 
transcript variant 2
Unknown
RPP25 2.288 ribonuclease P 25kDa 
subunit
RNA-binding
ENST00000244321 2.257 Homo sapiens similar to 
R28379_l
Unknown
FOSB 2.015 FBJ murine osteosarcoma 
viral oncogene homolog B
Regulator of cell 
proliferation, 
differentiation, and 
transformation
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MetaCore analysis identified enriched gene ontology processes within all gene lists 
from Tables 24-26. DNA repair was the top GO process (P=4.86xl0‘4) for the DU 145 
cells while both the LnCAP and PC-3 lists were significantly enriched for cell motility 
(P=7.90xl0'19 and P=T.26xlO"5 respectively). The gene list for the LnCAP cells was 
also enriched for the JAK/STAT cascade (P=6.08xl0'15) and the PC-3 list for the 
regulation of translation in response to stress (P=6.05xl0'5). DNA repair deficiency is 
associated with chromosomal instability and results in increased susceptibility to cancer. 
Chromosomal instability is in its turn associated with increased cell motility and 
metastasis formation (Roschke et ah 2008). The JAK/STAT pathway takes part in the 
regulation of cellular responses to cytokines and growth factors and has recently been 
linked to prostate cancer (Shen and Lentsch 2004).
4.4.3.4 Differences in gene expression between healthy and cancerous prostates 
A t-test with multiple test correction (Benjamini and Hochberg False Discovery Rate 
Correction was used as the test was performed on the microarray data) identified one 
gene as significantly differentially expressed (P= 0117) between healthy and cancerous 
prostate tissues: E2F5, a gene involved in cell cycle regulation with a central role in cell 
growth and proliferation, was expressed 8 fold higher in cancerous prostates. Four 
other genes were found to have similar expression profiles to E2F5 and are listed in 
Table 27. All 5 genes were overexpressed in the prostate cancer cell lines and tissues 
compared to the RWPE-1 cell line and healthy tissues.
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Table 27. Genes with similar expression profiles (Pearson r>0.95) to E2F5.
Gene Name Ra Description Function if known
FAM80A 0.978 family with sequence 
similarity 80, member A
Ribosomal modification protein
B4GALT3 0.962 UDP-Gal:betaGlcNAc beta 
1,4- galactosyltransferase, 
polypeptide 3
biosynthesis of different 
glycoconjugates and saccharide 
structures
KLHDC2 0.961 kelch domain containing 2 control of cell cycle and 
transcriptional regulation
OTUB2 0.955 Ovarian tumour domain, 
ubiquitin aldehyde binding 
2
cleaves proteins at the ubiquitin- 
protein bond
a Correlation coefficient to E2F5.
FAM80A and B4GALT3 are located on chromosome 1 while KLHDC2 and OTUB2 
are both located on chromosome 14. This is likely to be coincidence though as 
FAM80A and B4GALT3 have a 117 Mb gap and KLHDC2 and OTUB2 have a 44 Mb 
gap in between them.
4.4.3.5 The effect of Se and 5-AZA on selenoprotein and associated gene expression 
Two selenoproteins, SEPW1 and SELH, were up-regulated over 2-fold after Se 
treatment in the DU145 cell line (2.5 and 2.0 fold respectively) while SEPW1 was also 
up-regulated in the PC-3 cell line (2.3 fold). RNA levels from genes associated with 
selenoprotein translation did not change with Se-treatment except for RPL30 with a 
1.36 fold increase in gene expression. A full list of selenoproteins and gene expression 
values after Se treatment can be found in Appendix 3 Figure 1 and Table 1.
5-AZA treatment increased gene expression of DI03 (2.26 - 19.6 fold) and GPx2 (4.05- 
7.62 fold) in all cell lines while DI02 was only increased in the cancer cell lines (1.49- 
4.90 fold). SELV levels were up 3.02 fold in the DU145 cell line and SELM gene 
expression was increased in the RWPE-1 and PC-3 cell lines (4.80 and 3.56 fold
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respectively) after demethylation. Although below the two-fold threshold, SECISBP2 
expression was up-regulated with 5-AZA in all cell lines (1.46-1.89 fold) while 
EEFSEC was down-regulated with 5-AZA in all cell lines after treatment (0.63 - 0.92 
fold). With the 2-fold thresholds no selenoproteins were up-regulated with Se treatment 
after demethylation. The QPCR data in Figure 26 and 28, however, shows that GPx3 
and DI03 do have a significant increase in gene expression with Se supplementation 
after demethylation though the increase is less than two-fold. DI02, SELV and SELM 
do not show an additional increase in gene expression with Se supplementation after 
demethylation suggesting that they are not as susceptible to Se concentrations as GPx3 
and DI03. A full list of selenoproteins and the difference in expression with/without Se 
supplementation after demethylation is shown in Appendix 3 Figure 1 and Tables 2-3.
GPx2 was the only selenoprotein that was more than two fold down-regulated in cancer 
tissues vs healthy prostate tissues. Other selenoproteins, such as DI03 (1.67 fold), 
MsrBl (1.94 fold) and SEPP1 (1.75 fold) were also down-regulated.
4.5 Effect of Se and 5-AZA on global methylation of prostate 
cell lines
Global methylation analysis with pyrosequencing was performed to investigate the 
effect of demethylation by 5-AZA and Se on a global scale in the PC-3 prostate cancer 
cell line. Two biological replicates were assayed for each condition and an ANOVA 
test with Bonferroni correction found a significant difference (P=.01) between control 
cells and the treatment of cells with both Se and 5-AZA (Figure 36). This implies that 
Se can enhance the demethylation effect of 5-AZA.
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Global Methylation
ra 30-
Figure 36. Effect of 5-AZA and Se on global methylation in PC-3 cells. Error bars 
are SD of two technical replicates for each of two biological replicates. The technical 
replicates were added (n=4) for each condition and subjected to statistical analysis. 
*P=.01 with ANOVA and post-hoc test Bonferroni for multiple testing correction.
4.6 Effect of Se and 5-AZA on individual gene promoter 
methylation
Promoter methylation percentages were also measured after treatment with Se and/or 5- 
AZA in two single genes, GPx2 and BHMT (Figure 37). Due to sample quantity 
constraints only a single assay on one biological replicate was performed and no 
statistics are therefore available.
GPx2PC3 BHMT PC3
100
SS 60 «  60-
S2 40-
Figure 37. Effect of 5-AZA and/or Se on promoter methylation of GPx2 and 
BHMT in the prostate cancer PC-3 cell line measured by methylation PSQ. The
experiment was performed only once due to sample constraints (n=T).
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Different effects of the treatments were observed for the two genes. A decrease of 
promoter methylation in GPx2 was observed with Se and a combination of Se and 5- 
AZA treatment, but only the combination with Se and 5-AZA resulted in a slight 
demethylation of the promoter of BHMT.
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Chapter 4 Discussion: Gene expression and DNA 
methylation analysis of prostate cell
Substantial evidence now supports the view that epigenetic changes have a role in the 
development of cancer. Aberrant DNA methylation, both in the form of 
hypermethylation or hypomethylation, is an early event in carcinogenesis and has been 
linked to altered gene expression, chromosomal instability, mobilisation of retroviruses 
or transposons and transcriptional silencing of tumour suppressor genes (Jones and 
Baylin 2002).
The role of Se in cancer has been demonstrated in both in vitro and in vivo studies and 
the first aim of the project was to identify genes that are Se responsive in an 
unmethylated state but have become hypermethylated during cancer progression and 
thus not Se responsive in cancer cells. A second, but equally important question to be 
answered was whether Se supplementation had an effect on global DNA methylation.
Choice of treatment reagents and concentrations
A number of techniques have been developed to interrogate DNA methylation profiles, 
either on a single gene or at whole genome resolution. This study made use of the 
properties of 5-aza-2'-deoxycytidine (5-AZA), a demethylating agent, that has been 
extensively used in previous research to identify hypermethylated genes (Lodygin et al. 
2005; De Luca et al. 2007). A dose-response curve showed that a concentration of 10 
pM 5-AZA was highly effective in reducing promoter DNA methylation scores and in 
restoring gene expression of a hypermethylated gene, which is in accordance with the 
results published using the same 5-AZA concentration and prostate cancer cell lines 
(Lin et al 2001; Singal et al 2001).
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Sodium selenite is the preferred source of Se as selenite was shown to induce GPx 
activity more rapidly than selenomethionine (Rebsch et al 2006; Zeng et al. 2008). A 
concentration of 100 nM was chosen based on results available in the literature where 
100 nM significantly induced glutathione peroxidase and thioredoxin reductase activity 
(Maiorino et al. 1991; Brigelius-Flohe et al. 1995; Dreher et al. 1998; Menth et al. 
2005) and on a personal discussion with Dr Brigelius-Flohe (Brigelius-Flohe 2006). An 
in vitro experiment subsequently showed that 100 nM sodium selenite had a significant 
effect on selenoprotein RNA expression.
Establishment and validation of the methylation techniques
A first attempt to establish the DNA methylation profiling technique was the analysis of 
GSTP1, GPx3, GPx4 and Sep 15 by bisulphite conversion of unmethylated CpGs 
followed by cloning and sequencing. GSTP1 and GPx3 are two genes known to be 
hypermethylated in prostate cancer cell lines (Lodygin et al. 2005) and the results were 
in accordance with the published literature. Neither GPx4 nor Sep 15 were found to be 
differentially methylated in prostate cancer cell lines compared with the ‘normal’ 
prostate cell line. Methylation pyrosequencing is a cheaper and quicker method than 
bisulphite sequencing and was therefore validated using the same control genes, GSTP1 
and GPx3.
Validation of the gene re-expression microarray data
Initial quality control analysis of the data produced from the gene expression arrays 
showed very good correlation among the biological replicates from the prostate cell 
lines and tissues. The arrays were validated by gene expression QPCR for 8 individual 
genes and a correlation coefficient of 0.862 was obtained between QPCR and
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microarray data. This allowed using the microarray data for downstream data analysis. 
The same genes were also analysed by methylation PSQ to investigate the correlation 
between gene expression and DNA methylation patterns. GPx3 was hypermethylated 
and silenced in PC-3 and LnCAP prostate cancer cells as previously published (Lodygin 
et al. 2005) and responded to 5-AZA treatment. GPx3 RNA expression increased even 
further with Se supplementation after demethylation, which suggests that Se 
supplementation might be beneficial as an adjuvant therapy for patients who undergo 5- 
AZA treatment as GPx3 functions in the detoxification of peroxides and helps to protect 
the cells from oxidative damage (Esworthy et al. 1993).
Though overexpressed in rat breast tumours (Naiki-Ito et al 2007), treatment with 5- 
AZA increased GPx2 expression in all prostate cell lines and methylation analysis 
revealed GPx2 to be hypermethylated in all prostate cancer cell lines and prostate 
cancer tissue samples. Gene expression data on the prostate cancer samples used for 
methylation analysis also showed significant down-regulation of GPx2 transcript 
compared to healthy prostate controls. Rebsch and colleagues (Rebsch et al. 2006) have 
already shown GPx2 to be expressed solely in the ‘normal’ RWPE-1 and not in LnCAP 
or PC-3 prostate cancer cell lines but they have not made any suggestions as to the 
cause of the gene silencing. A similar gene re-expression study on prostate cancer cells 
also observed an increase (3.73 fold) in GPx2 RNA expression after demethylation in 
the PC-3 prostate cancer cell line (Kim et al. 2005). GPx2 is preferentially expressed in 
the intestinal system where it acts as a barrier against hydroperoxide absorption 
(Banning et al. 2005), though it is also highly expressed in the bladder and in the 
prostate (UniGene Hs.2704). GPx2 knockout mice develop intestinal cancer after 
exposure to bacteria suggesting it might be involved in counteracting inflammatory
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responses (Chu et al 2004). Mice deficient in GPx2 also have an increased mutation 
frequency associated with oxidative stress (Lee et al 2006). The authors suggest that 
gene mutations driven by inflammation can then lead to neoplastic transformation of the 
epithelium. Chronic inflammation is linked to prostate cancer (Palapattu et al 2005) 
and silencing GPx2 expression might be beneficial to cancer cells to develop in a 
chronic inflammatory state (Banning et al 2008).
Betaine homocysteine methyltransferase 1 and 2 (BHMT and BHMT2) were 
hypermethylated to some degree in all prostate cancer cells and tissues. Though not all 
cancerous tissue samples were significantly hypermethylated, the same four CpG sites 
(4 out of a possible 10) showed higher methylation frequencies in all, compared to both 
healthy prostate samples. BHMT catalyses the transfer of methyl groups from betaine 
to methylate homocysteine to re-form methionine. The function of BHMT2 is unknown 
though it has a similar cysteine rich region within a catalytic domain. BHMT protects 
cells from Hcy-induced injury (Ji et al 2007) and was found to be down-regulated in 
human liver cirrhosis and hepatocellular carcinoma (Avila et al 2000). Down- 
regulation of these enzymes might therefore increase Hey concentrations, which is 
accordance with observations that Hey can be predictive of cervical cancer risk 
(Weinstein et al 2001) though no such association has been made with prostate cancer 
risk. BHMT and BHMT2 are located next to each other on chromosome 5ql4.1 and 
their transcription start sites lie about 10 kb apart. Dimethylglycine dehydrogenase 
(DMGDH) encodes an enzyme involved in the catabolism of choline, the methyl donor 
for BHMT in one-carbon metabolism, and is located on the opposite strand with its 5' 
UTR starting 150 bp away from the 5' UTR of BHMT2. DMGDH, however, does not 
respond to 5-AZA treatment and is not down-regulated in the prostate cancer tissues
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compared to the healthy tissues. The proximate location of the three genes does suggest 
that they might be part of a locus control region. Neither BHMT nor BHMT2 have 
previously been found to be hypermethylated in cancer and further analysis on a larger 
sample set should identify whether these genes are hypermethylated and thereby 
downregulated in all prostate cancers.
These results confirm the association between gene expression and DNA methylation 
on a single gene level and validate the experimental approach taken to reach the aims 
set out in Section 1.5.2.
General gene expression results
Effect o f Se treatment on gene expression
Previously published microarray experiments have always used very high 
concentrations of Se supplementation in the micromolar range to induce cell apoptosis 
and necrosis. Using a much lower Se concentration allowed the investigation of the 
physiological consequences between marginally low Se intake and Se supplementation.
Se treatment influenced genes involved in a number of processes associated with 
carcinogenesis. Up-regulated gene lists for the three cancer cell lines were enriched for 
processes previously linked to cancer: cell adhesion, apoptosis and intracellular 
communication. HBP17, a gene up-regulated by Se and representing ‘the negative 
regulation of biological processes’ identified by MetaCore as an enriched gene ontology 
process after Se treatment in the LnCAP prostate cancer cell line, encodes a protein that 
binds to aFGF and bFGF, two fibroblast growth factors, that participate in proliferation, 
differentiation and cell migration and blocks their biological activities (Wu et al. 1991).
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Nidogen, a component of the basement membrane was one of the S e-up-regulated genes 
representing ‘the extracellular organisation’ identified by MetaCore for the PC-3 
prostate cancer cell line. This protein interacts with integrins and controls cell 
polarisation, migration and invasion by playing a role in cell interactions with the 
extracellular matrix (Ulazzi et al. 2007). Nidogen is also frequently hypermethylated in 
stomach and colon cancer and is suggested to favour migration and metastasis. Up- 
regulation of this gene after Se treatment may therefore limit metastasis formation, 
which is in accordance with the observation that Se might also be effective in 
preventing the progression and metastasis formation of prostate cancer (Rayman 2005).
Genes that were down-regulated after Se supplementation were enriched for the 
‘positive regulation of cell proliferation’. These were either oncogenes such as MYCN, 
which is amplified in approximately 20% of neuroblastomas and suppresses Dickkopf- 
1, a potent inhibitor of the wnt/beta-catenin pathway (Koppen et al. 2007), or they were 
mitogens such as TrKA, which is thought to be involved in the progression of various 
cancers through the activation of the MAP-kinase pathway (Hondermarck 2000). 
Evidence for this was provided when inhibition of the TrKA signalling pathway through 
ST ATI down-regulation resulted in prostate tumour growth inhibition (Foster et al. 
2004).
The Se concentration used in this project is in the physiological range. Between 1 and 
100 nM of sodium selenite is enough to reach the maximum level of GPx activity in 
culture (Brigelius-Flohe et al. 1995) while in humans this is reached with a daily intake 
of approximately 80 pg Se. A 100 nM Se treatment in culture would therefore be
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equivalent to the UK recommended daily intake of 75 and 60 pg/day for men and 
women respectively.
There are no reports available in the literature that have investigated the effect of 
physiological concentrations of sodium selenite supplementation, or any other Se source 
for that matter, on cancer cell lines with gene expression microarrays. Sodium selenite, 
when used in higher concentrations, can have an effect on apoptosis (Xiang et al. 2008), 
androgen receptor signalling (Husbeck et al 2006) and cell cycle (Jiang et al 2002). 
Taking these results together, sodium selenite can affect similar pathways with low and 
high concentrations though the reduced cell viability seen with higher concentrations 
was not observed in the present study. Sodium selenite has been used in one human 
study where healthy volunteers were supplemented with 100 pig/d. Se increased the 
expression of genes, measured in lymphocytes, with a function in protein biosynthesis 
(Pagmantidis et al 2008) but none of the genes mentioned in this paper were influenced 
by Se treatment. This is not surprising though, as there was a major difference in cell 
type and type of study.
SEPW1 and SELH were the only selenoproteins to be up-regulated more than two-fold 
by Se supplementation in this study. SEPW1 was also found to be sensitive to Se 
concentrations in Caco-2 cells (Pagmantidis et al 2005) and both SEPW1 and SELH 
are highly regulated by Se in rodents (Sunde et al 2008).
One gene was responsive to Se in all prostate cell lines, cone-rod homeobox (CRX), and 
plays a role in the differentiation of photoreceptor cells (Furukawa et al 1997). CRX is
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located 40 kb downstream from SEPW1 in the 19ql3.32 region, which is frequently lost 
in human diffuse gliomas (Smith et al. 2000).
Three genes, GRM3 a glutamate receptor, CYYR1 a recently identified gene with no 
known function and SULT2A1, a gene involved in the sulfate conjugation of steroids 
and located on the opposite strand 60 kb from CRX and 100 kb from SEPW1, were 
down-regulated in all three prostate cancer cell lines after Se treatment. The proximate 
location is likely to be coincidental as other nearby genes did not respond to Se 
supplementation. Glutamate is a neurotransmitter, which signals through glutamate 
receptors and has been reported to stimulate cultured lung carcinoma cells to proliferate. 
Glutamate-stimulated cell proliferation can be blocked by glutamate receptor antagonists 
(Rzeski et al. 2001) while transgenic mice with an ectopically expressed glutamate 
receptor developed melanoma, further supporting a role for GRM3 in tumourigenesis 
(Pollock et al. 2003). SULT2A1 is a gene whose product sulfates 
dehydroepiandrosterone and other structurally-related steroids and has been reported to 
contribute to the metabolic activation of procarcinogens (Glatt 1997; Thomae et al. 
2002). Down-regulation of these genes by Se supplementation might therefore have a 
negative effect on carcinogenesis.
The reason why Se influenced gene expression of these genes is unknown though there 
is evidence that Se can act as an intracellular redox modulator to influence the 
expression of genes as shown with sodium selenite treatment of the LnCAP prostate 
cancer cell line (Zhong and Oberley 2001). The authors hypothesise that sodium 
selenite treatment increases GPx activity that uses glutathione (GSH) as a substrate. 
This causes a shift in the GSH/GSSH (GSSH is the oxidised product of GSH) and will
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alter cysteine residues in proteins, which has downstream effects on protein-protein and 
protein-DNA interactions. These redox modifications can therefore result in altered 
gene expression regulation (Zhong and Oberley 2001).
Effect o f 5-AZA on gene expression
Demethylation identified a great number of potentially hypermethylated genes that were 
down-regulated in prostate cancer tissues. These genes were involved in apoptosis, 
negative regulation of cellular processes, cell communication and DNA damage 
response. One of the genes that represented the ‘negative regulation of cellular 
processes’ was PER2. PER2 or Period-2 is part of the circadian clock, which controls 
the expression of cell-cycle related genes. Disturbances in PER2 expression may 
therefore benefit the survival of cancer cells and promote carcinogenesis (Xiang et al. 
2008). PER2 has already been shown to be down-regulated in a number of breast 
cancer cell lines and transfection of the gene into breast cancer cells induced apoptosis 
with cyclin D1 down-regulation and p53 up-regulation (Chen et al 2005).
In DU145 cells, 6 keratin genes (KRT13-17 and KRT27) were up-regulated after 5- 
AZA treatment while there was only one in LnCAP cells (KRT15) and one in PC-3 
cells (KRT17). The genes, which are responsible for the structural integrity of epithelial 
cells, are down-regulated in the cancer cell lines and tissues compared to their normal 
counterparts. DU 145, LnCAP and PC-3 cells have previously been shown to have 
distinct keratin expression patterns (van Leenders et al 2001). In that study, KRT5 was 
expressed in 28.9% of prostate cancer metastases and in the PC-3 and LnCAP prostate 
cancer cell lines, KRT14 was not expressed in any of the samples while KRT18 was 
expressed in all cancer samples. In accordance with their results, the data from the
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present study shows that KRT18 is not differentially regulated in the cell lines neither is 
it in the tissues while KRT14 is down-regulated in the cell lines and tissues. The studies 
disagree on the data of KRT5. In the study from van Leendert KRT5 is present in the 
PC-3 and LnCAP prostate cancer cell lines while the data presented in this project 
shows that KRT5 is down-regulated in all prostate cancer cell lines and tissues, van 
Leenders and colleagues do note that a sub-population from the DU 145 cell line had 
low KRT5 levels (shown by immunohistochemistry), which might account for some of 
the differences between the two studies.
There were 14 genes up-regulated in all prostate cancer cell lines with 5-AZA treatment 
that were down-regulated in the prostate cancer tissue samples compared to the healthy 
prostates. The gene ontology programme MetaCore identified ‘the regulation of 
development’ as an enriched process within this gene list. This process was represented 
by ID4, LM02, WNT3A and DOK7. ID4, a gene hypermethylated in 30% of primary 
gastric adenocarcinoma tumours (Chan et al 2003), plays a critical role in early 
embryogenesis and is involved in angiogenesis, lymphocyte development, cell cycle 
control and cellular senescence (Chan et al. 2003). LM02 plays a central role in 
hematopoietic development. It is hypermethylated in embryonic stem cells and in 
cancer cell lines (Calvanese et al. 2008). DOK7 is a muscle protein essential for 
neuromuscular synaptogenesis while WNT3A activates the WNT pathway, which is 
involved in the differentiation and proliferation of cells. All four genes were clearly 
upregulated with 5-AZA and down-regulated in the prostate cancer tissues compared to 
the healthy tissues even though the currently known function of some of these genes, for 
example WNT3A might suggest that it would be beneficial for cancer cells to have this 
gene expressed. Previous published examinations of cancer methylation patterns have
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supported a stem cell origin of prostate cancer (Cooper and Foster 2008). Calvanese 
and colleagues (Calvanese et al 2008) suggest that silencing of developmental genes 
through epigenetic marks (histone H3 lysine 27 and H3 lysine 4 methylation) might 
confer a predisposition to hypermethylation in cancer. This is in accordance with the 
hypothesis of the stem cell origin of cancer (Clarke and Fuller 2006) and would explain 
the results obtained. Because the histone marks are present in the embryonic stem cells, 
the risks for hypermethylation of those genes are carried through to each differentiated 
cell and suggests that hypermethylation of these genes can occur in each cancer tissue 
type.
A number of selenoproteins were upregulated with 5-AZA supplementation. DI02 had 
higher expression in the ‘normal’ RWPE-1 prostate cell line compared to the cancerous 
prostate cell lines and was up-regulated with 5-AZA in all prostate cancer cell lines. In 
addition, expression profiles from the cancerous prostates reveal that DI02 was 
expressed, though at a slightly lower level than the normal prostates. This suggests that 
DI02 might be hypermethylated in prostate cancer. Type 2 iodothyronine deiodinase 
activates thyroxine (T4) by deiodination to triiodothyronine (T3) and is under-expressed 
in benign and malignant thyroid tumours (Amaldi et al 2005) but over-expressed in a 
mesothelioma cell line compared to normal mesothelial cells (Curcio et al 2001). 
DIOl on the other hand, which has the same function as DI02 but is thought to provide 
more T3 for circulation compared to DI02 that generates T3 from T4 from local T4 
sources for intracellular demands (Kohrle et al 2005). DIOl was significantly up- 
regulated in the LnCAP prostate cancer cell line compared to the other prostate cell 
lines and was also 1.5 fold up-regulated in the prostate cancer tissues compared to the 
healthy prostate tissues. T3 is known to up-regulate cellular proliferation only in the
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LnCAP and not in other prostate cancer cell lines, including the DU145 and PC-3 cell 
lines, by down-regulating the expression of B-cell translocation gene 2 (BTG2) (Hsieh 
and Juang 2005; Tsui et al. 2008). BTG2 is an anti-proliferative protein and its 
deactivation in embryonic stem cells leads to the disruption of DNA damage-induced 
G2/M cell cycle arrest (Rouault et al. 1996). BTG2 gene expression is induced by p53, 
a known tumour suppressor with a role in the DNA damage cellular response pathway, 
and loss of BTG2 has been associated with prostate cancer progression (Tsui et al 
2008).
Before the present study it was unknown why T3 had a growth effect on the LnCAP cell 
line and not in other prostate cancer cell lines. The androgen-dependency of the LnCAP 
cells as well as the expression of the different thyroid receptors has been investigated 
and excluded as possible causes. The overexpression of DIOl in the LnCAP prostate 
cancer cell line provides a very good alternative to explain why T3 has an effect on cell 
growth only in this cell line. From these results a hypothesis can therefore be generated 
that the over-expression of DIOl in LnCAP cells increases the conversion of T4 to T3 
resulting in the down-regulation of BTG2 and increased proliferation of the prostate 
cancer cells.
GPx2 was exclusively hypermethylated in the prostate cancer cell lines and tissues as 
mentioned before in this discussion. DI03 was up-regulated with 5-AZA treatment and 
hypermethylated in the prostate cancer cell lines but not down-regulated. DI03 was not 
hypermethylated in any of the prostate cancer tumour tissues, which highlights the fact 
that DNA methylation patterns differ between cancer cell lines and tumour tissues. 
DI03 is a putative imprinted gene demonstrated by the high overall methylation % in
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all of the samples and explains the increase in gene expression to demethylation. 
SELM, SELV and SELX (MsrBl) also had increased gene expression after 5-AZA 
treatment in some of the prostate cancer cell lines and were down-regulated in the 
prostate cancer tissues. They can be considered as potential hypermethylated genes 
though this would have to be verified using methylation sequencing.
Effect o f Se supplementation after demethylation
Supplementing cells with Se after they were treated with 5-AZA allowed the 
identification of hypermethylated genes in prostate cancer that would be Se-responsive 
in an unmethylated state. The gene ontology processes enriched in each of the cell lines 
have been previously identified in cancer cells: DNA repair (Jacinto et al 2007; Arai et 
al 2008), cell motility and response to stress (Arai et al 2006). The deregulation of the 
JAK/STAT pathway is closely associated with tumourigenesis and participates in the 
regulation of cell proliferation (Alpini and DeMorrow 2007). STAT1, a transcription 
factor involved in the JAK/STAT pathway that was up-regulated with Se 
supplementation after demethylation, was recently shown to be down-regulated in 
prostate cancer. STAT1 silencing in the PC-3 prostate cancer cell line was associated 
with increased production of proangiogenic signalling CXC chemokines (Shen and 
Lentsch 2004). The induction of these genes by Se after demethylation suggests that Se 
supplementation might be beneficial for patients receiving 5-AZA as it might increase 
the expression of the genes involved in the aforementioned pathways to counter tumour 
development more effectively.
The strategy of cancer therapy with adjuvant Se supplementation is not new and has 
been proven to further increase apoptosis in lymphoma cells in patients with Non-
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Hodgkin’s lymphoma treated with standard chemotherapy (Asfour et al 2008) and 
increase disease control in solid tumours in combination with irinotecan, a 
topiosomerase 1 inhibitor (Fakih et al 2005). Toxic side effects of chemotherapy can 
also be alleviated with Se supplementation (Federico et al 2001; Sieja and Talerczyk
2004). In addition, tamoxifen-resistant breast cancer cells undergo apoptosis when 
therapy is combined with methylseleninic acid (Li et al 2008).
GPx3 and DI03 were the only selenoproteins to show a significant increase in gene 
expression with Se supplementation after demethylation. DI02, SELV, SELM and 
SELX gene expression did not increase further with Se supplementation after 
demethylation, even though their gene expression values increased with 5-AZA alone. 
This might be caused by a higher resistance to nonsense-mediated decay as GPx3 is 
known to be sensitive to this phenomenon (Muller et al 2003).
Differentially expressed genes in prostate cancer tissues
One gene was differentially expressed in all cancer cell lines and tissues compared to 
the normal cell lines and tissues: E2F5, a gene involved in cell cycle regulation, was 
significantly overexpressed in prostate cancer cell lines and tissues. This has been 
previously reported in a meta-analysis of studies investigating gene expression 
signatures of prostate cancer by Rhodes and colleagues (Rhodes and Chinnaiyan 2005) 
and in prostate cancer cell lines LnCAP and PC-3 where E2F5 was shown to be 
respectively 3.5 and 8.5 fold overexpressed (Yegnasubramanian et al 2008). Pearson 
correlation with the gene expression profile of E2F5 identified 4 other genes that were 
overexpressed in the prostate cancer cell lines and tissues: FAM80A, B4GALT3, 
KLHDC2 and OTUB2.
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0TUB2 (Ovarian tumour domain 2) is homologues to the Ovarian tumour gene product 
of Drosophila (Makarova et al. 2000) and is a deubituitylating enzyme though its 
precise function in cancer is unknown. KLHDC2 (Kelch domain-containing protein 2 
or hepatocellular carcinoma-associated antigen 2 or host cell factor 1) and inhibits the 
activity of transcription factor LZIP/CREB3 through direct interaction with its 
canonical CRE element. LZIP/CREB3 is a growth suppressor and is down-regulated in 
hepatocellular carcinomas (Chin et al. 2005). Loss of LZIP/CREB3 in NIH3T3 cells 
induces morphological transformation and anchorage independent growth (Jin et al. 
2000). Over-expression of KLHDC2 can therefore increase cellular proliferation in the 
prostate cancer cell lines. KLHDC1, which is located approximately 15 kb from 
KLHDC2 differs in cellular localisation and function and was not over-expressed in the 
prostate cancer samples. B4GALT3 is a membrane-bound glycoprotein that is mainly 
involved in the synthesis of the first N-acetyllactosamine unit of poly-N- 
acetyllactosamine chains. The poly-N-acetyllactosamine chains in N-glycans have been 
found to promote tumor progression and metastasis (Zhou 2003). Selectins can bind 
these chains and thereby facilitate carcinoma metastasis. Moreover, the overexpression 
of B4GALT3 is in accordance with recent evidence from studies of various carcinomas 
that point to an association of altered glycosylation with a poor prognosis for patients 
(Borsig 2004). FAM80A is a ribosomal modification protein and has a predicted ATP- 
grasp fold. Its exact function is unknown. These results give an indication which 
processes prostate cancer cells employ to increase cellular proliferation and migration. 
Further analysis on a larger number of cancerous prostates should clarify whether these 
genes can be used as prostate cancer specific biomarkers.
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Global methylation of prostate cancer cell lines and tissues
Se deficiency can cause DNA hypomethylation in rats even though in similar conditions 
it can increase DNA methyltransferase (DNMT) protein levels in the colon (Davis and 
Uthus 2003; Uthus et al 2006). By contrast, in nuclear extracts of human colon 
carcinomas DNMT activity was inhibited by selenite as measured by the incorporation 
of methyl groups (Fiala et al 1998). Selenium can also affect DNA methylation when 
methyl donors are being used for the methylation of selenium compounds to Se(CH3), 
Se(CH3)2 and Se(CH3)3 instead of being used for DNA methylation reactions as 
suggested by Zeng and colleagues (Zeng et al 2005).
In the current study, treatment with 5-AZA and Se together significantly decreased 
global methylation levels while 5-AZA and Se individually had a smaller, non­
significant effect. On a single gene resolution, Se and a combination of 5-AZA and Se 
treatment decreased methylation levels of GPx2 in the PC-3 cell line, while the 5-AZA 
and Se combination had an effect on BHMT promoter DNA methylation.
Even though BHMT DNA methylation levels were decreased by 5-AZA and Se 
treatment in the PC-3 cell line, only a moderate increase in RNA expression was 
observed (1.6 fold). In the DU145 cell line however, BHMT RNA expression was 
significantly increased with a combined Se and 5-AZA treatment (14.5 fold). It is 
possible that BHMT gene expression in the PC-3 cells is inhibited by other means than 
hypermethylation or that the DU 145 cell line has activators that are not present in the 
PC-3 cell line. GPx2 gene expression was not increased with Se treatment even though 
DNA methylation levels were decreased at least as much as with 5-AZA and Se
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treatment suggesting that 5-AZA might activate different mechanisms than Se, which 
induce GPx2 transcription.
The effect of 5-AZA on promoter DNA methylation levels in this study is greater than 
the decrease observed by Yang and colleagues (Yang et al 2004) (13% vs 6% 
respectively), which could be explained by the differences in concentration of 5-AZA 
and duration of the treatment. Yang and colleagues used 5 pM for 3 days while in this 
study 10 pM was used for 4 days. In a study conducted by Ramachandran and 
colleagues (Ramachandran et al 2007), 10 pM sodium selenite or 150 pM 
selenomethionine had no effect on GSTP1 or RASFF1A methylation or gene expression 
in the same prostate cancer cell lines. A recent publication contradicts these results: 
selenite was shown to have a slightly greater demethylation effect than 5-AZA where 
selenite decreased GSTP1, APC and CSR1 promoter DNA and H3-Lys9 methylation 
levels while it increased H3-Lys9 acetylation levels LnCAP cells resulting in a net 
increase in RNA expression (Xiang et al 2008). At the same time, global DNA 
methylation levels, DNMT1 and DNMT3A RNA expression were lowered with selenite 
treatment compared to controls. In the present study, GSTP1 RNA expression was 
increased after selenite treatment in RWPE-1 and PC-3 but not in LnCAP cells. No 
effect of Se, 5-AZA or both was observed on APC or CSR1 (now called SCARA3) in 
any of the cell lines. The differences between the results could be explained by the dose 
and duration of treatment. Xiang and colleagues used either 0.5 or 1.5 pM sodium 
selenite for up to two weeks and Ramachandran and colleagues used 10 pM for 96 
hours, which is significantly higher than the 100 nM used in the present study.
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To summarise, Se and 5-AZA supplementation individually and on their own increased 
RNA expression of genes involved in anti-carcinogenic pathways while Se decreased 
RNA expression of genes involved in the proliferation of cells. SEPW1 and SELH 
were the only selenoproteins to be up-regulated with Se treatment, which is in 
accordance with previously published results. GPx2, BHMT and BHMT2, previously 
unknown to be hypermethylated in cancer, were identified to be hypermethylated and 
down-regulated in prostate cancer cells and tissues. The addition of Se after 
demethylation caused a significant increase in GPx3 gene expression, a gene commonly 
hypermethylated in prostate cancer. Because of the function of GPx2 and GPx3 in 
antioxidative defence, these results can be considered as very important findings. 
DI02, SELM, SELV and SELX (MsrBl) were also responsive to 5-AZA 
supplementation in the prostate cancer cell lines and were down-regulated in the 
prostate cancer tissues supporting the hypothesis that they are hypermethylated genes. 
A large number of keratin genes were found to be responsive in the DU 145 cell line 
compared to the other cell lines indicating that silencing of these genes plays an 
important role in this cell line. The cancer stem cell hypothesis was supported by data 
from this project as a number of genes involved in development were found to be 
hypermethylated and thereby down-regulated in all prostate cancer cell lines and 
tissues. DIOl, a 5' deiodinase enzyme producing the active thyroid hormone 
triiodothyronine (T3), from its inactive form thyroxine (T4) was shown to be 
overexpressed only in the LnCAP prostate cancer cell line. As T3 stimulates cellular 
proliferation only in the LnCAP cell line, a hypothesis was generated that DIOl 
overexpression is responsible for an increased T4 to T3 turnover resulting in enhanced 
cellular proliferation. Five genes, including E2F5, B4GALT3 and KLHDC2 were 
identified as over-expressed genes in the prostate cancer cell lines and tissues indicating
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that the cell cycle and glycosylation are major targets in prostate cancer. 5-AZA and Se 
supplementation together, and not individually, were shown to significantly decrease 
global methylation levels of the PC-3 prostate cancer cell line.
In order to further enhance our understanding of the role DNA methylation in prostate 
cancer, a different technique called Methylated DNA ImmunoPrecipitation in 
combination with promoter tiling arrays was used. This provided high resolution data 
on the methylation pattern of the prostate cancer cell lines and healthy prostate samples 
that was combined with the data from the gene re-expression experiment.
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Chapter 5 Analysis of genome-wide DNA methylation in 
prostate cancer
5.1 Introduction
There are a number of techniques available to study DNA methylation changes on a 
whole genome scale. The RNA microarray and gene re-expression approach was used 
in the previous chapter (Chapter 4) to identify potentially hypermethylated genes by 
treating cell lines with a demethylating agent. An advantage of this approach is that the 
detection of the hypermethylated CpG sites is linked to the transcriptional status of the 
genes. A disadvantage of the technique is that it is an indirect approach for the 
identification of methylated DNA. Though the demethylation mechanism of 5-AZA is 
well known and treatment of cell lines has been shown to up-regulate hypermethylated 
genes, it is also known to be toxic to cells (Davidson et al. 1992; Juttermann et al.
1994).
A different approach called Methylated DNA Immunoprecipitation (MeDIP) was 
recently published in Nature (Weber et al. 2005). This technique is based on the actual 
methylation state of the DNA as it makes use of an antibody to recognise methylated 
cytosines. The ratio of output over input DNA provides an accurate quantitative 
measurement of DNA methylation. This technique has an obvious advantage as it 
directly measures DNA methylation. This technique has been used to study the 
hypermethylome of colon cancer cells (Weber et al 2005; Jacinto and Esteller 2007), 
Arabidopsis (Zhang et al. 2006), breast cancer cells (Cheng et al. 2008) and normal 
human fibroblasts (Weber et al. 2007).
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The combination of RNA and DNA analysis on a whole genome scale provides an 
unprecedented opportunity to use the strengths of both techniques to correlate 
hypermethylation with gene silencing directly.
5.1.1 Project outline
The MeDIP procedure was validated and DNA from all prostate cell lines extracted 
from the experiment described in Chapter 4 together with DNA from two healthy 
prostates was subject to MeDIP and hybridised to human promoter tiling arrays. 
Bioinformatic analysis provided lists of hypermethylated genes in cancer cell lines 
compared to the healthy prostate tissues. Gene ontology identified enriched pathways 
within the hypermethylated gene lists. The methylation status of hypermethylated 
genes in all cancer cell lines was validated with methylation pyrosequencing. The 
correlation between the gene re-expression technique and MeDIP was investigated as 
was the correlation between hypermethylation and gene expression. Localised clusters 
of hypermethylated genes were identified on each chromosome for all cancer cell lines.
5.1 MeDIP procedure validation
The MeDIP procedure was validated by comparing the enrichment ratios between two 
genes: (i) SELS, a gene known not to be methylated in prostate cancer (section 4.4.3) 
and (ii) GSTP1, a gene known to be hypermethylated in prostate cancer (section 4.4.3). 
DNA extracted from the PC-3, DU 145, LnCAP prostate cancer cell lines and healthy 
prostate tissue “prostate B” was subject to the adjusted MeDIP procedure as described 
in the Material and Methods Chapter 2. Two techniques were employed to determine
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whether GSTP1 was enriched after MeDIP: methylation pyrosequencing and DNA 
QPCR.
Promoter methylation profiles of GSTP1 for both fractions were analysed using 
methylation pyrosequencing (Figures 38). GSTP1 showed an average of 26% 
methylation before enrichment (input fraction) that increased to 78% after enrichment.
GSTP1 Pre-MeDIP
B1 : TYGGAGGTYGYGAGGTTTTYGTTGGAGTTTYGTYGTYGTAGTTTTYGTTATTAGTGAGTAYGYGYGGTTYGYGTTTTYGGGGA
28%  | 28%  | 26%  | 28%  | 27%  | 24% | 27% |  27%  | 30% 119%  | 23% 125% | 20% 125%  |
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GSTP1 Post-MeDIP
C1 : TYGGAGGTYGYGAGGTTTTYGTTGGAGTTTYGTYGTYGTAGTTTTYGTTATTAGTGAGTAYGYGYGGTTYGYGTTTTYGGGGA
85 % | 83%  | 78%  | 82% | 80%  | 77% | 82% | 80%  | 84%  | 61%  | 73% | 78% |66% | 77% |
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Figure 38. DNA Methylation pyrograms of GSTP1 before and after MeDIP. The
height of the bars represents the number of incorporated nucleotides. The dispensation 
order of nucleotides is shown on the top. Values in boxes represent CpG site 
methylation percentages. A box is blue when it has passed the methylation software 
quality control criteria and yellow when it needs to be checked manually. GSTP1 pre- 
MeDIP average methylation is 26%. GSTP1 post-MeDIP average methylation is 78%. 
The methylation score for GSTP1 was increased after MeDIP compared to the pre- 
MeDIP fraction confirming that the procedure enriches for methylated sequences.
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DNA QPCR primers specific for both genes were designed to amplify a fragment in the 
putative promoter region and were used to determine the enrichment ratios in both input 
and enriched fractions. SELS (unmethylated) was taken as a calibrator to determine the 
enrichment ratio of GSTP1 (methylated) in the post-MeDIP fraction.
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Figure 39. Validation of MeDIP with QPCR for genes SELS and GSTP1 with 
prostate cancer cell lines and healthy prostate B. Error bars are SD.
SELS DNA was present in the pre-MeDIP fractions for all the prostate cancer cell lines 
and healthy prostate B but not in the post-MeDIP fractions except for healthy prostate 
B. GSTP1 DNA was present in both pre- and post-MeDIP fraction for all the prostate 
cancer cell lines, but only present in the pre-MeDIP fraction for healthy prostate B
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DNA. This confirms that MeDIP only enriches methylated DNA sequences. In order 
to asses the ratio of enrichment GSTP1 post-MeDIP values were divided by SELS post- 
MeDIP values. Using SelS as the calibrator, GSTP1 DNA was enriched with an 
average of 59 fold compared to SELS in the cancer cell lines while no GSTP1 DNA 
was enriched in the healthy prostate tissue. This technique confirmed again that MeDIP 
is able to highly enrich methylated sequences over unmethylated sequences.
5.2 Analysis of the prostate cancer methylome through MeDIP 
and promoter tiling arrays
The promoter methylation status of all prostate cell lines, RWPE-1, DU 145, LnCAP and 
PC-3, and two healthy prostate tissues, prostate F and B, were determined on a whole 
genome scale by methylated DNA immunoprecipitation, followed by microarray 
detection. The DNA extracts were taken from the same cell preparations as those used 
in the gene re-expression experiments described in the previous chapter (Chapter 4) to 
ensure comparability between RNA expression and DNA promoter methylation. The 
Agilent ChlP-on-ChIP human promoter array covers regions of -5.5 kb to + 2.5 kb (8 kb 
in total) relative to the transcription start site with 60-mer probes spaced about 295 bp 
apart. The array contained 488k probes representing over 17,000 transcripts based on 
UCSC hgl8 and NCBI build 36.1 databases. After normalisation and processing of the 
data, 457,951 probes passed filtering and quality checks and were used for further 
analysis.
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5.2.1 Control gene promoter methylation
Data generated by Agilent microarray scanning software, Feature Extraction, was 
entered into a data analysis programme from Agilent, Chip Analytics. UCSC genome 
web browser track files were produced after dye swap and intra-array normalisation and 
were added as custom tracks to the UCSC genome browser that allowed zooming in on 
individual genes.
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Figure 40 . UCSC genome browser result for GPx3 and GSTP1. Filled boxes 
represent probe on the array. Darker boxes mean more methylated. Red boxes indicate 
hypermethylated probes compared to normal cell line RWPE-l or healthy prostate 
tissue.
Both GPx3 and GSTP1 had hypermethylated probes in all cancer cell lines and not in 
RWPE-l cells or healthy prostate tissue. The probes were located close to the 
transcription start site and within or next to a CpG island. The data confirm that MeDIP 
is a valid tool to identify hypermethylated genes in cancer cell lines.
Chapter 5 -  MeDIP
5.2.2 Probe d ensity  p lots
Differentially methylated probes between normal and cancerous samples (e.g. healthy 
prostate versus PC-3) were determined by the non-parametric t-test in R (version 2.5.0) 
(http://www.R-project.org, R Development Core Team) using the multi-test package of 
bioconductor (Gentleman et al. 2004). Resultant P-values were corrected using the 
Benjamini and Hochberg false discovery rate correction (Benjamini and Hochberg
1995) and probes that had a corrected P-value of <0.05 were classed as significantly 
differentially methylated between conditions. The statistical measurements were 
limited to 700 bp upstream and 200 bp downstream the annotated start site to reduce 
noise caused by distant probes as suggested by Weber and colleagues (Weber et al
2005). Differentially methylated probes that lie to the right of the distribution (i.e. have 
a positive log2 MeDIP/control ratio) were of interest to this study.
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Figure 41. Probe density plots for each cell line representing differentially 
methylated probes of prostate cell lines compared to healthy prostate tissue in Iog2 
scale.
A bimodal distribution representing methylated and unmethylated probes was observed 
in all probe density plots and different thresholds can be used to generate gene lists of 
hypermethylated genes compared to healthy prostate tissue. Thresholds were put at >1, 
>2, >3 and >4-fold and the number of genes for each list can be found in Table 28.
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Table 28. Numbers of genes in all cell lines with at least two hypermethylated 
probes compared to healthy prostate tissue.
Gene list Number of genes - RWPE-1 1 fold
RWPE-1 >1 fold 1141
RWPE-1 >2 fold 343
RWPE-1 >3 fold 112
RWPE-1 >4 fold 17
DU 145 >1 fold 1277 707
DU 145 >2 fold 533 278 a
DU 145 >3 fold 272 146
DU 145 >4 fold 147 75
LnCAP >1 fold 1165 692
LnCAP >2 fold 564 330 a
LnCAP >3 fold 307 170
LnCAP >4 fold 162 86
PC-3 >1 fold 1805 1061
PC-3 >2 fold 866 427 a
PC-3 >3 fold 415 200
PC-3 >4 fold 179 78
a Gene list analysed with MetaCore in section 5.2.4.
Among all three prostate cancer cell lines there were 444 genes in common that were 
more than 1 fold enriched in the MeDIP i.e. were methylated. When this list was 
compared with the >l-fold enriched RWPE-1 genes, 170 genes were left. When the >4- 
fold enriched gene lists for all cancer cell lines were compared, 25 genes were 
identified, taking off genes in common that were over 1-fold enriched in the RWPE-1 
cell line, 11 genes were left (Table 29).
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Table 29. Hypermethylated (>4-fold enriched in MeDIP) genes common to all 
three prostate cancer cell lines but not to the RWPE-1 ‘normal’ prostate cell line.
Symbol Description Function if known
ADAMTS12
ADAM metallopeptidase with 
thrombospondin type 1 motif, 12
Disintegrin and 
metalloproteinase
ESD
esterase D/formylglutathione 
hydrolase
Loss of heterozygosity 
required for retinoblastoma 
induction
USP4
ubiquitin specific peptidase 4 (proto­ Prevents the degradation of
oncogene) the A2A receptor
TRIM9 tripartite motif-containing 9
Possibly down-regulates the 
release of neurotransmitters
RNF152 ring finger protein 152 Unknown
SIM1 single-minded homolog 1 Unknown
PRR14 proline rich 14 Unknown
PPP1R3C
protein phosphatase 1, regulatory Reversible protein
(inhibitor) subunit 3C phosphorylation
OPRK1 opioid receptor, kappa 1 Adenylate cyclase inhibitor
LAYN layilin
Actin-cytoskeleton
organisation
GABRR1
gamma-aminobutyric acid receptor, Down-regulates the release
rho 1 of neurotransmitters
ADAMTS12 was the only gene to be significantly down regulated in the same prostate 
cancer tissues (P<.05; Unpaired t-test). Data from the gene re-expression experiment in 
which a different set of cancerous prostates was profiled (Chapter 4) showed evidence 
of down-regulation of PPP1R3C (P<.05; Unpaired t-test) as well. PPP1R3C was down- 
regulated in the cancer cell lines as well and gene expression was induced by 5-AZA 
treatment suggesting it is a true hypermethylated gene.
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5.2.4 G ene O ntology a n a ly sis
Gene ontology can be used to look for common functions or pathways in which genes 
are involved. The list containing genes that were >4-fold enriched/hypermethylated 
genes common in all cancer cells lines but not in the RWPE-1 cell line was subjected to 
gene ontology analysis. The top biological process was ‘vesicle-mediated transport4 
(P= 1.24x1 O'12) that was represented by USP4, TRIM9, SIM1, OPRK1 and GABRR1. 
This process is discussed in greater detail in the discussion but briefly, the genes 
representing the ‘vesicle-mediated transport’ process are involved in neurotransmitter 
release that is regulated by vesicular transport.
Lists containing genes that were at least 2 fold enriched/hypermethylated in each 
prostate cancer cell line but not in the ‘normal’ prostate RWPE-1 cell line were 
submitted for gene ontology analysis in MetaCore version 4.5 (Table 30).
Table 30. Network interaction analysis of significantly enriched genes.
Cell line N a GO processb P value
DU 145 278 Establishment and/or maintenance of chromatin 7.65xlO'J1
architecture
Cell communication 1.33xl0'12
LnCAP 330 Negative regulation of biological process 1.21xl0'24
Actin cytoskeleton organisation and biogenesis 2.60xl0'15
PC-3 427 Actin cytoskeleton organisation and biogenesis 4.99xl0'19
Cell cycle 6.69X10'09
A llc 170 Actin cytoskeleton organisation and biogenesis 1.14xl0'18
a Number of genes present in the gene list.
t .
Analysis was conducted with MetaCore software (version). 
c Genes in common between all prostate cancer cells lines but not with the ‘normal’ 
prostate RWPE-1 cell line.
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The top gene ontology process for genes at least two fold enriched in the DU 145 and 
not in the RWPE-1 cell line was the establishment and/or maintenance of chromatin 
architecture (P=7.65xl0'31) followed by cell communication (P=1.33xl0'12). Negative 
regulation of biological processes (P= 1.2lxlO'24) and cell cycle (P=6.69xlO‘09) were 
enriched in the LnCAP and PC-3 cell lines respectively while actin cytoskeleton 
organisation and biogenesis (P=2.60xl0'15 and P=4.99xl0'19) were enriched in both cell 
lines. This process was also significant (P=1.14xl0"18) in genes enriched in all cancer 
cells lines and not in the RWPE-1 cell line. A gene that was part of the negative 
regulation of biological processes was gremlin. Gremlin is an inhibitor of the TGF beta 
signalling pathway that regulates many intra- and inter-cellular processes. The pathway 
is frequently deregulated in cancer and gremlin itself is frequently hypermethylated and 
down-regulated in cancer cell lines and cancer tissues, including prostate cancer tissues 
(Suzuki et al. 2005). Hypermethylation of gremlin, HPP1 and RUNX3, two other 
members of the TGF signalling pathway, is inversely correlated with prognosis in 
patients with bladder and prostate cancer (Suzuki et al. 2005).
5.2.3 Validation o f MeDIP m ethylation data
The methylation status of five of the genes found to be hypermethylated (>4-fold 
enriched in MeDIP) in prostate cancer cell lines (Table 29; ESD, USP4, SIM1, 
PPP1R3C and OPRK1) was also investigated with methylation pyrosequencing in all 
prostate cell lines, the healthy prostate samples used previously and additional prostate 
cancer samples obtained from Prof. Colin Cooper (Figure 42).
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Figure 42. Promoter methylation profiles for OPRK1, PPP1R3C, SIM1, ESD and 
USP4 with methylation PSQ. CaPla-5 are prostate cancer samples with CaPla and 
CaPlb originating form the same individual. Black spots represent CpG sites. The bar 
is the average methylation %.
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All genes except for ESD were hypermethylated in the prostate cancer cell lines 
compared to the ‘normal’ prostate RWPE-1 cell line and the healthy prostate tissues. 
ESD was not hypermethylated in the DU145 cell line though the mean methylation 
percentage of the LnCAP and PC-3 cell lines was higher compared to the RWPE-1 cell 
line (8.5 and 9.0 vs 3.2%). These results confirm that MeDIP was able to identify genes 
that were hypermethylated in the cancer cell lines.
No prostate cancer tissue samples were hypermethylated in the promoter region of 
OPRK1 and only cancer sample CaP5 had an average methylation % in the ESD 
promoter three times higher than in the healthy prostate samples (14.7 vs 4.9 and 4.3%). 
PPP1R3C was hypermethylated (P<.001) in half of all cancer samples (CaPla, CaPlb 
and CaP4), SIM1 was hypermethylated in sample CaPla (P<.05) and USP4 was 
hypermethylated in samples CaP4 (P<.001) and CaP5 (P<.01). Gene expression data 
from the prostate cancer samples compared to three healthy prostate samples (other than 
Prostate F and Prostate B) provided by Prof Colin Cooper does not show a difference in 
any of the samples for any of the genes in Table 29 except for ADAMTS12 that is 
significantly downregulated in cancer compared healthy prostate samples (P<.05).
LAYN, RNF152 and ADAMTS12 were investigated by Mr Matt Cooper. All three 
genes were hypermethylated in the cancer cell lines, again validating the MeDIP 
protocol. LAYN was also hypermethylated in cancer tissue sample CaP4, RNF152 was 
hypermethylated in samples CaPla and CaP4 while ADAMTS12 was hypermethylated 
in all cancer samples (Cooper 2008).
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In addition, the methylation status of two isoforms from one known tumour suppressor 
gene, CDKN2A, was investigated. The isoform 4, pl4(ARF), mRNA consists of 
26,740 bp while isoform 1, pl6(INK4a) is smaller at only 7,288 bp. The putative 
promoter of isoform 1 is located within intron 1 of isoform 4. Both putative promoter 
regions were sequenced using methylation PSQ (Figure 43).
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Figure 43. Methylation PSQ profiles for two isoforms of CDKN2A.
pl4(ARF) was not hypermethylated in any of the cell lines and tissues while 
pl6(INK4a) was hypermethylated in the PC-3 cell line compared to the RWPE-1 cell 
line (P<.001) and cancerous tissue sample CaPla was hypermethylated compared to 
both healthy prostates (P<.001). These results show that the CDKN2A isoforms are 
differentially methylated, however, no gene expression microarray data was available 
for the two individual isoforms so it was not possible to determine whether the 
differential methylation was responsible for any differential expression.
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5.2.7 Integration o f gen om ic DNA m ethylation profiles with gen om e-  
w ide exp ression
Correlation between promoter methylation and gene expression 
Promoter hypermethylation has been associated with gene silencing at individual gene 
resolution in previous published studies. Using the gene expression data from the 
previous chapter (Chapter 4) and the MeDIP data, hypermethylation and gene 
expression were correlated on a whole genome scale.
Plots were generated by using the statistical package R. By putting the r values from 
the correlations calculated from the MeDIP and gene expression data in bins ranging 
from -1 to +1, the number of gene r-values was counted and divided by the total amount 
of gene r-values in the whole analysis. Observations on the correlation between gene 
expression and DNA methylation can be made by comparing the frequency of the r- 
values on the Y-axis with the correlation values on the X-axis.
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Figure 44. Plots visualising the frequency of correlation between gene expression
and MeDIP. X -axis: R values. Y-axis: frequency.
In all cell lines, except for the PC-3 prostate cancer cell line, the frequency of negative 
correlations is higher compared to the frequency of positive correlations between gene 
expression and DNA methylation; this indicates that DNA methylation is associated 
with gene silencing as would be expected. In the PC-3 cell line the opposite was 
observed: the frequency of positive correlations was higher compared to the frequency 
of negative correlations between gene expression and DNA methylation. The reason 
why the PC-3 prostate cancer cell line is different compared to the other cell lines is 
unknown. The positive correlation between DNA methylation and gene silencing has 
been observed before, however, in a sarcoma cell line (Sadikovic et al. 2008).
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In order to further narrow down the list of functionally relevant changes in DNA 
methylation, the MeDIP data was integrated with the gene re-expression data. 
Hundreds of genes were identified to be hypermethylated using the MeDIP approach in 
the cancer cell lines (Table 28) and the lists were compared with a two-way VENN 
diagram to genes under-expressed (1-way ANOVA, P<.01 and 2 fold down-regulated, 
n=79) in the cancer tissues compared to the healthy tissues. There were 5 genes 
hypermethylated in DU 145 cells and under-expressed in the cancer tissues (JMJD2D, 
MBNL2, PLCB1, SCRT2 and SLC4A11), 10 genes in LnCAP cells (BCL11B, 
C14orf4, CALML3, CCND2, LHX1, MBNL2, PLCB1, PSIP1, SLC4A11 and SNPH) 
while there were 9 genes in PC-3 cells (BCL11B, CCNP2, GALNAC45-6ST, 
NEUROG3, NGFR, PRKAG1, RAB38, SCRT2 and SLC4A11). One gene was 
hypermethylated and under-expressed in common between all cell lines: SLC4A11 
(also named BTR1 and NaBCl), a sodium borate transporter previously shown to be 
essential for cell growth and cell proliferation (Park et al 2004).
Correlation between promoter methylation and the effect o f 5-AZA and Se on gene 
expression
Propensity plots from gene expression and MeDIP data were generated in Excel to 
investigate the influence of 5-AZA and/or Se on hypermethylated genes (Figure 45). 
The genes were divided in those up- or down-regulated after treatment. The propensity 
was determined by counting the number of genes that are hypermethylated (have a log2 
cancer/normal MeDIP ratio > -0.1) and have up- or down-regulation in their gene 
expression (log2 ratio > -0.1 or < -0.1) compared to control cells and dividing it by the 
total number of hypermethylated genes. This was repeated for each treatment compared 
to control cells.
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Figure 45 . Propensity plot to visualise the effect of 5-AZA and/or Se on gene
expression of hypermethylated genes. S: Se; M: Control; A: 5-AZA; B: 5-AZA and 
Se.
There is a much lower propensity for hypermethylated genes to be down-regulated by 
any treatment, as expected, particularly for Se treatment of the DU145 and ‘normal’ 
RWPE-1 prostate cell lines. There is a higher propensity for hypermethylated genes to 
be up-regulated by any treatment, and in DU 145 and ‘normal’ RWPE-1 prostate cell 
lines, this is more marked for Se than for either 5-AZA or 5-AZA+Se. These results 
show that Se can increase the expression of hypermethylated genes and has a larger 
effect than 5-AZA in the ‘normal’ RWPE-1 and DU145 prostate cell lines. A 
combination of 5-AZA and Se supplementation does not show evidence of a synergistic 
or additive effect.
The overlap of genes identified by 5-AZA in the previous chapter (Chapter 4) with the 
genes identified by MeDIP was investigated. Genes that were expressed more than 2- 
fold with 5-AZA, in the cancer cell lines only and not in the RWPE-1 cells, and that
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were down-regulated in cancer tissues were compared to the MeDIP identified genes 
using a two-way VENN diagram. DU 145 had 193 genes up-regulated with 5-AZA of 
which 28 were also identified as hypermethylated by MeDIP, in LnCAP cells 26 out of 
the 183 genes were identified by MeDIP and 15 out of the 112 genes in the PC-3 cells. 
These figures indicate that both techniques have a 7-7.5% overlap. One gene was in 
common between those gene lists: LYPD5 or LY6/PLAUR domain containing 5 with 
no known function.
Genes identified by Se supplementation after demethylation from the previous results 
chapter (Chapter 4) were compared to the genes enriched with MeDIP. Out of a 
possible 13 genes in DU145 cells, two were enriched in MeDIP (RIOK7 and GPR87). 
In LnCAP cells four genes (FAM83A, NPAL2, ANXA2 and C19orf33) were enriched 
out of a possible 13 while five genes (SCUBE2, BDNF, SART2, FAM83A and FOSB) 
were enriched in PC-3 cells out of a possible 15.
5.2.7 Selenoprotein  enrichm ent
A comparison was made between those selenoproteins that are at least two-fold 
enriched during MeDIP with at least one probe within the promoter region (+700 to - 
200 bp) and those whose gene expression was up-regulated by 5-AZA (Table 31) using 
the gene expression microarray data with a similar two-fold threshold.
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Table 31. Selenoproteins enriched by MeDIP and/or up-regulated by 5-AZA.
Values are fold-MeDIP-enrichment in the cell line compared to healthy prostate tissues. 
Values in brackets are fold up-regulation of gene expression by 5-AZA. Blank values 
mean that the 2-fold threshold was not reached.
RWPE-1 DU 145 LnCAP PC-3
DI02 2.1 2.9 (2.8) 2.5 5.6 (4.9)
DI03 (2.8) (19.6) (3.3) (2.3)
GPX2 (5.8) 2.2 (7.6) 4.6 (4.0) 3.3 (4.5)
GPX3 2.7 (2.7) 2.5 12.7 12.4
SELK 2.6 2.7 2.1
SELM (4.8) (3.6)
SELS (2.4)
SELV (3.0)
SEPP1 5.7 2.7 2.9 3.6 (2.3)
TXNRD1 (2.5)
Ten out of 25 selenoproteins were either enriched with MeDIP or showed increased 
gene expression after 5-AZA treatment. No selenoprotein was enriched and up- 
regulated by 5-AZA in cancer cells only. DI02 was enriched in the DU145 (2.9 fold) 
and PC-3 (5.6 fold) cell lines but up-regulated with 5-AZA in all cell lines. DI03 was 
upregulated in all cells lines by 5-AZA but not identified by MeDIP as a 
hypermethylated gene. This is to be expected as the MeDIP ratios are calculated 
according the fold difference compared to the healthy tissues in which DI03 is also 
enriched and thus not detected as enriched/hypermethylated. Consequently DI03 was 
not found to be hypermethylated in the prostate cancer cell lines compared with the 
‘normal’ RWPE-1 cell line.
GPx2 is the only selenoprotein that was methylated in cancer cells and not in RWPE-1 
cells, though it was upregulated in all cell lines with 5-AZA. GPx3 was highly
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methylated in LnCAP and PC-3 cells (12.7 and 12.4 fold respectively) and less so in 
RWPE-1 (2.7 fold) and DU145 cells (2.5 fold). 5-AZA only influenced GPx3 
expression in RWPE-1 cells (2.7 fold increase). A comparison between MeDIP and 
PSQ data (section 4.4.3) for both GPx2 and GPx3 shows there is perfect concordance 
between the two techniques. All three cancer cell lines were enriched for GPx2 with 
MeDIP (Table 31) while PSQ showed promoter hypermethylation for the same cell 
lines (Figure 30). GPx3 was highly enriched in LnCAP and PC-3 cells with MeDIP 
(Table 31) and PSQ confirmed the hypermethylation state for both cell lines (Figure 
26).
SELK was enriched in RWPE-1 (2.6 fold), DU145 (2.7 fold) and PC-3 cells (2.1 fold) 
but 5-AZA did not influence its mRNA expression. SELM mRNA expression was up­
regulated with 5-AZA treatment in RWPE-1 (4.8 fold) and PC-3 cells (3.6 fold) but no 
probes were enriched with MeDIP for any of the cell lines. An increase in SELS (2.4 
fold) and TxnrDl (2.5 fold) gene expression was observed after 5-AZA treatment in 
RWPE-1 cells respectively, but no probes were enriched for either gene. The same 
observation was made for SELV in DU 145 cells (3.0 fold). SEPP1 was enriched in all 
cell lines and 5-AZA treatment caused gene expression up-regulation in PC-3 cells (2.3 
fold). SEPP1 methylation profiles were subsequently investigated in all cell lines and 
tissues by methylation pyrosequencing. All samples had high methylation levels (69- 
90%) with no difference between normal and cancer samples (Cooper 2008).
From these results GPx2, GPx3 and DI02 should be considered as potential 
hypermethylated genes. There is a 25% overlap between the selenoprotein genes shown 
to be up-regulated by 5-AZA and enriched by MeDIP. As both techniques have shown
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to identify true hypermethylated genes they are complementary and can be used 
together to investigate DNA methylation.
5.2.8 Hyperm ethylated g en e  c lu sters
Clustering of hypermethylated genes was investigated by plotting all probes along the 
X-axis and the enrichment/input ratio along the Y-axis using the statistical package R. 
Four different layers were imported into the plots: all probes that (1) passed filtering (2) 
all probes that were significantly enriched (methylated) in healthy prostate tissue (3) all 
probes that were significantly hypermethylated in the prostate cancer cell lines 
compared to healthy prostate tissue (4) were in the upstream region (+700 to -200 bp) 
and that were significantly hypermethylated in the prostate cancer cell lines compared 
to the healthy prostate tissue. The plots for each chromosome can be found in 
Appendix 4.
Clear clusters were visually identified for each chromosome in each cell line and are 
summarised in Table 32.
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Table 32. Clusters identified in prostate cancer cells per chromosome.
Chromosome Location Comments a Cell line
3 3p21.31 -3p21.1 No known clusters DU145, LnCAP, PC-3
5 5ql3.3-14.3 No known clusters DU145, LnCAP, PC-3
5ql4.1 BHMT and BHMT2 DU145, LnCAP, PC-3
5q22.3 No known clusters DU145, LnCAP, PC-3
5q31.2-5q31.3 PCDH cluster DU145, LnCAP, PC-3
6 6p22.1 HIST1H cluster DU145, LnCAP, PC-3
7 7pl5.2 HOXA cluster DU145, LnCAP, PC-3
7q22.1 No known clusters DU145, LnCAP, PC-3
7q32.1-7q32.3 No known clusters DU145, LnCAP, PC-3
7q36.1 No known clusters DU145, LnCAP
8 8q24.3 No known clusters DU145, LnCAP, PC-3
9 9pl3.3 No known clusters DU145, LnCAP, PC-3
11 llql2.3-13.1 No known clusters DU145, LnCAP, PC-3
12 12pl3.31 No known clusters DU145, LnCAP, PC-3
12ql3.13 HOXC cluster DU145, LnCAP, PC-3
16 16pl3.3 No known clusters DU 145, LnCAP, PC-3
16pl 1.2 No known clusters DU145, LnCAP, PC-3
16ql3 MT1 cluster DU145, LnCAP, PC-3
16q22.1 No known clusters DU145, LnCAP, PC-3
17 17pl3.1 No known clusters DU145, LnCAP, PC-3
17q21.2 KRT cluster DU145, LnCAP, PC-3
17q25.1 No known clusters DU145, PC-3
20 20ql3.33 Unknown clusters DU145, LnCAP, PC-3
21 21q22.11 Oligl and 01ig2 DU145, LnCAP, PC-3
a Comments refer to known groups of genes from the same family within the cluster.
The majority of promoter enriched gene clusters were observed in each cell line. Most 
notable are the protocadherin (PCDH), HIST1H, HOXA, HOXC, metallothionein 
(MT1), and keratin (KRT) clusters as they consist of genes known to belong to the same 
family. It is important to note that not all clusters have been mentioned in Table 32 as 
many more clusters are present in the data that make up of two or three genes and have 
not been investigated in detail yet. Interestingly, chromosome 7 was the only 
chromosome in all the cancer cell lines that did not have a single enriched probe in the 
putative promoter region (+200 to -700 bp). The clusters that were identified had 
enriched probes outside this region.
193
Chapter 5 -  MeDIP
One example of clusters of hypermethylated genes in DU145 cells is given in Figure 46. 
The cluster consists of 11 HOXC genes with hypermethylated probes spread over the 
region 12ql3.3.
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Figure 46. Chromosome 12 in DU145 cells. Red box indicates the HOXC cluster.
7 7Probes plotted are located between 5x10 -  5.5x10 bp. Grey spots: All probes that 
passed filtering. Green: All probes that were significantly enriched after 
immunoprecipitation in healthy prostate tissues. Red: All probes that were significantly 
hypermethylated in the prostate cancer cell lines compared to healthy prostate tissue. 
Blue: Probes that were in the upstream region (+700 to -200 bp) and that were 
significantly hypermethylated in the prostate cancer cell lines compared to the healthy 
prostate tissue.
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5.3 Global methylation analysis of prostate cell lines and 
tissues and the effect of Se and 5-AZA
5.3.1 Global m ethylation an a ly sis  o f prostate t is su e s
Besides local hypermethylation, global hypomethylation is a common event in prostate 
cancer (Schulz et al. 2002). To measure the extent of global hypomethylation in the 
prostate cancer samples, a pyrosequencing assay was designed to determine the global 
methylation percentage of four CpG sites within the conserved Alu sequence (adapted 
from (Yang et al 2004)). All prostate tissues, healthy (n=2) and cancerous (Gleason 
Score=8; n=5), were subjected to global methylation analysis. Global methylation of 
the Alu sequence was decreased by 29%, although this did not reach statistical 
significance in cancerous prostates compared to healthy prostates (Figure 47). 
Reductions in global methylation varied between 12 and 46% in the cancerous 
prostates.
P ro sta te  t i s s u e  g lo b a l m eth ylation
n=2 n=5
Figure 47. Global methylation in normal and cancerous prostate tissue. Average 
Alu sequence methylation percentages by methylation pyrosequencing for each tissue 
type. Error bars are SD.
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5.3.2 Global m ethylation of prostate cell lines
The same strategy to measure global hypomethylation for the prostate cancer samples 
was used for each prostate cell line (Figure 48). The LnCAP prostate cancer cell line 
was hypomethylated, with 26% lower average methylation, compared to the ’normal’ 
RWPE-1 cell line.
Figure 48. Global methylation in prostate cell lines. Error bars are SD and represent 
the methylation percentages of the four CpG sites in the Alu sequence for each cell line.
G lobal m ethylation  o f p rostate  cell lines
N=1
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Chapter 5 Discussion: Analysis of genome-wide DNA 
methylation in prostate cancer
The majority of epigenetic research conducted into carcinogenesis has investigated 
DNA methylation patterns within cancer cells lines and tumour tissues on single genes. 
Soon after embarking on our studies into genome-wide DNA methylation in prostate 
cancer and its correlation with gene expression and Se inducibility, some studies were 
published using a similar approach.
In this study the primary aim was to use methylated DNA immunoprecipitation to 
investigate the hypermethylome of prostate cancer cells and to investigate the 
association between hypermethylation and gene silencing on a genome-wide scale, but 
also with particular reference to Se-inducible genes. MeDIP makes use of an antibody 
specific for methylated cytosines (Weber, 2005) and allows for comparison of the 
degree of DNA methylation in cancer cells versus normal counterpart tissues. The 
DNA used for this study originated from the same cell culture samples used in the 
previous gene re-expression experiment. This experimental design allowed for an 
integrative approach of MeDIP and gene re-expression data on a whole genome scale 
and to evaluate the effect of Se and 5-AZA on genes identified as hypermethylated by 
MeDIP.
Identification of hypermethylated genes in prostate cancer by MeDIP
In the present study, genes were determined to be hypermethylated in the prostate 
cancer cell lines when 2 or more probes were enriched in the MeDIP fraction compared 
to the healthy prostate tissues. The number of hypermethylated genes in the prostate 
cancer cell lines was significantly higher compared to the ‘normal’ RWPE-1 prostate
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cells when considering genes enriched more than four-fold. This suggests that the 
hypermethylome of the RWPE-1 cells is more closely associated with the healthy 
prostate tissues than the prostate cancer cell lines, which is consistent with the origin of 
the RWPE-1 cells as in v/Yro-transformed normal prostate epithelial cells.
The gene ontology software program MetaCore identified the actin cytoskeletal 
organisation and biogenesis as a process enriched in the two-fold hypermethylated gene 
list of all cancer cell lines (Table 30). Consistent with this, actin cytoskeleton is known 
to be involved in diverse cellular functions including migration, ion channel activity, 
secretion, metastasis, apoptosis and cell survival (Lambrechts et al. 2004). 
Deregulation of this process by gene silencing could promote cancer cell invasiveness 
and lead to metastasis formation. Indeed, the cancer cell lines used in this experiment 
were all metastases derived prostate cancer cell lines. This process was also identified 
in other studies using prostate and liver cancer cell lines and tissues (Arai et al. 2006; 
Schulz et al. 2007). Other processes identified were cell communication, the ‘negative 
regulation of biological processes’ and the cell cycle, all of which are frequently 
associated with hypermethylated genes in cancer cells (Al-Romaih et al. 2007; Esteller 
2007; Sadikovic et al. 2008). As these processes have been identified through different 
techniques in the literature, it suggests the novel MeDIP-chip combination is a suitable 
technique to identify hypermethylated genes.
Eleven genes were more than four-fold hypermethylated in all cancer cell lines. Gene 
ontology identified the vesicle-mediated transport process as being significantly 
enriched in this list represented by genes USP4, TRIM9, SIM1, OPRK1 and GABRR1. 
Vesicle-mediated transport has been found previously to be dysregulated in low grade
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breast cancer tumours (Alexe et al. 2007) and has been linked with cell invasion, 
metastasis and cell cycle regulation (Wright 2008). Neurotransmitters are released via 
Ca2+-triggered exocytosis, a vesicle-mediated transport mechanism, and can induce or 
inhibit migration, invasion and metastasis of primary tumour cells to other distant sites 
(Entschladen et al 2004). Both GABRR1 and OPRK1 down-regulate the release of 
neurotransmitters in different ways. OPRK1 is an adenylate cyclase inhibitor that 
results in the reduction of cAMP production and subsequent inhibition of 
neurotransmitter release by exocytosis. Though epithelial cells do not release 
neurotransmitters, supplementation with opioids can inhibit cell growth in lung cancer 
cells (Maneckjee and Minna 1990) and prostate cancer cells in culture (Kampa et al 
2001). GABRR1, which inhibits neurotransmitter exocytosis by opening an integral 
chloride channel, can inhibit norepinephrine-induced migration of breast and colon 
carcinoma cells (Joseph et al 2002; Drell et al 2003) when cells are supplemented with 
its ligand, gamma-aminobutyric acid. GABRR1 has also been found to be down- 
regulated in basal cell carcinoma (NCBI GEO GSE6520). TRIM9 has 98% amino acid 
sequence identity with Spring, a gene recently identified in rat that interacts with 
SNAP-25. SNAP-25 is part of the vesicle-transport regulating the SNARE complex (Li 
et al 2001). The interaction of Spring with SNAP-25 blocks the SNARE signal to 
execute the fusion of the vesicle to its target and the release of neurotransmitters (Li et 
al 2001). Down-regulation and mislocalisation of the SNARE complex has been 
shown to play a role in the progression of prostate cancer (Li 2003). SIM1, which is 
frequently hypermethylated in breast cancer (Agrawal et al 2007), plays a role in the 
development of the central nervous system though its specific function has not been 
elucidated yet. USP4 on the other hand, which is located next to GPxl on 3p21.31, is a 
proto-oncogene with a consensus binding sequence for the retinoblastoma gene family
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(Gupta et al. 1993) and has been shown to be up-regulated in lung cancer tissues (Gray 
et al. 1995). USP4 prevents the degradation of the A2A receptor prolonging its ‘shelf 
life’ on the cell membrane and preventing the recycling of the receptor by endocytosis. 
The accumulation of the A2A receptor results in an increase of adenylate cyclase and 
subsequent cAMP concentrations that results in an increase in neurotransmitter release 
(Milojevic et al. 2006). As USP4 seems to have the opposite effect on neurotransmitter 
release compared to the G-protein coupled gene products OPRK1 and GABRR1, an 
alternative effect must be gained through the silencing of these genes in prostate cancer. 
This alternative effect of either of these genes has not been fully elucidated yet though 
evidence points towards an effect on the actin cytoskeleton (Panagiotou et al 1999).
The six other hypermethylated genes were ADAMTS12, LAYN, ESD, PPP1R3C, 
RNF152 and PRR14. ADAMTS12, a disintegrin and metalloproteinase, exhibits a 
tumour suppressive role by modulating the Ras-dependent ERK signalling pathway by 
diminishing ERK phosphorylation and was shown to act as an anti-angiogenic protease 
with tumour inhibiting properties in epithelial and endothelial cells (Llamazares et al.
2007). ADAMTS12 silencing could therefore lead to increased cell proliferation via 
deregulation of the MAPK/ERK signalling pathway. LAYN encodes for Layilin, a 
protein involved in the actin-cytoskeleton organisation. Layilin binds to Talin that in its 
turn binds to integrins and actin (Borowsky and Hynes 1998). Cell shape, determined 
by the actin cytoskeleton, is essential for cell motility and layilin is an adhesion 
molecule situated between the membrane ruffles and the extracellular matrix during cell 
migration. Tetraspanins, a family of proteins also involved in the actin cytoskeleton 
organisation and localised in the membrane ruffles, are hypermethylated in myeloma 
cell lines (Drucker et al. 2006). Hypermethylation of layilin could therefore lead to
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increased cell motility and metastasis by deregulation of the actin cytoskeleton. Loss of 
heterozygosity of ESD, coding for Esterase D, and the RB locus (both located on 
13ql4.1) is required for retinoblastoma tumour induction (Godbout et al. 1983). In 
accordance with the results from Godbout’s study, gene silencing of ESD through 
hypermethylation might also be a contributing factor for tumour development. 
RNF152, a ring finger protein, has previously been shown to be down-regulated in 
breast and prostate cancer cell lines (Yamamoto and Yamamoto 2007) though its 
function is currently unknown. PPP1R3C, a protein with a reversible protein 
phosphorylation function, has previously been shown to be frequently down-regulated 
and hypermethylated in melanoma cell lines (Bonazzi et al. 2008) and it is down- 
regulated in head and neck/oral squamous cell carcinomas (Ye et al 2008). At present, 
no information is available on PRR14 coding for Proline rich 14.
Most of the 11 hypermethylated genes seem to have a putative role in anti­
carcinogenesis except for USP4 and PRR14. None of these genes, however, were 
significantly down-regulated in the prostate cancer tissue samples (n=6, 3 individuals) 
obtained from Prof. Cooper, except for ADAMTS12. RNA expression results from the 
gene re-expression chapter add PPP1R3C and LAYN as down-regulated genes in 
prostate cancer tissue samples (n=6, 5 individuals) kindly provided to us by Dr Corruba. 
The difference in RNA expression between the sample sets could be explained by the 
higher Gleason score for the set provided by Dr Corruba (GS 8 versus GS 6-7) as 
hypermethylation events increase with more differentiated tumours and by the inter­
individual differences in hypermethylated gene profiles between cancerous prostates. 
The other genes can not be disregarded as potential hypermethylated genes because the
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number of prostate tissue samples in this study is too low to exclude these genes from 
being hypermethylated and silenced in prostate cancer.
The hypermethylation state of genes in the prostate cancer cell lines does not 
automatically mean they are hypermethylated in the cancer tissue samples as well. It is 
known that cancer cell lines generally have a higher level of CpG island 
hypermethylation than primary tumours (Paz et al. 2003). Therefore the DNA 
methylation profiles of 5 genes chosen from those discussed above were analysed by 
pyrosequencing in the prostate cancer samples. PPP1R3C, SIM1 and USP4 were 
significantly hypermethylated in one or more samples. Gene expression, however, was 
not specifically down-regulated in the individual hypermethylated cancer samples, 
except for ADAMTS12, which suggests that hypermethylation did not have an effect on 
gene expression perhaps because of the position of the hypermethylated CpGs within 
the promoter.
CDKN2A isoforms are differentially methylated in prostate cancer
The promoter methylation state of a well known tumour suppressor gene, CDKN2A, 
was investigated. CDKN2A has been found to be hypermethylated in a variety of 
cancers but it encodes for several isoforms of the protein of which two were analysed in 
this study: pl6(INK4a) and pl4(ARF). These isoforms differ in their 5' UTRs and were 
therefore independently analysed. Both 5' UTRs were sequenced and a difference 
between the two promoters was observed with pl6(INK4a) being hypermethylated in 
the PC-3 prostate cancer cell line and in one prostate cancer sample while pl4(ARF) 
was not methylated in any of the prostate samples. The isoforms are therefore 
differentially methylated in prostate cancer, which might indicate that silencing of
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pl6(INK4a) is more crucial to prostate carcinogenesis than silencing of pl4(ARF). 
pl6(INK4a) inhibits the phosphorylation of the retinoblastoma tumour suppressor while 
pl4(ARF) is p53 dependent. These results are in accordance with previously published 
results that show that pl6(INK4a) hypermethylation and down-regulation is a more 
common event than pl4(ARF) hypermethylation (Konishi et al. 2002). This suggests 
that the inhibition of phosphorylation of the retinoblastoma gene by pl6(INK4a) is 
more common event in prostate cancer than the induction of the p53 DNA damage 
repair pathway.
Integration of gene re-expression and MeDIP data
Promoter methylation profiles from the MeDIP data and gene expression data from the 
gene re-expression experiment from the previous chapter (Chapter 4 were correlated on 
a whole genome level. The results showed that hypermethylated genes generally had 
lower gene expression values compared to unmethylated genes except in PC-3 cells 
where the inverse was true. This inverse correlation was also observed on a whole 
genome scale in leukemia tumours (Figueroa et al. 2008) in addition to the positive 
correlation between gene expression and H3K9 acetylation and the inverse correlation 
between DNA methylation and H3K9 acetylation. H3K9 acetylation was not 
investigated in the present study. The positive correlation between hypermethylation 
and gene expression in the PC-3 cells has also been observed recently in a different cell 
line. Sadikovic and colleagues (Sadikovic et al. 2008) found that in the U20S cells, a 
sarcoma cell line, genes were not only affected by hypermethylation and under­
expression but the majority of hypermethylated genes was over-expressed. No 
explanation was given in the paper for this association.
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Both 5-AZA and Se had an effect on hypermethylated genes as revealed by comparing 
hypermethylated genes identified by MeDIP with their gene expression values after Se 
supplementation. The increase in expression of hypermethylated genes after 5-AZA has 
been shown before in numerous papers but only recently was Se shown to have an 
effect on re-expression of hypermethylated genes as well. As noted in the previous 
chapter (Chapter 4) Xiang and colleagues showed that selenite demethylated GSTP1, 
APC and CSR1 promoters in addition to a global demethylation effect (Xiang et al
2008). The finding were corroborated by the results from a gene re-expression 
experiment on a single gene level (Figure 37) and again in the here in combination with 
the MeDIP data on a whole-genome level. From Figure 45 it is clear that Se had a 
greater effect than 5-AZA, especially in the ‘normal’ RWPE-1 and cancerous DU 145 
prostate cells, which is in accordance with the results from Xiang and colleagues (Xiang 
et al. 2008). These results showed that Se alone has a greater effect than 5-AZA, even 
when the two treatments were combined, on hypermethylated gene expression. It is 
possible that in the RWPE-1 and DU145 prostate cells, 5-AZA might be more toxic, 
preventing genes being up-regulated by Se in the presence of 5-AZA and conversely 
making them more likely to be down-regulated by 5-AZA, as observed. Cytidine 
deaminase, an enzyme inhibiting the activity of 5-AZA and possibly responsible for the 
increase in toxicity, was not expressed less in the ‘normal’ RWPE-1 and DU145 
compared to the LnCAP and PC-3 prostate cell lines and can therefore be excluded as a 
possible cause.
Figueroa and colleagues found that gene expression and CHIP studies did not identify 
the same hypermethylated genes but only showed partial overlap due to the differences 
in technique and detection (Figueroa et al. 2008). The same observation was also made
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in the present study when MeDIP data and 5-AZA-mediated gene re-expression data 
were compared. Though both techniques identified real hypermethylated genes as 
confirmed by methylation PSQ, the gene lists only partially overlapped due to their 
inherent differences in methylation detection.
Hypermethylated selenoproteins in prostate cancer
Of particular interest were the selenoproteins because of their reliance on the presence 
of Se. Besides GPx3, GPx2 was also found to be hypermethylated exclusively in 
prostate cancer cell lines and tissues, and DI02 is another likely candidate according to 
MeDIP and gene re-expression data. The DNA methylation profile of DI02 will have 
to be investigated in greater detail in order to confirm this. Selenoproteins SELM, 
SELV and SELX (MsrBl) that responded to 5-AZA treatment in one or more cell lines 
were not enriched by MeDIP and will have to be sequenced in order to exclude them as 
hypermethylated genes.
Hypermethylated genes are frequently found in functional clusters
Hypermethylation of genes is not always restricted to the single gene level and when 
DNA methylation patterns were investigated on a genome wide scale, as in this study, 
clusters of hypermethylated genes were identified that appear to be the result of long 
range epigenetic silencing. Clusters of hypermethylated genes were identified by 
visually inspecting the data and by comparing the identified cluster regions in the UCSC 
genome browser for the identification of known gene families. A large number of 
clusters were found that belonged to very specific gene families. This phenomenon has 
been observed before and described in a limited number of papers. The observations 
from these papers were reviewed by Clark (Clark 2007). Only one paper describes the
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clustering of hypermethylated genes on a whole genome level (Keshet et al. 2006) 
though the authors do not give details on which clusters were identified. Out of the 
seven clusters mentioned by Clark (Clark 2007), three were identified by MeDIP in the 
present study: 2ql4.2, 7pl5.2 and 9pl3.
Ten other clusters were identified in the prostate cancer cell lines that are known to 
belong to specific gene families. Other clusters could not be easily classified but many 
may be of interest. Specific members of the protocadherin cluster on 5q31.2-5q31.3 
have been identified previously as a cluster of hypermethylated genes in osteosarcoma 
cells (Sadikovic et al. 2008). The exact function of protocadherins has not been 
elucidated yet but in vitro and in vivo evidence points to a tumour suppressor role 
(Okazaki et al. 2002). The HIST1H cluster on 6p22.1 is located in a region frequently 
deleted in melanoma cell lines (Trent et al. 1990), B-cell lymphoma (Nagai et al. 1999) 
and in breast cancer where loss of heterozygosity was more prevalent in high grade 
compared to low grade tumours (Piao et al. 2001). The HOXA gene cluster is a family 
of genes that encode transcriptional regulators that play critical roles in cell 
development and differentiation. The cluster is located on 7pl5.2 and consists of 10 
HOXA genes that have been previously identified as hypermethylated in breast cancer 
(Novak et al. 2006). Though several HOXC genes (HOXC4-6 and HOXC8) have been 
shown to be overexpressed in the same prostate cancer cell lines (Miller et al. 2003) 
they were, together with the HOXA cluster, also found to be hypermethylated in PC-3 
cells (HOXC5-10) (Gal-Yam et al. 2008) and to be preferential targets of DNA 
methylation in lung cancer (Rauch et al. 2007). This further suggests that 
hypermethylated genes can also be over-expressed in prostate cancer, which is 
consistent with the results previously discusses where the PC-3 prostate cancer cell line
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showed a positive correlation between DNA methylation and gene expression. The 
metallothionein gene family encodes for at least 14 genes and pseudo genes and is 
located on 16ql3. They function in a protective mechanism against heavy-metal 
toxicity (Klaassen et al 1999), oxidative stress (Kumari et al 1998) and can activate the 
pro-apoptotic gene p53 (Fan and Cherian 2002). A cluster identified on 17q21.2 
consists of keratin genes. The keratin genes are responsible for the structural integrity 
of epithelial cells and some have been shown to be absent in prostate cancer tumours 
compared to normal prostate tissues (Brawer et al 1985). OLIG1, a gene involved in 
nerve cell development, has been shown to be hypermethylated and down-regulated in 
non-small cell lung cancer (Brena et al. 2007). Reduced OLIG1 protein expression was 
also associated with reduced survival. OLIG2 on the other hand was 100% 
hypermethylated in 12 melanoma cell lines (Tellez et al 2006) and in acute myeloid 
leukemia cell lines and patients (Kroeger et al 2008). Both genes are located next to 
each other on 21 q22.11.
It is important to note though, that when a cluster was identified not all members of the 
gene family were necessarily hypermethylated. Clusters of hypermethylated genes for 
which no known gene family was identified regularly contained genes that have been 
previously reported to be hypermethylated in cancer. An example can be found in the 
cluster located on chromosome 3 (3p21.2-3) that harbours genes such as RASSF1 and 
ZMYND10. Both genes are frequently hypermethylated in prostate cancer (Kuzmin et 
al 2002) and the whole region containing eight tumour suppressor genes has already 
been identified as a tumour suppressor cluster (Hesson et al 2007).
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Besides hypermethylation, deletions of genomic regions are frequent events in cancer 
cells. When regions are deleted that contain tumour suppressor genes, homozygous or 
heterozygous, this could provide an advantage for tumours. The occurrence of this 
phenomenon has been shown to regularly coincide with regions of hypermethylation 
providing ‘the second-hit’ in Knudson’s two-hit model for carcinogenesis (Knudson 
1971). The 3p21.3 region mentioned before, has also been shown to be deleted in a 
number of cancers (Hesson et al 2007) while eight other clusters identified in the 
present study (5ql3.3, 5ql4.1, 5q22.3, 6p22.1, 16ql3, 16q22.1, 17q21.2and 21q22.1) 
were also shown to be deleted in prostate cancer (Pettus et al. 2004). Five of these 
belong to known gene families (BHMT1 and 2, HIST1H, MT1, KRT and Oligl and 2).
It is apparent from these results that hypermethylation of promoters does not only occur 
randomly and on a single gene level. The clustering of hypermethylated genes clearly 
shows orchestrated silencing of genes with similar function in order to present the cells 
with a selective advantage for tumour growth. Similar clustering on a genome wide 
scale has been observed in colorectal cancer cell line Caco-2 (Keshet et al. 2006) 
though no comments were given about the type of genes that clustered together. It is 
still unknown why functional clusters of genes become hypermethylated in cancer 
though clues are emerging from the literature. Highly expressed genes also cluster 
together in chromosomal domains (Caron et al 2001). In addition, research conducted 
by Feltus and colleagues found that the sequence context determined whether it was 
prone to methylation or not (Feltus et al 2006). They also found that methylation- 
prone sequences are associated with CpG islands and were non-randomly distributed 
throughout the genome. The authors suggested that these methylation-prone sequences
208
Chapter 5 -  MeDIP
might contain binding sites for proteins involved in the promotion or prevention of 
aberrant DNA methylation (Feltus et al 2006).
Global methylation levels of prostate cancer
Global hypomethylation of LINE repetitive elements is a general phenomenon in 
prostate cancer and precedes hypermethylation (Florl et al. 2004). Global 
hypomethylation analysis was investigated in this study by methylation PSQ of the 
conserved Alu sequences (SINEs) (Yang et al. 2004) and revealed general 
hypomethylation of all prostate cancer tissue samples with three samples having 
reductions over 40%. The decrease in global methylation observed in the LnCAP cell 
line is perfectly in line with results published by Yegnasubramanian and colleagues 
(Yegnasubramanian et al. 2008) who showed that LnCAP cells had lower methylation 
scores, as measured by LINE-1 methylation, compared to normal and other prostate 
cancer cell lines including the PC-3 and DU 145 cell lines. The same observations were 
also made in prostate cancer tumours with lymph node involvement where DNA 
hypomethylation was most pronounced compared to other types of prostate cancer 
metastases (Santourlidis et al 1999; Schulz et al 2002). The global methylation results 
confirm the cancerous origins of the prostate cancer samples and the co-existence of 
two seemingly opposite DNA methylation events in prostate cancer being local-regional 
hypermethylation and ‘global’ hypomethylation.
In summary, the MeDIP procedure identified a number of genes that were not 
previously known to be hypermethylated in cancer cells that showed inter-individual 
differences in methylation profiles from patients with the same Gleason grade. 
Combining both microarray data sets (5-AZA-mediated gene re-expression and MeDIP)
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showed there is a higher propensity for hypermethylated genes to be up-regulated by 
any of the treatments used in this study (Se, 5-AZA or Se+5-AZA). It also showed that 
gene expression and hypermethylation were inversely correlated in the cell lines except 
for the PC-3 prostate cancer cell line. A number of hypermethylated gene clusters were 
identified in all prostate cancer cell lines and global methylation analysis showed lower 
methylation scores for prostate cancer tissues and LnCAP cells compared to their 
normal counterparts.
The final conclusion summarises all findings of this project and aims to bring together 
the three results and discussion chapters.
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Final Conclusion
The analysis of the effect of selenium (Se) on one-carbon metabolism is important in 
order to gain an understanding of how Se can influence cancer risk. One-carbon 
metabolism is responsible for the production of methyl groups that can be used in DNA 
methylation reactions and therefore plays a major role in cancer aetiology. Se has been 
associated with homocysteine (Hey) but studies in humans and rats have produced 
opposite results. Evidence for a more direct role of Se in DNA methylation is still 
lacking. This PhD thesis aimed to improve the understanding of Se and its effect on 
one-carbon metabolism and DNA methylation by using a combined nutri-epigenomic 
approach.
Two types of studies were undertaken during the course of this PhD: (i) a statistical 
analysis of a randomised, double-blind, placebo controlled intervention trial to 
determine the effect of Se on one-carbon metabolism and investigate the interactions 
between the different nutrients analysed, (ii) An epigenomic and transcriptional 
investigation into the effect of Se on DNA methylation in prostate cancer.
From the statistical analysis of the results produced by the PRESICE pilot trial it 
became apparent that Se concentrations were indeed inversely correlated with tHcy 
concentrations in males (P<.05) though the effect of Se on tHcy was very small 
(R2=1.8%). In females Se was only inversely correlated with tHcy when they had high 
folate concentrations (P<.05). On the other hand, Se supplementation with 100 or 300 
pg/day did not have an additional effect on tHcy concentrations in either gender. A 
hypothesis was generated that the relationship between Se and tHcy was secondary to
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the inflammation response in elderly people based on published findings that 
inflammatory markers can decrease the major Se sources in plasma. These data suggest 
that it is unlikely that Se exerts a direct effect on DNA methylation through the one- 
carbon pathway.
The product of one-carbon metabolism is the production of methyl groups that can be 
used in DNA methylation reactions. The aberrant methylation of DNA is an early event 
in carcinogenesis and has been suggested to play a causative role in the progression of 
prostate cancer. The second study of this PhD investigated at a molecular level whether 
Se had an effect on DNA methylation. The integrative experimental design used in this 
project to study DNA methylation profiles by MeDIP, gene re-expression after 
demethylation with 5-AZA, and the effect of Se on these processes, proved to be a 
valid and useful approach.
The combination of gene re-expression using a demethylating agent with and without 
Se supplementation allowed for the identification of Se-responsive genes, 
hypermethylated genes and hypermethylated genes that would be Se-responsive in an 
unmethylated state. Se supplementation increased the expression of genes involved in 
anti-carcinogenic pathways while decreasing expression of genes involved in the 
proliferation of cells. One gene, CRX, was up-regulated in all prostate cell lines after 
Se treatment. 5-AZA identified 14 genes to be hypermethylated in all prostate cancer 
cell lines and more than two-fold down-regulated in the prostate cancer tissues. Four of 
these genes were involved in embryonic development pathways, an observation that 
supports the stem cell cancer origin hypothesis.
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GPx2, a selenoprotein previously unknown to be hypermethylated in cancer, was 
identified to be exclusively hypermethylated in prostate cancer cells and tissues. GPx2 
is an anti-inflammatory protein and silencing of this gene might confer a selective 
advantage for prostate cell proliferation. BHMT and BHMT2, two enzymes with 
homocysteine methyltransferase activity, were hypermethylated to some degree in all 
prostate cancer cells and tissues. Decreased BHMT activity could result in increased 
homocysteine concentrations though this has not been associated with prostate cancer 
yet. DI02, SELM, SELV and SELX (MsrBl) were up-regulated by 5-AZA and 
enriched by MeDIP in at least one prostate cancer cell line and down-regulated in the 
prostate cancer tissues. Further methylation sequencing should clarify whether these 
are bonafide hypermethylated genes. DI02 is a selenoprotein that generates thyroid 
hormone T3 from the prohormone T4, like its homolog DIOl. Its transcription is 
inhibited by T3 as a feedback loop in contrast to DIOl, which is stimulated by T3 
(Kohrle et al. 2005). As T3 stimulates growth of cancer cells it would therefore be 
advantageous for cancer cells to have DIOl over-expressed and DI02 silenced. SELM 
contains an active-site redox motif suggesting it can alter the cell’s redox status. 
Altering the cell redox status changes gene expression and could therefore be an 
advantage for tumour cells. SELV has no known function while MsrBl reduces 
oxidised methionine sulfoxide residues back to methionine and hereby protects the cell 
from oxidative stress. Hypermethylation and down-regulation of this gene has been 
shown previously (De Luca et al 2007).
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5-AZA and Se together significantly decreased global methylation levels of the PC-3 
prostate cancer cell line. This is a novel finding and strokes with results published by 
Xiang and colleagues that show that both 5-AZA and Se have demethylating properties 
on individual promoters (Xiang et al. 2008).
5-AZA and Se treatment identified a number of hypermethylated genes in cancer cells 
that would be Se-responsive in an unmethylated state. GPx3, a gene known to be 
sensitive to Se concentrations and that is hypermethylated in prostate cancer, was shown 
to have increased RNA expression with Se supplementation after the initial increase 
with demethylation. Other genes that responded to Se supplementation after 
demethylation were identified for each cell line and were involved in DNA repair, cell 
motility, the JAK/STAT signalling pathway and the regulation of translation in response 
to stress. The reactivation of these pathways with Se supplementation after 
demethylation is an indication that Se supplementation might be beneficial as an 
adjuvant therapy alongside the use of demethylating agents.
DIOl, a selenoprotein that produces the active thyroid hormone T3 from its inactive 
form T4, was overexpressed in the LnCAP prostate cancer cell line. Exogenous T3 
treatment increases cell proliferation only in the LnCAP cell line and not in the PC-3 or 
DU 145 cell lines. DIOl overexpression in the LnCAP cell line might therefore increase 
T3 production resulting in enhanced cell growth.
Four genes with similar gene expression profiles as E2F5 were over-expressed in all 
prostate cancer cell lines and tissues. These included KLHDC2 that is involved in cell 
cycle control and B4GALT3, a glycosyl transferase, suggesting that these might be
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important in the aetiology of prostate cancer. The precise function of the other two 
genes FAM80A and OTUB2 is currently unknown.
The MeDIP-chip technique was applied to identify hypermethylated genes through a 
more direct approach using an antibody specific for methylated cytosines. It identified 
11 genes that were hypermethylated in all cancer cell lines and, perhaps surprisingly, 
five of these genes were involved in vesicle-mediated transport. The gene re-expression 
data was integrated with the data produced by the MeDIP-chip and an inverse 
correlation between gene expression and DNA methylation was observed, except in the 
PC-3 prostate cell line, for which apparent anomaly an explanation is not immediately 
obvious. This combined approach also allowed investigation of the effect of Se on 
hypermethylated genes identified through MeDIP. Se was shown to have a greater 
effect than 5-AZA, even when combined, on expression of hypermethylated genes and 
this was more marked in the ‘normal RWPE-1 ’ and DU145 prostate cell lines. This was 
unexpected and several hypotheses are possible why Se had a greater effect on 
hypermethylated genes than 5-AZA alone or in combination with it. It is possible that 
Se can demethylate and inhibit repressors that 5-AZA can not, or that 5-AZA 
mechanistically activates expression inhibitors. Selenium can also have an effect on 
other proteins such as methyl-binding proteins that bind methylated CpGs or histone 
acetylators that could be inhibited by 5-AZA.
CDKN2A produces two isoforms that are differentially methylated and possibly 
regulated in prostate cancer of which only pl6(INK4a) was found to be 
hypermethylated in the PC-3 prostate cancer cell line and in one prostate cancer sample 
(out of a possible 6). pl6(INK4a) inhibits the phosphorylation of the retinoblastoma
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tumour suppressor and silencing of this gene can therefore enhance tumour growth . 
These results show again that the methylation pyrosequencing technique works well to 
detect methylation differences in between genes and samples.
Clusters of hypermethylated genes belonging to the same gene family were observed in 
all cancer cell lines pointing to orchestrated hypermethylation events occurring during 
carcinogenesis. Global methylation profiles of prostate cancer tissues confirmed 
decreased methylation levels in prostate cancer.
In summary, the role of Se in one-carbon metabolism was investigated on a metabolic 
and molecular level. Se was found to be inversely correlated with tHcy although the 
effect of Se on tHcy variation was limited and a hypothesis was generated suggesting an 
indirect relationship, involving inflammation, between the two factors. On a molecular 
level on the other hand, Se appears to play a direct role in one-carbon metabolism by 
decreasing global methylation levels, and may be implicated in the observed increased 
expression of hypermethylated genes. The results suggest that Se supplementation after 
demethylation can have a beneficial effect on cancer treatment by increasing the 
expression of genes in cancer-protective pathways.
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The inverse correlation between Se and tHcy concentrations has been demonstrated in 
an elderly UK population and a hypothesis was generated that this correlation is 
dependent on the extent of inflammation. To prove this hypothesis it is necessary to 
measure markers of inflammation such as IL-6, IFN-y, CRP. This would allow 
analysis of the association of these markers with Se and tHcy concentrations. The 
determination of selenoprotein concentrations and activity would also shed some light 
on how inflammation affects the main source of Se in plasma. The activity of enzymes 
involved in one-carbon metabolism BHMT, GNMT and GCL are crucial for the 
removal of excess tHcy and are influenced by Se concentrations in rats and mice. 
Currently it is unknown whether this is also true in humans. This could be tested by (i) 
measuring the activity of these enzymes in a Se intervention study and analysing the 
correlation between the activities and the concentrations of Se and tHcy; (ii) in vitro test 
of the influence of Se on cysteine-rich regions present within the catalytic domain of 
BHMT.
Aberrant hypermethylation events increase with age, which is one of the reasons why 
cancer incidence also increases with age. Because the study population of the
PRECISE pilot trial had an average age of 66, it would be reasonable to assume that
\
aberrant hypermethylation of genes has occurred in these individuals. When taking into 
account that in the second project of this PhD Se may have been acting to demethylate 
DNA on a global and regional level, even though statistical significance was not 
reached, it would be interesting to investigate the effect of Se supplementation on blood 
leukocyte DNA methylation directly within the PRECISE pilot trial. At the same time,
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the level of DNA methylation can also be correlated to the other factors measured in the 
study: folate, homocysteine, vitamin B12 and B6 status as all of these have an important 
role in the production of the methyl groups.
In this thesis several genes were found to have increased gene expression after 
demethylation and/or were enriched with MeDIP. A limit of this project was the low 
number of healthy and cancerous tissue samples. Therefore the hypermethylation state 
of the genes identified in this project will have to be confirmed in a larger and a more 
diverse sample set including hyperplastic prostates, prostates with PIN lesions and 
different stages of prostate cancer to investigate the involvement of DNA methylation in 
prostate cancer aetiology and progression. Especially in the case of GPx2, a 
selenoprotein that was found to be hypermethylated and down-regulated in all prostate 
cancer cell lines and tumour tissues, it is important to establish at what point during 
carcinogenesis the promoter becomes hypermethylated. As in the case of GPx3 in 
oesophageal cancer (Lee et al. 2005), a progressive loss of GPx2 expression might 
elucidate why in human colorectal adenomas GPx2 expression is the highest in early 
adenomas and progressively decreases in the late stages of malignancy (Florian et al. 
2001).
The function of most of the genes identified to be hypermethylated in the prostate 
cancer tissues is still unknown, especially with respect to their role in prostate cancer. 
Functional analysis using siRNA to knock-down specific gene expression might give 
some indication on whether these genes are important for prostate tumourigenesis and 
their role in cancer development. The same strategy can be used to functionally analyse 
the genes found to be over-expressed in the prostate cancer cell lines and tissues.
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Compared to the ‘normal’ RWPE-1 prostate cell line, the selenoprotein GPX3 was 
hypermethylated in the LnCAP and PC-3 prostate cancer cell lines while there was only 
one CpG site (+34) hypermethylated in the DU 145 cell line. This CpG site is part of a 
putative binding site for the SP1 transcription factor and might prevent SP1 binding in a 
methylated state. An assay can be set up to (i) determine whether the site indeed binds 
SP1 and (ii) whether the methylated state of CpG +34 interferes with SP1 and (iii) 
whether this has an effect on GPx3 RNA expression.
After demethylation, detection of GPx3 mRNA was further increased in the prostate 
cancer cell lines with Se supplementation. This could also be tested in in vivo models 
where protein concentrations and activity could confirm the beneficial effect of Se 
supplementation after demethylation on antioxidant defence. GPx3 has also been 
shown to be down-regulated in Hiirthle cell carcinomas and cell lines (Menth et al. 
2005). It is very likely that in these types of cancer GPx3 is also silenced through 
hypermethylation.
Down-regulation and hypermethylation of a number of genes such as GPx2, GPx3, 
BHMT, BHMT2 and ADAMTS12 has been shown to be a regular occurrence in the 
prostate cancer cell lines and tumour tissues. It would be interesting to investigate 
whether transient expression using constructs of genes, individually and combined, has 
an effect on cell growth.
DIOl, a selenoenzyme with 5' deiodinase activity for the conversion of T4 into its 
active T3 form, was shown to be overexpressed in the LnCAP prostate cancer cell line 
and in the prostate cancer tissues compared to their normal counterparts. The
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hypothesis that was generated stated that DIOl over-expression increases T3 
concentrations causing a down-regulation of BTG2 promoter activity and subsequent 
increase in cellular proliferation. This hypothesis can be tested by knocking down 
DIOl in the LnCAP cells by siRNA and measuring BTG2 expression, T3 
concentrations and cellular proliferation after T4 supplementation. If T3 concentrations 
decrease and BTG2 promoter activity increases with an associated decrease in cellular 
proliferation it would prove the involvement of DIOl in LnCAP cellular proliferation 
via a T3 mediated pathway.
Se was shown to have a demethylating effect on the promoters of GPx2 and BHMT 
though not enough sample was available at the time for multiple biological replicates. 
This will have to be replicated and at the same time, the effect on histone methylation 
and acetylation state of these promoters can be investigated.
Other sources of Se need to be investigated for their global and local demethylation 
effects. Sodium selenite, the Se source used in the present project, is an inorganic form 
of Se and is not usually consumed by humans. Sodium selenite was chosen for this 
study as it can induce selenoprotein expression much quicker than selenomethionine. 
Selenomethionine on the other hand is an organic source of Se and is present as the 
major Se form of Se supplementation tablets. One study has shown that supplementing 
LnCAP prostate cancer cells with 100 pM SeMet results in promoter DNA 
demethylation and RNA and protein re-expression of GSTP1 (Xiang et al 2008) though 
it is unknown whether lower concentrations of SeMet have a similar effect and if other 
hypermethylated genes are also affected.
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In recently published research, DNA methylation patterns have been correlated on a 
whole genome scale with histone methylation patterns (Meissner et al 2008). To gain a 
further understanding of the epigenetics of prostate cancer the same technique to 
immunopreciptate methylated DNA can be employed to enrich genomic fragments 
associated with acetylated or methylated histones. In addition, comparative genomic 
hybridisation showed that regions of hypermethylation correlated with genomic gain 
(Sadikovic et al 2008). It would be interesting to perform a similar analysis in prostate 
cancer and combine it with the MeDIP data obtained in the present study.
A number of additional bioinformatic analyses can be performed. Besides clusters of 
hypermethylated genes, clusters of hypomethylated genes are also a possibility as 
shown in a paper published by Novak and colleagues (Novak et al 2006). The 
sequence context of the hypermethylated and hypomethylated regions can be 
investigated for motifs and correlated with methylation status.
And finally, a difference in promoter methylation of the two isoforms of the tumour 
suppressor CDKN2A was detected in a small number of cancerous prostates. This has 
to be expanded into a larger and more diverse tissue set and the effect on isoform 
expression needs to be investigated.
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Appendix
A ppendix 1. R ecip es for buffers and growth m edia
SOC medium
For 1 L: 20 g tryptone, 5 g yeast extract, 0.5 g NaCl and 2.5 ml 1 M KCL adjusted 
to pH 7 with NaOH, autoclaved, add 20 ml sterile 1 M glucose.
Agar
For 500 mL: 5 g tryptone, 2.5 g yeast-extract, 2.5 g NaCl, add reverse osmosis 
water to just under 500 mL, adjust pH to 7 with NaOH in solution, add 7.5 g agar, 
autoclave.
XGAL, IPTG, ampicillin
Ampicillin: 50 mg/ml in H2O and filter sterilise. IPTG: 4% solutions, dissolve 2 g 
IPTG in 48 ml H2O, adjust to 50 ml with H2O and filter sterilise. X-GAL: 50 
mg/ml in dimethylformamide.
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Appendix 2. Examples of PCR optimisation using gel 
electrophoresis
An example for primer set optimisation is given in Figure 1. Lane 4 with primers 
GPx3_Fl + GPx3_Rl and GPx3_F2 + GPx3_R3 gave a clear band (±530 bp) for the 
expected amplicon length of 531 bp.
1 2 3 4 5 6 7 8 9  10
Figure 1. GPx3 amplicon 1 PCR primer set test on a 2% TBE agarose gel. Lane 1: 50 
bp ladder; Lane 2, 3, 5-9: non-specific primer combinations; Lane 4: primer set 
GPx3_Fl + GPx3_Rl (1st round) and GPx3_F2 + G Px3Jt3  (2nd round); Lane 10: 100
bp ladder.
Primer sets were preferred that covered larger regions and only if they were specific 
enough to produce a single band. After a specific primer set was chosen for a region of 
a gene, gradient PCRs were used to determine the optimal annealing temperature 
(Figure 2). In this case, for the second amplicon of GPx3, an annealing temperature of 
54.5 °C was considered optimal as no additional bands were observed except for the 
expected PCR product of 301 bp.
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1 2 3 4 5 6 7 8 9  10
Figure 2. GPx3 amplicon 2 gradient PCR on a 2% TBE agarose gel. Lane 1: 50 bp 
ladder ; Lane 2-9: Tm gradient from 48.6 (lane 2) to 54.5 °C (lane 9) with primers 
GPx3 FI + GPx3_Rl (1st round) and GPx3_F2 + GPx3_R3 (2nd round); Lane 10: 100
bp ladder.
Primers sets were optimised for all four genes to maximise the number of CpGs present 
in the amplicon and preferably located within the CpG island of the promoter of the 
gene. An overview of the physical location of the amplicons relative to the transcription 
start site is given in Table 22.
After PCR, the amplicons for GSTP1, GPx3, GPx4 and Sep 15 were transfected into 
pGEM plasmids, transformed into JM109 competent cells and grown on agar plates. 
After 24h individual white (positive insert) colonies were selected and plated out. The 
direction of the insert was checked with PCR for each colony with a universal M l3 
primer, which binds as a forward primer to the pGEM plasmid, in combination with the 
reverse primer specific for each individual amplicon. An example is given in Figure 3.
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1 2 3 4 5 6 7 8 9 1011 12
B
13 14 15 16 17 18 19 20 21 22 23 24
Figure 3. Sepl 5 positive plasmid insert check on a 2% TBE agarose gel. Lanes 1,12 
and 13: 100 bp ladder; lanes 2-11, 14-22: products generated by M l3 and reverse 
primer Sepl5_R2. Lanes 2-4, 8, 10, 14-15, 18-22 have inserts in the correct direction.
Figure 3 shows the products produced for Sep 15. Inserts that were inserted in the 
correct direction (Lanes 2-4, 8, 10, 14-15, 18-22) were sub-cloned on individual agar 
plates. After 24h the length and integrity of the plasmids was checked on agarose gels 
before plasmid DNA extraction. An example for GSTP1 plasmid constructs is given in 
Figure 4.
1 2 3 4 5 6
5 kb 
2  kb 
1 kb
Figure 4. pGEM plasmid GSTP1 constructs on a 1% TBE agarose gel. Lane 1: super 
coiled plasmid ladder; Lanes 2-6: individual clones of GSTP1.
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Appendix 3. Selenoproteins and gene expression values after 
treatment
Figure 1. Heatmap of selenoprotein and associated genes mRNA expression after 
treatment. R=RWPE-1, D=DU145, L=LnCAP, P=PC-3. M=control, A=5-AZA, S=Se, 
B=5-AZA+Se. Green: low expression vs universal reference RNA. Red: high 
expression vs universal reference RNA. Grey indicates poor data.
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Table 1. Gene expression changes of selenoproteins after Se treatment in all cell lines.
RWPE-1 DU 145 LnCAP PC-3
DIOl 0.67 0.51 1.16 1.00
DI02 1.04 1.58 0.65 0.98
DI03 1.85 1.07 1.34 1.13
GPX1 0.92 1.11 0.98 1.03
GPX2 1.21 1.34 0.76 1.05
GPX3 1.05 1.02 0.87 0.86
GPX4 1.04 1.12 0.92 1.02
GPX6 0.98 1.16 1.04 1.15
SELO 0.93 0.78 1.2 0.81
SELH 1.14 2.02 0.77 1.87
SELI 0.89 1.11 0.96 1.63
SELK 1.03 1.04 0.74 0.86
SELM 1.09 0.91 0.75 0.98
SELS 1.07 0.87 1.15 0.84
SELT 0.98 1.00 0.72 0.97
SELV 0.86 1.64 0.6 1.00
SEP 15 0.89 1.33 0.51 1.16
SEPHS2 0.92 0.9 0.95 0.9
SEPN1 1.06 0.96 1.3 0.94
SEPP1 NA NA 0.68 1.38
SEPW1 1.02 2.46 1.29 2.29
SELX 1.05 1.05 0.64 1.37
TXNRD1 1.31 1.09 1.4 0.83
TXNRD2 0.91 0.82 1.29 1.21
TXNRD3 1.00 0.89 1.42 1.08
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Table 2. Gene expression changes of selenoproteins after 5-AZA treatment in all cell 
lines. H/C: Healthy prostates/cancerous prostates.
RWPE-1 DU 145 LnCAP PC-3 H/C
DIOl 1.05 1.69 1.66 0.93 0.68
DI02 0.75 2.8 1.49 4.9 1.25
DI03 2.78 19.6 3.35 2.26 1.67
GPX1 0.88 0.82 0.92 1.14 0.83
GPX2 5.8 7.62 4.05 4.46 7.6
GPX3 2.74 1.00 1.33 1.00 1.68
GPX4 1.08 0.88 1.07 1.26 1.2
GPX6 1.00 1.02 0.98 0.9 0.74
SELO 0.51 0.86 1.08 0.70 0.97
SELH 0.71 0.87 0.8 1.27 0.77
SELI 0.60 0.91 1.14 1.48 0.53
SELK 1.80 1.28 0.72 1.53 1.33
SELM 4.8 1.61 0.90 3.56 1.39
SELS 1.63 0.95 1.06 1.45 1.02
SELT 1.04 0.5 0.64 0.81 0.93
SELV 0.79 3.02 1.00 1.13 1.26
SEP 15 1.14 0.94 0.65 1.15 0.67
SEPHS2 0.84 1.16 1.62 0.87 0.7
SEPN1 0.66 0.65 1.07 0.74 0.87
SEPP1 NA NA 1.02 2.34 1.75
SEPW1 1.23 0.85 0.54 1.51 1.34
SELX 1.04 0.98 0.83 1.70 1.94
TXNRD1 2.49 0.92 1.8 1.14 1.05
TXNRD2 0.44 0.63 1.4 0.85 0.92
TXNRD3 0.81 0.64 1.22 0.88 0.89
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Table 3. Gene expression changes of selenoproteins after 5-AZA treatment and Se 
supplementation in all cell lines.
RWPE-1 DU 145 LnCAP PC-3
DIOl 0.67 0.51 1.16 1.00
DI02 1.04 1.58 0.65 0.98
DI03 1.85 1.07 1.34 1.13
GPX1 0.92 1.11 0.98 1.03
GPX2 1.21 1.34 0.76 1.05
GPX3 1.05 1.02 0.87 0.86
GPX4 1.04 1.12 0.92 1.02
GPX6 0.98 1.16 1.04 1.15
SELO 0.93 0.78 1.2 0.81
SELH 1.14 2.02 0.77 1.87
SELI 0.89 1.11 0.96 1.63
SELK 1.03 1.04 0.74 0.86
SELM 1.09 0.91 0.75 0.98
SELS 1.07 0.87 1.15 0.84
SELT 0.98 1.00 0.72 0.97
SELV 0.86 1.64 0.6 1.00
SEP 15 0.89 1.33 0.51 1.16
SEPHS2 0.92 0.9 0.95 0.9
SEPN1 1.06 0.96 1.3 0.94
SEPP1 NA NA 0.68 1.38
SEPW1 1.02 2.46 1.29 2.29
SELX 1.05 1.05 0.64 1.37
TXNRD1 1.31 1.09 1.4 0.83
TXNRD2 0.91 0.82 1.29 1.21
TXNRD3 1.00 0.89 1.42 1.08
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Appendix 4. C lusters o f hyperm ethylated g e n e s  in prostate cancer  
cell lines
All probes from the promoter tiling microarray were plotted in graphs along each 
chromosome. Chromosomes are shown in cell lines that displayed clear clusters (red 
arrow). Known gene families or chromosome bands with hypermethylated gene 
clusters have been annotated.
Legend
Grey spots: All probes that passed filtering. Green: All probes that were significantly 
enriched after immunoprecipitation in healthy prostate tissues. Red: All probes that 
were significantly hypermethylated in the prostate cancer cell lines compared to healthy 
prostate tissue. Blue: Probes that were in the upstream region (+700 to -200 bp) and 
that were significantly hypermethylated in the prostate cancer cell lines compared to the 
healthy prostate tissue.
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